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An implantable closed-loop insulin delivery device (INsmart device) containing a 
glucose responsive gel has been developed within the INsmart research group, over a 
period of 10 years, to mimic pancreas. In this thesis, the reliability and performance 
capability of the INsmart device was studied for future clinical use.  
Investigations into the device material compatibility with insulin solution, assessed by 
monitoring insulin loss and degradant formation over a period of 31 days using RP-
HPLC have shown that stainless steel and titanium are the most compatible materials. 
Polycarbonate contributes to insulin loss after 11 days, resin might not be the best 
material and polyurethane is the least compatible for future device designs. 
To study insulin delivery mechanism and kinetics from the device, fluorescently 
labelled human insulin (FITC-insulin) was synthesised and characterised using RP-
HPLC and MS, to produce a product with predominantly di-labelled conjugate (>75%) 
with no unreacted FITC or native insulin. Clinically used insulin analogues were also 
fluorescently labelled to produce predominantly di-labelled FITC-insulin conjugate with 
potential future biological and in vitro applications.  
The drug release mechanism from the glucose sensitive gel held in the INsmart device, 
studied using fluorescein sodium was determined as a Fickian diffusion controlled 
release mechanism. The diffusion coefficient (D) for FITC-insulin in the non-
polymerised dex2M-conA gel (NP gel) determined using mathematical models, QSS 




/s and in the cross-linked dex500MA-




/s. In response to physiologically 
relevant glucose triggers in the NP gel, the diffusivity of FITC-insulin increases with 
increasing glucose concentrations, showing a second order polynomial fit, device thus 
showing glucose sensitivity and graded response, mimicking pancreas. Rheological 
measurements further confirmed the gel glucose responsiveness demonstrated by a third 
order polynomial fit between FITC-insulin D and the NP complex viscosity in response 
to increasing glucose concentration. The knowledge of FITC-insulin diffusion kinetics 
in the gel has aided in making some theoretical predictions for the capability and 
performance of the INsmart device. Alternate device geometry and design optimisation 
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Chapter 1 Introduction  
 
The primary focus of the work presented in this thesis was to investigate the 
performance capability and reliability of an implantable closed-loop insulin delivery 
device, INsmart for clinical use in treatment of sufferers of type 1 diabetes. A basic 
understanding of the disease and associated complications are presented in this chapter; 
a detailed account of the numerous effects on the body however is too vast to be studied 
here. Insulin structure and stability aspects are also presented, followed by current 
disease management strategies. 
 
1.1 Control of blood sugar 
Plasma glucose levels are normally maintained within a narrow range of 3.5-5.5 
mmolL
-1
 through the insulin-glucose-glucagon regulatory mechanism and are governed 
by a negative biochemical feedback (‘closed-loop’) that operates continuously and 
automatically and provides an appropriate response to the glucose levels. Normal 
glucose control is maintained through the antagonistic action of the two pancreatic 
hormones, insulin and glucagon. An overview of normal glucose homoeostasis is 











Figure 1-1: Overview of glucose homoeostasis under normal and diabetic condition 
(Ajmera et al., 2013). 
 
In normal individuals, high blood glucose levels (post meal) stimulates insulin secretion 
by pancreatic islet -cells and suppresses glucagon secretion from α-cells, which 
enables the muscle and other cells to take up glucose for energy and store them as 
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glycogen in liver. In low glucose conditions, glucagon secretion by pancreatic -cells 
counter regulates the glucose level by inducing the breakdown of glycogen into glucose 
(refer to Figure 1-1a). When this synchronised regulatory mechanism is disrupted, it 
leads to diabetes (Ajmera et al., 2013). 
Inefficient uptake of plasma glucose in diabetic individuals occur due to insufficient or 
lack of insulin production by -cells, or the insulin resistance of target cells. This result 
in persistent high plasma glucose levels (hyperglycaemia) (refer to Figure 1-1b). This 
condition is often accompanied by absolute or relative excess of glucagon which causes 
higher rate of hepatic glucose production than utilisation, which further contributes to 
hyperglycaemia (refer to Figure 1-1b) (Dunning and Gerich, 2007; Puri and Hebrok, 
2012; Talchai et al., 2012). Another defect observed in diabetic patients is impaired 
secretory response of α-cells to low-glucose concentrations, which leads to the risk of 
episodes of severe hypoglycaemia, especially in patients exposed to excessive insulin 
during treatment or to extreme physical activities carried out as part of self-management 
(refer to Figure 1-1b) (Cryer, 2002).  
The mechanism of insulin release from normal pancreatic beta cells is more or less 
constant within the beta cells, irrespective of blood glucose levels. It is stored within 
vacuoles pending release via exocytosis and release into plasma is primarily triggered 




Figure 1-2: Role of islet β-cell metabolic activation by fuels and neurohormonal 
agonists in insulin secretion (main pathway highlighted in red), PC=pyruvate 
carboxylase. PDH=pyruvate dehydrogenase. Ach-R, GIP-R, GLP-1-R, FFAR1, α-ADR-
R are all receptor on β-cell surface.OAA, oxaloacetate; CoA=coenzyme A. 
Δ_m=change in plasma membrane potential. Mal-CoA=malonyl-CoA. LC-CoA=long-
chain acyl-CoA (Nolan, Damm and Prentki, 2011). 
 
A pancreatic beta cell senses the concentration of glucose in plasma as glucose can 
equilibrate rapidly across the β-cell membrane due to the expression of the high 
capacity, low affinity glucose transporter-2 (MacDonald, Joseph and Rorsman, 2005). 
Glucose enters the β-cell by facilitated diffusion through glucose transporters (GLUT1 
and 2). The next irreversible step of glucose phosphorylation catalysed by a single 
enzyme glucokinase (GK) appears to be rate limiting for β-cell glycolytic flux under 
normal physiological conditions, so that GK is regarded as the β-cell 'glucose sensor', 
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underlying the dependence of the β-cell insulin secretory response to glucose in the 
physiological range (Fridlyand and Philipson, 2010).   
Once phosphorylated, glucose is metabolised via glycolysis to pyruvate and in the 
mitochondria to acetyl-CoA, which is then oxidised in the TCA cycle. These actions 
lead to an increased cytosolic ratio of ATP to ADP, which closes the K
+
 ATP channels, 
depolarises the plasma membrane potential, and opens voltage-gated Ca
2+
 channels, 
causing influx of Ca
2+
 and the triggering of insulin-granule exocytosis. A number of 
other processes also simultaneously occur which enhance the pathway and augment 
insulin secretion. The β-cell also responds to other neurohormonal and metabolic 
extracellular signals via various plasma membrane receptors.  
In diabetic individuals, the targets for self monitored blood glucose levels before meals 
are 4-8 mmol/L for children, and 4-7 mmol/L for adults and 2 hours post prandial is < 
10 mmol/L for children and < 8.5 mmol/L for adults (Montague, 1983; Shier, Butler and 
Lewis, 2003; Gandy, 2014; NICE, 2004; NICE, 2008). Concentrations outside of this 
range for a long period can be harmful, particularly in the brain for which glucose is the 
primary fuel. In hypoglycaemic conditions the brain will become starved of glucose and 
the patient can become comatose. In the long term, hypoglycaemia and hyperglycaemia 
can cause a range of problems. Most diabetic individuals maintain glycaemia control by 
measuring their blood glucose several times a day or with occasional HbA1c readings. 
HbA1c is the level of the covalent conjugation of glucose with haemoglobin which is a 
descriptor and predictor of likely health outcomes. Internationally, the target HbA1c 
level for most people is 53 mmol/mol (7.0%) or less (Gandy, 2014).  
 
1.2 Diabetes mellitus 
Diabetes mellitus can be described as a group of metabolic diseases characterised by 
persistent hyperglycaemia due to inefficient uptake of plasma glucose by muscles and 
other cells, which is caused by deficient insulin secretion or by resistance to the actions 
of insulin combined with relative insulin deficiency. Insulin resistance and insulin 
deficiency lead to the abnormalities of carbohydrate, fat, and protein metabolism that 
are characteristic of diabetes mellitus, chronic hyperglycaemia which is characteristic of 
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diabetes causes long-term damage, dysfunction, and failure of various organs, especially 
the eyes, kidneys, nerves, heart, and blood vessels (American Diabetes Association, 
2008). “Diabetes mellitus” means “excessive excretion of sweet urine”, based on the 
characteristic symptoms of the condition which is excretion of large amounts of glucose 
in the urine, a condition known as glucosuria.  
Diabetes mellitus is a relatively common disease; the affected population shows some 
degree of abnormality in glucose metabolism that is indicative of diabetes itself or a 
tendency towards it. Some key facts published by WHO (Fact sheet No312, reviewed 
October 2013), state that 347 (314-382) million people in 2008 worldwide (representing 
nearly 5% of the world’s population) have diabetes. This is an increase from 153 (127-
182) million in 1980 and is expected to affect 552 million people by 2030. This 
provides some idea of escalation of the condition. The study published in Lancet by 
Danaei, Finucane et al summarised that diabetes is rising globally, driven by population 
growth, ageing and by increasing age-specific prevalence. The study highlighted the 
necessity for effective preventive interventions and for health systems to be prepared to 
detect and manage diabetes and its follow-on effects (Danaei et al., 2011). An estimated 
3.4 million people died from consequences of diabetes in 2004 (World Health 
Organization, 2009). According to WHO, diabetes will be the 7
th
 leading cause of death 
in 2030 (World Health Organization, 2011a). 
The International Diabetes Federation (IDF) in 2013 estimated that (of the adult world 
population of 4.6 billion) the five countries with the largest numbers of people with 
diabetes were China (98.4 million), India (65.1 million), the United States of America 
(24.4 million), Brazil (11.9 million) and Russian Federation (10.9 million). The IDF 
also reported that in 2013 the five countries with the highest diabetes prevalence in the 
adult population were Tokelau (37.5%), Federated States of Micronesia (35.0%), 
Marshall Islands (34.9%), Kiribati (28.8%) and Cook Islands (25.7%). Low and middle 
income countries face the greatest burden of diabetes (Diabetes UK, 2012; International 
Diabetes Federation, 2013). 
Based on the 2011 study of prevalence of diabetes in the adult population across the 
UK, gives an average prevalence of 4.45 per cent in adults. It is estimated that more 
than one in 20 people in the UK has diabetes (diagnosed or undiagnosed). Most health 
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experts agree that the UK is facing a huge increase in the number of people with 
diabetes. By 2025 it is estimated that five million people will have diabetes. Most of 
these cases will be T2DM diabetes, because of the ageing population and rapidly rising 
numbers of overweight and obese people. The figures are alarming and confirm that 
diabetes is one of the biggest health challenges facing the UK today. To curb this 
growing health crisis with reduction in associated deaths from diabetes and its 
complications, Diabetes UK propose increasing awareness of the risks along with 
lifestyle changes, improving self-management and access to integrated diabetes care 
services (Diabetes UK, 2012). 
The financial burden from diabetes management on the individual and the health 
services are immense. In the UK it is currently estimated that about 10 per cent of the 
NHS budget is spent on diabetes. The challenge for producing effective affordable 
treatments is therefore large, growing and global (Diabetes UK, 2012).  
Reduction in the risk of complications has been shown with good diabetes management; 
however failure to do so has been associated with serious complications including heart 
disease, stroke, blindness, kidney disease and amputations leading to disability and 
premature mortality. There is also a substantial financial cost to diabetes care as well as 
costs to the lives of people with diabetes. Half the people with type 2 diabetes show 
signs of complications by the time they are diagnosed. These complications may begin 
five to six years before diagnosis and the actual onset of diabetes may be ten years or 
more before clinical diagnosis (Diabetes UK, 2012).  
There are three main types of diabetes; 
Type 1 diabetes mellitus (T1DM) – TIDM results from the metabolic defect that stems 
from an autoimmune destruction of pancreatic β-cells in the pancreatic islets of 
Langerhans with a consequent inability to produce sufficient insulin. The causes of 
T1DM are not yet known but have been shown to be due to a combination of genetic 
predisposition and environmental conditions, such as exposure to certain viruses or 
other associated autoimmune condition (Holt and Kumar, 2010)(TEDDY Study Group, 
2008). T1DM has an early onset in life and symptoms quickly become severe. The 
classical symptoms include polydipsia (intake of large volumes of water), polyuria 
(frequent urination), hyperglycaemia, and (usually) recent unexplained loss of weight 
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along with at least two of the following characteristic features – rapid onset of 
symptoms over days or weeks, glucosuria or blood glucose markedly raised, ketones in 
the urine or blood or family history of T1DM. T1DM is a condition wherein the insulin 
activity is not impaired but there is an absolute insulin deficiency causing persistent 
hyperglycaemia. The condition therefore responds to insulin replacements. 
T1DM requires both insulin therapy and careful lifelong control of the balance between 
dietary intake and insulin dose. Without insulin replacement, people developing T1DM 
risk surviving and with which they can participate normally in the usual daily activities, 
but still are at risk of associated complications. T1DM individuals are at risk of ;  
 metabolic complications such as hyperglycaemic ketoacidosis, hypoglycaemia, 
dyslipidaemia;  
 macrovascular complications such as cardiovascular, cerebrovascular, peripheral 
vascular disease;  
 microvascular complications such as retinopathy, nephropathy, sensory, motor, and 
autonomic neuropathy;  
 psychological complications such as depression and anxiety. 
 other complications associated with non-adherence to recommended management in 
children and young adults due to family conflict or risky behaviour. Pregnant women 
have increased risks of complications, such as: hypertension and pre-eclampsia, 
foetal and neonatal complications such as congenital malformations, and macrosomia 
(Brownlee, 2001; Brownlee, 2005).  
 
Type 2 diabetes mellitus (T2DM) – T2DM is caused by insulin resistance and a 
relative insulin deficiency resulting in persistent hyperglycaemia. T2DM is slow to 
develop (typically in older, obese individuals); the symptoms are milder and often go 
unrecognized at first often with complications developing before diagnosis. Excessive 
thirst, polyuria, polydipsia are characteristic symptoms (similar to T1DM) of T2DM 
(Nelson and Cox, 2008). 
T2DM is often referred to as insulin–resistant diabetes but in fact is a group of diseases 
where the regulatory activity of insulin is disordered due to a combination of insulin 
resistance, pancreatic beta-cell failure resulting in insufficient insulin secretion or some 
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feature of the insulin-responsive system being defective, in spite of insulin production. 
People with T2DM differ in the levels of increased insulin resistance and decreased 
insulin secretion. Genetic susceptibility is linked to increased body weight, physical 
inactivity and age-related weight gain (Williams, 2003; American Diabetes Association, 
2008). T2DM is often associated with a strong familial predisposition and thus a 
positive family history confers a 2.4-fold increased risk for T2DM, however the 
genetics of T2DM are complex and not clearly defined. Only a handful of genes have 
been identified: genes for calpain 10, potassium inward-rectifier 6.2, peroxisome 
proliferator-activated receptor gamma, insulin receptor substrate-1, and some others 
(Stumvoll, Goldstein and van Haeften, 2005). Ethnicity affects the prevalence of 
T2DM; a greater than 10-fold difference is seen between high-risk and low-risk ethnic 
groups. Also T2DM is more prevalent in adults who had low birth weight for gestational 
age (BMA, 2004; National Diabetes Support Team, 2006). Polycystic ovary syndrome 
can increase the risk of impaired glucose tolerance and diabetes.  
The additional risk factors for T2DM include obesity, lack of physical activity, history 
of gestational diabetes, impaired glucose tolerance, impaired fasting glucose, drug 
therapy, cigarette smoking, low fibre and high glycaemic index diet (Hundal and 
Inzucchi, 2003, Srinivasan et al., 2008, Hu et al., 2001). The so-called metabolic 
syndrome (a combination of obesity, hypertension, and dyslipidaemia) increases the 
likelihood of T2DM (Srinivasan et al., 2008).  
Individuals with T2DM diabetes are at increased risk of developing microvascular and 
macrovascular complications (Khunti et al., 2006; Srinivasan et al., 2008). The 
complications of T2DM diabetes are associated with high blood pressure, high lipid 
levels, muscle damage, foot, eye, renal problems (nephropathy) and neuropathy (NICE, 
2008). Randomized controlled trials have suggested that high BP values in people with 
T2DM diabetes are linked to a rapid decline in renal function. Higher levels of 
triglycerides present immediate risks of pancreatitis. Intensive BP control can reduce 
progression of microvascular complications. Reviewing the feet of people with diabetes 
regularly and keeping blood glucose, blood fats and blood pressure under control can 
prevent some of the complications associated with the feet. Diabetes is the most 
common cause of lower limb amputations.  
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Though the complications of T1DM and T2DM diabetes are essentially the same, in 
poorly controlled individuals microvascular complications tend to be more common in 
T1DM diabetes where as macrovascular complications are more common in T2DM 
diabetes. The major causes of mortality are similar, though there is a greater reduction in 
life expectancy in T1DM diabetes than T2DM diabetes. 
The association between obesity, diabetes, the metabolic syndrome and cancer 
(Giovannucci et al., 2010; Renehan et al., 2008), have been investigated over a long 
period of time and hyperinsulinemia and /or insulin resistance have been established as 
major factors in its pathogenesis. T2DM has been associated with a range of cancers 
including breast, colorectum and bladder (Johnson et al., 2012), while association of 
T1DM and cancer remains more speculative. 
 
Gestational diabetes mellitus (GDM) - GDM is defined as a condition that arises 
during pregnancy (usually during the second or third trimester) in a previously 
undiagnosed female and occurs as the body cannot produce enough insulin to meet the 
extra needs of pregnancy resulting in abnormally high glucose levels. GDM results from 
an increased severity of insulin resistance as well as an impairment of the compensatory 
increase in insulin secretion during pregnancy. Pregnancy serves as a metabolic stress 
and uncovers underlying insulin resistance and beta cell dysfunction (Singh and 
Rastogi, 2008). GDM affects up to 5 per cent of all pregnancies and is normally 
transitory and resolves after delivery. Women who are overweight or obese are at a 
higher risk of GDM and approximately 7% are at risk of going on to developing T2DM 
diabetes. Children born to mothers with GDM also have a higher risk of suffering from 
obesity and T2DM in later life.  
 
Other specific types of diabetes include monogenic diabetes which is due to a single 
gene defect. It was previously known as 'Maturity-Onset Diabetes in the Young', MODY 
which is related to lifestyle/obesity in teenagers and is in fact T2DM. Other specific 






1.3.1 Insulin structure 
One of the outstanding achievements of modern medicine has been the discovery of use 
of insulin as an injected therapeutic agent for the treatment of diabetes.  Due credit goes 
to (Banting and Best, 1922) for the isolation of insulin from pancreas in 1922, which 
has been one of the exciting discoveries in medicine of the last century. Since then, 
insulin has been one of the most extensively studied molecules of biochemistry. Banting 
and Best were successful in isolating a concentrated pancreatic secretion which 
demonstrated lowering of blood glucose in animals and under careful control in humans 
with diabetes with relatively low toxicity. Following this discovery, crude extracts of 
cow, pig and sheep pancreas were used to treat diabetes until purified insulin was 
successfully crystallized by (Abel, 1926) and by (Scott, 1934), when zinc – insulin was 
crystallized.  
Structure at synthesis 
The insulin molecule is originally synthesised in the human body as preproinsulin 
composed of 110 amino acids in the beta cells of the pancreas. The ‘signal peptide’ 
comprising of 24 amino acids are removed by enzyme action from one end of the chain 
when it passes through the endoplasmic reticulum, leaving another form (pro-insulin) 
behind. Further 2 amino acids are removed by another enzyme carboxypeptidase E. The 
proinsulin, as shown in Figure 1-3 folds and bends to give the molecule its final 
structure. The middle C-peptide section ("the C chain") of 33 amino-acids is then 
removed by the action of the enzymes prohormone convertase 1 and 2, converting it 
into the final structure with 2 chains, A and B. Insulin and C-peptide are packaged 
together in the secretory granule. On stimulation of the beta cell, C-peptide and insulin 






Figure 1-3: The structure of human proinsulin, the precursor molecule to insulin. The 
33 amino acid peptide that connects the amino terminus (NH2-) of the A chain to the 
carboxyl terminus (-COOH) of the B chain is called connecting peptide (C-peptide) 
(taken from (Voet and Voet, 1995), p.193).  
 
The human insulin molecule consists of two polypeptide chains (A and B), linked to 
each other by two disulfide bonds, containing 51 amino acid residues and is illustrated 
in Figure 1-3. The A chain consists of 21 residues with an additional disulfide loop 
between A6 and A11 whereas the longer B chain consists of 30 residues. The three-
dimensional structure of the insulin molecule is formed of three α-helices (residues A1–
A8, A12–A18 and B9–B19) and a β-strand from B21 to B30 constrained by the intra-
and two interchain disulphide bonds. The nonpolar cysteine residues A6-A11 and the 
aliphatic side chains of residues A2, A16, B11 and B15 constitute the hydrophobic core 
of the insulin monomer and the surface is covered by both polar and nonpolar residues. 
The A chain and the B9-B19 helix form a stable structural unit, whereas the B25-B30 
and B1-B8 segments are variable in conformation. Phenol or m-cresol is usually added 




Insulin imparts its biological effects as a monomer. Insulin exists in its active 
monomeric form (Cahill Jr, 1971), in solutions at neutral pH, only at low concentrations 





M (physiological concentrations ~ 1 ng/mL) (Frank, Pekar and Veros, 1972; 
Blundell et al., 1972).  
Despite the variations in amino acid sequence in insulin from other animal species, the 
folding and packing of the two chains into their three dimensional conformation are 
essentially the same in all insulins. Insulin from the hystricomorph rodent family show 
the highest number of amino acid substitutions; for example guinea pig insulin contains 
18 residues different from the respective positions in human insulin. Of the other insulin 
used for pharmaceutical preparations, porcine (refer to Figure 1-4) and bovine insulins 
contain alanine in position B30 and bovine insulin contains alanine in position A8 and 







Figure 1-4: The chemical structure of pig insulin as determined by (Brown, Sanger and 
Kitai, 1955). 
 
At higher concentrations the insulin monomers self-associates to form dimers where 
two identical monomers come together to form an antiparallel β-sheet between the two 
COOH-terminal of B23 and B30 residues, this further packs ProB28 against B20 to B24 
residues.  The two molecules in a dimer are held together by, hydrophobic interactions, 
nonpolar forces and stabilized by four hydrogen bonds between monomer residues B24 
and B26 (Baker et al., 1988; Brange et al., 1990).  
In the presence of zinc and in higher concentrations at acidic or neutral pH, three dimers 
assemble to form a soluble, globular protein structure, a hexamer as shown in Figure 
1-5 (Baker et al., 1988). Though the insulin monomer represents a small motif of 
protein folding, the zinc-hexamers exhibits key features of globular proteins; such as 
secondary structure elements (the α-helix, 310-helix, β-sheet and the β-turn), tertiary 
organisation of hydrophobic core, specific interfaces for self-assembly and allosteric 
regulation through ligand-dependent conformational changes (Baker et al., 1988; Weiss, 
2013). The zinc ions are situated in the polar channel in the centre of the hexamer 
coordinated to B10 His. The hexamer can adopt two different states – T-state and R-
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state which refers to an extended or a α-helical conformation of the B-chain N-terminal 
respectively.  The R-state which is more stable and has lesser tendency to dissociate is 
induced by phenol in the presence of zinc ions and thus is a property of the hexamer 
(Brange and Langkjaer, 1993). This R-state where the B1-B8 α-helices are stabilized at 
the dimer-dimer interface of a hexamer occurs in the presence of phenol or cresol 
molecules and its position restricts the zinc-ion diffusing out of the hexamer 
(Derewenda et al., 1989; Kaarsholm, Ko and Dunn, 1989). 
In aqueous and neutral solutions and at higher concentrations ≥ 2mM, insulin molecules 
have a propensity to dimerise and it further assembles into hexamers in the presence of 
zinc ions which ensures its stability. However, as insulin binds to its receptor as a 
monomer, this property of forming hexamer is not necessary for the biological activity 
of the hormone.  
 
  
Figure 1-5:  a: Atoms in the 2Zn insulin hexamer viewed along the crystal threefold 
axis, as determined by (Baker et al., 1988); b: The R6 Human insulin hexamer (non-
symmetric), NMR structure. Protein chains are coloured from the N-terminal to the C-
terminal using a colour gradient (Chang et al., 1997). 
 
Insulin Analogues:  The insulin hexamer crystal structure elucidated by Hodgkin et al 
in 1969 still continues to provide insight for biosynthesis processes and forms the basis 
for modern efforts to optimize its molecular properties for use in treatment of diabetes 




design have immensely helped in modifying the insulin molecule to modulate its 
pharmacokinetic and pharmacodynamic properties (Brange, 1997; Freeman, 2009). This 
has been made possible as it has been demonstrated that surface amino acids residues in 
a native insulin molecule, including dimers and hexamers can be altered independent of 
the receptor binding surfaces (Shoelson et al., 1992).This has resulted in insulin 
analogue formulations currently used clinically which are rapid-acting formulations 
intended for bolus injection before meals or use in pumps and long-acting basal 
formulations intended for once-a-day injections. Some of the insulin analogues created 
in this manner, along with the strategies used for creating them are described in 
Chapter 4. 
 
1.3.2 Insulin stability 
The structural integrity of a therapeutic protein is essential for the maintenance of its 
physiological and pharmacological activity, thus its efficacy.  Insulin stability is 
critically dependent on the conformational flexibility within the insulin molecule which 
controls the rate of spontaneous structural transformation and can be categorized as 
physical or chemical alterations in the molecule. These have mutual influence; changes 
in conformation affect the susceptibility of the molecule for chemical attack and vice 
versa. A variety of physical modifications of the secondary and quaternary structure 
(which include denaturation, adsorption, precipitation, fibrillation and aggregation) and 
chemical changes of the primary structure (yielding insulin derivatives) are known to 
affect insulin and insulin preparations during storage and use.  
 
1.3.2.1 Physical stability 
Physical instability is manifested as macroscopically visible changes observed when 
handling or use of insulin such as increase in solution viscosity, precipitation from 





Denaturation or unfolding is the loss of the physical native three-dimensional or 
globular structure with no change to their chemical composition. Denaturation could be 
thermal denaturation induced by elevated temperatures resulting in formation of 
irreversible aggregates, cold denaturation occurring well below the freezing point of 
water or chemical denaturation due to binding of chaotropes such as urea and 
guanidinium hydrochloride that disrupt the 3D molecular structure of proteins(Manning 
et al., 2010). 
The insulin lost due to adsorption/adhesion is inversely proportional to insulin 
concentration (negligible for higher concentrations such as 5 IU/ml (~ 0.2 mg/ml)) and 
varies with the material, being more prone to be adsorbed to hydrophobic than to 




Precipitation can occur in insulin solutions due to a number of factors. Generally 
reduction in insulin solubility due to pH changes or introduction of Zn 
2+ 
or other 
divalent metal ions results in formation of amorphous or crystalline precipitates in 
insulin solutions as shown in the adapted illustration, Figure 1-6 (Brange et al., 1987). 
The isoelectric precipitation (pI) value for native insulin is 5.4 (Jensen, 2009). Small 
amounts of leachable material from device materials or container closure systems could 
bring the insulin solution in its isoelectric precipitation zone (pH 4.5 – 6.5), especially if 
the solution is unbuffered (Melberg et al., 1988). Also, absorption of buffer leading to 





Figure 1-6: Schematic diagram showing the influence of increasing zinc and insulin 
concentration on precipitation of insulin (adapted from (Brange et al., 1987)). The 
shaded area represents the insulin precipitation zone.  
 
Fibrillation 
Under the influence of heat, insulin has a tendency to undergo conformational changes 
resulting in linear aggregation or fibrillation which precedes precipitation. Waugh has 
shown that observable fibrillation precedes precipitation by a nucleation growth 
mechanism involving three or four insulin monomers (Waugh, 1946a; Waugh, 1946b; 
Waugh et al., 1953, Weiss, 2013). Elevated temperatures are required for nucleus 
formation; however subsequent growth into fibrils can occur at low temperatures 
(Waugh et al., 1953). The fibril nuclei formation probably proceeds via monomerisation 
of oligomeric insulin. A mechanism for fibrillation using computer simulations of 
insulin aggregation has been reported where partially unfolded insulin monomers have 
shown to associate and form intermediate assemblies (Sluzky et al., 1991; Sluzky, 
Klibanov and Langer, 1992). The slow formation of intermediates, commonly observed 
as a lag time in fibrillation, reaches a critical size (170nm in diameter corresponding to 
~100 molecules) which has sufficient surface area for stability and for interactions with 
native insulin molecules. 
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Neutral solutions containing low concentrations of hexameric insulin are more prone to 
fibrillation. It is thought that fibrillation, which involves dissociation of insulin 
hexamers and conformational changes of the monomer, probably precedes adsorption 
(Phillips et al., 2012). Addition of glycerol and some polysaccharides to insulin 
solutions significantly increase physical stability however they significantly decrease 
the chemical and biological stability. Addition of calcium and zinc ions improves the 
physical stability of neutral insulin preparations at higher concentrations. A marked 
fibrillation-inhibitory effect is obtained by low concentrations of lecithin or a synthetic 
detergent for example 400U/mL pump insulin marketed by Aventis has detergent 
(Genapol®). The most effective stabilization is seen when these methods are combined. 
Bovine insulin is more prone to fibrillation than human or porcine insulins, due to A8 
Alanine residue on the hexameric surfaces aiding interactions with hydrophobic 
surfaces. It has been shown that in the presence of higher molecular contaminants such 
as covalent dimer, proinsulin etc. insulin has lesser propensity to fibrillation (Brange et 
al., 1982).  
 
Aggregation  
There is no single pathway by which aggregation occurs and a number of factors can 
contribute to protein aggregation such as incorrect folding during protein expression, 
perturbation of the native conformation during purification, formulation, freeze-
thawing, freeze-drying, ultrafiltration/diafiltration, vial and syringe filling, pumping, 
transportation or storage. It is thus important to consider the intrinsic conformational 
stability of the protein as well as the protein-protein interaction (Manning et al., 2010). 
General mechanisms of protein aggregation as described by Philo (Philo and Arakawa, 
2009) are association of native monomers e.g. assembly of insulin hexamers, 
aggregation of conformationally altered monomers, aggregation of chemically modified 
monomers, nucleation controlled aggregation which involves formation of nucleus or 
seed and surface induced aggregation. Non-native aggregation can cause a number of 
undesirable effects such as adverse immunological effects during therapy, reduced 




1.3.2.2 Chemical stability 
Chemical instability involves covalent modification of the protein amino acid sequence 
(primary structure) leading to bond formation or cleavage. Chemical instabilities can be 
classified as following;  
 
Hydrolytic reactions 
The principle hydrolytic products in acidic and neutral solutions are acid-catalysed 
deamidation of residue Asn 
A21
 (A21 desamido insulin) (Sundby, 1962) and base-
catalysed deamidation of residue Asn 
B3
 (B3 desamido insulin). The B3 transformation 
leads to formation of a mixture of isoAsp and Asp derivatives (Brange et al., 1992b). 
Deamidation is discussed in detail in Chapter 3. Hydrolytic chain cleavage of the A-
chain at A8-A9 occurs in crystalline suspensions of rhombohedral crystals in presence 
of additional free zinc ions (Brange, 1992c).  
 
Formation of covalent dimers and oligomers 
Covalent insulin dimers (CID) and oligomers are formed at ambient or higher 
temperatures during storage in neutral solutions and in amorphously precipitated insulin 
(Brange and Langkjaer, 1993). These are formed through transamidation wherein amine 
groups on one molecule (predominantly the B1 α-amino group) reacts with side chain 
carboxyamide groups on another molecule (usually in the A chain) (Weiss, 2013). The 
rate of CID formation varies with composition, formulation and in some instances the 
concentration of the preparations and is only slightly influenced by species. In 
crystalline insulin zinc suspensions, following prolonged storage at temperatures above 
25°C, successive transamidation of insulin molecules with already formed insulin 
dimers lead to formation of trimers and tetramers (Brange, Havelund and Hougaard, 
1992a). Insulin analogues with the B1 α-amino group blocked by direct addition of 
polyethylene glycol or thyronine have been investigated to avoid B1-mediated 
transpeptidation (Hirsch, 2005). 
 
Disulfide Interchange Reactions 
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Disulfide interchange reactions which require juxtaposition of disulfide bridges from 
different insulin molecules are initiated by cleavage of cystine A7-B7 by hydrolysis or 
β-elimination (Manning, Patel and Borchardt, 1989). In regular formulations such 
polymers are detected (Brange, Havelund and Hougaard, 1992a).  
 
1.3.2.3 Influence of pH, auxiliary substances and temperature 
Deterioration due to different hydrolysis reactions is at a minimum at around pH 6.5, 
whereas acidic pH 4 is optimum for formation of covalent dimers and oliogomers. In 
alkaline media (pH >9) accelerated formation of covalent oligomers and polymers is 
observed as a function of pH. With increasing pH, increasing formation of B3 
deamidation products has been observed (Brange, Havelund and Hougaard, 1992a). 
Isotonic substances and preservatives influence the stability of insulin preparations by 
their effect on deamidation and CID formation. Among preservatives, it was found that 
there is a gradation in the stabilizing effect namely phenol > m-cresol > methylparaben 
and for isotonic agents, NaCl > glycerol > glucose (Brange and Langkjaer, 1992e). 
Temperature is a major influence in all pharmaceutical insulin preparations. The rate of 
deamidation and formation of higher molecular weight (HMWT) products increases 
with increase in temperature (Brange, Havelund and Hougaard, 1992a; Brange et al., 
1992b; Brange and Langkjaer, 1993). 
 
1.4 Disease management 
Over the past 30 years, dramatic changes have occurred in the management of T1DM 
diabetes mellitus. Insulin replacement strategies, administering smaller doses of insulin 
(basal doses) throughout the day and appropriate insulin doses (bolus doses) as needed 
to supplement for additional anticipated carbohydrate intake or subtract for exercise 
have made it possible to maintain near-normal glycaemia in most patients, though very 
stringent regimen is required. The aim of insulin replacement therapy in general is to 
normalize blood glucose in order to prevent rapid death from ketoacidosis and to delay 
and reduce the associated complications of diabetes. The following diabetes 




1.4.1 Orally administered drugs 
Getting the support for intensive lifestyle behaviour change which include healthy diet, 
regular physical activity, maintaining a normal body weight and avoiding tobacco use 
can prevent or delay the onset of T2DM diabetes (Hirsch, 1999; THE COST OF 
DIABETES: REPORT, 2014). However, most people with T2DM diabetes will 
eventually need treatment with oral hypoglycaemic agents. The agents currently widely 
used include metformin, sulphonylureas, meglitinides (nateglinide, repaglinide) or 
combined oral drug treatment (may reduce HbA1c levels more than monotherapy). 
These show a reduction in HbA1c in a range from 0.4 to 2% but also have been 
associated with developing hypoglycaemia (Diabetes UK, 2012). Sulfonylureas act by 
improving insulin action and secretion following a meal, however, sulfonylureas do not 
show a dose-dependent relationship with efficacy (Groop, 1992; Moser, Morris and 
Garg, 2012). Sulfonylureas alone may become inadequate with the progression of the 
disease and many patients may need to add insulin to their regimen or combine with a 
dimethylbiguanide to reach treatment goals (Wright et al., 2002). Dimethylbiguanide 
(metformin) acts by increasing insulin sensitivity thereby decreasing insulin resistance 
in T2DM and also works to decrease gluconeogenesis by the liver, further decreasing 
fasting glucose (Bailey and Turner, 1996; Moser, Morris and Garg, 2012). Some other 
drugs in development for T2DM include glucokinase activators, which increase glucose 
uptake by the liver, sodium-glucose transporter-2 (SGLT2) inhibitors, which increase 
glucose loss in the urine resulting in weight loss and modest improvement in glycaemic 
control (Bailey et al., 2013) and organ (liver) specific medications. Some studies, have 
pointed out that individual or group intensive educational programmes may also 
contribute to reduce HbA1c compared with usual care (Hundal and Inzucchi, 2003). 
Structured education courses to help understand and manage their condition and annual 
checks of blood glucose levels, blood pressure, cholesterol, eyes, feet, kidneys, weight 
and smoking status are all recommended by NICE and are essential for people to keep 
on top of their diabetes. There are now widely-used cost-saving drugs to reduce blood 




1.4.2 Subcutaneous injections 
Since the discovery of insulin, various formulations have been developed for 
subcutaneous delivery in an attempt to imitate the physiological insulin response. This 
has dramatically improved the prospects of people with diabetes. However, the initial 
unmodified insulin preparations varied greatly in potency, contained many impurities, 
resulted in significant elevation of circulating insulin antibodies and had short duration 
of action which meant that multiple daily subcutaneous injections were required. 
Formulations with additives such as protamine and zinc (“intermediate-acting” neutral 
protamine Hagedorn (NPH) insulin in the 1940s and the lente family of insulins in the 
1950s) were the first successful attempts to prolong insulin's action (Hirsch, 2010).  
However, these formulations were still associated with considerable variability of effect 
and a pronounced peak in their time–action profile. As the pharmacokinetics of these 
preparations given subcutaneously, did not match the profiles of physiological insulin 
secretion, new long-acting insulin analogues with altered properties which would better 
satisfy basal insulin requirements over the entire day were developed with the advance 
of the rDNA technology in the 1980s. Significant efforts have been made since to alter 
the physicochemical and pharmacological properties of insulin to aid development of 
optimal basal-bolus strategies for improved insulin therapy (Brange and Vølund, 1999). 
A basal-bolus regimen is now common for T1DM patients. Long-acting insulin (insulin 
glargine and insulin detemir) administered once daily at bedtime or, ideally, twice daily 
to meet basal needs in combination with rapid acting bolus insulin at either mealtime or 
premeal taking into account the content of a specific meal are now firmly established as 
key tools in the battle against diabetes (Hirsch, 2010). Patients with T1DM diabetes 
typically require an insulin dosage of 0.5 to 1.0 units per kg per day, however newly 
diagnosed patients may require lower amounts because of some continued endogenous 
insulin production. The flexible insulin regimens are based on response to self-
monitoring of blood glucose levels and carbohydrate intake (Owens, 2002). Insulin 
degludec, which demonstrates comparable efficacy to insulin glargine, is now being 
evaluated for administration at less frequent intervals (Owens, 2011).  
This treatment regimen however does not always maintain normoglycaemia and the 
resulting hyperglycaemia is responsible for the long term complications in patients such 
as eye disease leading to blindness, kidney damage, renal failure, nerve damage and loss 
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of various organs (Graves and Eisenbarth, 1999). The effectiveness of an insulin 
regimen is influenced by physicochemical factors such as onset, peak and duration of 
action plus patient factors such as individual variations in insulin absorption, levels of 




Continuous subcutaneous insulin infusions (CSII) delivered using pumps has a number 
of advantages over multiple daily injections (MDI) including better glycaemic control 
as measured by HbA1c, modest reduction in insulin dose and higher patient compliance 
and satisfaction (Skyler, 2010). Disadvantages include higher costs of therapy, risk of 
incidence of non delivery and diabetic ketoacidosis and the need to be attached to the 
system (Meneghini and Sparrow-Bodenmiller, 2010). Advances in technology have 
improved the functionality of pumps and added features that provide greater control of 
insulin delivery such as programming of delivery of multiple doses by time, ability to 
calculate recommended bolus dose based on meal carbohydrate content, memory 
displays of past insulin delivery and wireless uploading of blood glucose values to the 
pump from blood glucose meter (Moser, Morris and Garg, 2012). Patch-pumps where 
the infusion component sits directly on skin offers increased ease of use by eliminating 
pump tubings (Skyler, 2010). 
Diabetic patients still need to read glucose content from the blood and use these blood 
glucose values to decide their insulin dosages. Finger prick glucose measurements, 
often regarded as cumbersome and uncomfortable by patients, only provide information 
about a single point in time, so it is difficult to discern trends in decline or raises in 
blood glucose levels. In non-diabetic individuals normal HbA1c values are maintained 
without risking hypoglycaemia because of the meticulous interplay of the humoral 
signalling. Therefore there have been attempts to mimic these using informative 
feedback systems using pump systems with which dose rates can be intelligently 
adjusted and ultimately automated (Kerr and Partridge, 2011). Continuous glucose 
monitoring systems (CGM) measure interstitial fluids continually and use several 
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algorithms to calculate current blood glucose values. They consist of a small needle 
which is inserted in the abdominal subcutaneous fat, the tip of the needle houses a small 
glucose sensor which can measure glucose levels in the fluid which surrounds the fatty 
tissue. However, despite the small size of glucose molecule there is a delay 
(approximately 18 to 30 minutes) associated with equilibration of glucose in 
subcutaneous tissue fluids and blood glucose content as the glucose molecules have to 
diffuse through tissues and then to the sensor (Taylor and Sahota, 2013b; Nielsen et al., 
2005). There is limited evidence for the effectiveness of real-time continuous glucose 
monitoring use in children, adults and patients with poorly controlled diabetes. The 
largest improvements in glycaemia control were seen for sensor-augmented insulin 
pump therapy in patients with poorly controlled diabetes who had not used an insulin 
pump before. There are indications that higher compliance of wearing the CGM device 
improves the HbA1c levels for patients using MDI or CSII therapy (Garg et al., 
2011);(Gilliam and Hirsch, 2009). Examples of CGM devices in current clinical use 
include DexCom SEVEN* PLUS, Medtronic MiniMed Paradigm®, REAL-Time and 
Guardian®. 
 
Closed-loop insulin delivery systems  
Diabetic condition is characterised by real-time calorie turnover as well as chronically 
raised prandial glucose levels, thus control needs a basal and boost dose of insulin. In 
addition to this there are changes imposed by secondary factors such as exercise which 
might use glucose from glycogen mobilised by glucagon or glucose from blood which 
need insulin to move it into cells depending on blood glucose levels at start of exercise. 
Another affecting factor is physiological stresses which are thought to be mediated by 
the sympathetic, counter-regulatory systems and can raise insulin requirements by more 
than half. Therefore the delivery systems must achieve real-time response and cope with 
the variations with basal and boost doses. A closed-loop system, which automatically 
monitors the change in glucose levels and accordingly dispenses an accurate dose of 
insulin, would present an ideal insulin therapy for long-term routine patient care. Closed 
systems are completely automated systems which should calculate and administer the 
required dose accurately and continuously in real time. The main concept for closed 
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systems is based on its ability to maintain near normal glycaemic levels real-time, to 
prevent long term effects of hyperglycaemia caused by the lag time, to drive the 
healthcare cost down especially the cost associated with complications and to improve 
the quality of life for patients. 
The closed loop system should accomplish the following criteria; be glucose-specific 
and respond in an acceptable timescale and in a dose-related manner, be able to transmit 
the variable release rate in real time to plasma, impart detailed control without undue 
oscillation, deal with local visceral insulin and glucose levels, operate long term without 
leak of insulin or components or creation of other harm, should not produce increased 
need (‘down regulation’), deliver readily available insulin or analogues and not need 
specific conjugates such as glycosylated forms (Taylor and Sahota, 2013b). 
There are several potential routes forward to use closed loop ideology for the practical 
management of diabetes. Implanting pancreatic islet is a biological solution to 
delivering insulin via a closed loop system (Senior et al., 2012). Islet transplantation is 
currently an accepted modality to treat selected diabetic patients with frequent 
hypoglycaemias and severe glycaemic liability. However the main deterrents to this 
solution include chronic graft function most likely associated with immune rejection, 
recurrence of autoimmunity or chronic exposure to potentially carcinogenic 
immunosuppressant agents (Pepper et al., 2013). 
There have been many biological, electronic and chemical approaches to designing of 
closed loop systems but no fully operational portable system exists. Electronic systems 
have attempted to close the loop, but these still need some sort of manual intervention. 
Electronic systems as described by Hovorka group (Hovorka et al., 2010) comprising of 
an electronic sensor, namely a CGMS sensor, pump delivery system in combination 
with advanced control algorithm to compute the quantum dose per unit time is a half 
way solution between a conventional pump use and a closed loop system. The major 
shortcoming of this system was suboptimum accuracy of the sensing device. Most of 
the systems available show a failure to give a timely pre-prandial dose to control the 
later surge and then giving an over compensation leading to hypoglycaemic condition 
much akin to conventional dose systems (Taylor and Sahota, 2013a). 
27 
 
A closed-loop artificial pancreas is being attempted to be developed using the 
Medtronic implantable pump (Renard, 2008) or the Diaport (Taylor and Sahota, 2013a) 
and a model based controller which uses a control algorithm to regulate glucose levels 
by adjusting insulin delivery. The Medtronic Veo system is half way between 
conventional pump and a closed loop system, here the electronic sensor is in 
communication with the pump but must still receive manual instruction for insulin dose. 
It is capable of automatically suspending insulin delivery for up to two hours if an 
impending hypo is detected electronically, however with a risk of hyperglycaemia. 
Diaport is a simpler and more practical surgically implanted device for continuous 
intraperitoneal infusion of insulin, aimed at reducing the long lag associated with 
subcutaneous insulin delivery. These still are not the ideal systems as both suffer from 
sensor delays relating to the subcutaneous environment or peritoneal cavity 
environment and thus postprandial surge cannot yet be controlled automatically.  
 
Innovative technologies  
The closed loop delivery system comprising electronic sensor and pump systems have 
been so far been well represented commercially and in clinical studies. However 
technology with these systems still has to overcome sensor associated time lags and 
inability to mimic real-time responses. Alternative systems are being researched based 
on chemically controlled reservoirs where insulin can be delivered through a glucose 
sensitive membrane or hydrogel as a function of glucose present ( Abdekhodaie and Wu, 
2009; Zhang et al., 2006; Tanna et al., 2006a; Tanna et al., 2006b)  
One such innovation, wherein the sensor and the delivery system is the same 
component, is the device using a glucose sensitive biomaterial developed by Taylor et 
al. The system has been shown to perform satisfactorily in diabetic rats and pigs. 




Chapter 2 Development of an 
implantable closed-loop insulin delivery 
device, INsmart 
 
In this chapter the design of the implantable closed-loop insulin delivery device, 
INsmart device is presented, including its performance in previous in vivo experiments. 
The various aspects that need consideration for further development of the device are 
presented along with the aims and objectives for the work covered in this project. 
 
2.1 Design of device 
The device in this investigation is an innovative system in terms of insulin delivery. The 
device is a completely implantable peritoneal artificial pancreas.  It houses a novel 
glucose-sensitive gel, kept in place by a rigid casing, which forms a gateway to the 
insulin reservoir and it is designed to both sense glucose and deliver insulin in the 
peritoneal cavity. The gel exhibits a fast gel-sol transition with a primary and practically 
specific response to glucose. The formulation of this biomaterial and its specific 
properties are further discussed in the section below. The device would be implanted 
between the lowest rib and the hip and topped up with insulin every few weeks. The 
device can be refilled with insulin via subcutaneous ports. The device is in preclinical 
development stage. The original concept, originated within the INsmart group, is 
covered by patents (Taylor, 1992); (Taylor, 1993), the current and operating patents 
which cover the glucose sensing gel and device design include (Taylor, 2001; Taylor, 
2013b; Taylor, 2013a). The working prototypes were designed and manufactured by 
Renfrew International, Leicester, UK (refer to Figure 2-1 for the interim working 
prototype).  
Advantages of this device  
 A closed-loop device. 
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 Based on a glucose –specific chemical response 
 Rapid response and accurate dose administered, removes the need to inject 
insulin manually 
 No electronic or moving parts 
 Simple and cheap solution for all diabetes patients. 
 Simple to implant and easily refillable 
 Needs no immunosuppressive drugs 
 Not visible externally and hence socially preferable to external portable pumps. 
 
             
                
Figure 2-1: Figure of the device (CAD), the actual device with Luer connections 
(interim working prototype) and the device with refill needle ports (Taylor, 2013b). 
 
The parts of an interim working prototype, which was used for this project, are 
discussed below; 
2.1.1 Components  
The design has sequential arrangements of membranes, gel spacer and grids as shown in 
Figure 2-2. The design prevents any distortion of the membranes during assembly and 
prevents any internal swelling. All the parts of the device can be removed and cleaned 
30 
 
(for the experimental model). The working model parts contain stainless steel (Grade 
316), polycarbonate (a thermoplastic polymer containing monomer bisphenol A) and 
resin (a polyurethane two part thermosetting resin made of polyol and isocyanate 
mixed). In future designs, there are plans to replace the resin part with polyurethane (a 
long chain thermoplastic polymer made up of polyol and isocyanate mixed) and make 
the device entirely of polycarbonate in order to make it lighter. The tubing connecting 
the luer connections from the device to the fill ports under the skin are polyethylene-
lined polyurethane (manufactured by SAI, Strategic Applications Incorporated) to give 
bio and insulin compatibility, refer to Figure 2-3.  
 
 





Figure 2-3: Figure showing the refill plumbing circuits.  
 
2.1.2 Glucose responsive gel 
The gel, which exhibits a fast gel-sol transition with a primary and practically specific 
response to glucose is a viscoelastic, hydrophilic material that is formed from an 
interaction between a branched glucose polymer, dextran (produced by Leuconostoc 
mesenteroides) and the lectin concanavalin A (con A) from Canavalia ensiformis (Jack 
bean) (Type VI) with glucose-specific receptors (Tanna et al., 2006a; Tanna et al., 
2006b). The lectin, con A, itself is a protein (RMM 104kDa) which exists as a dimer 
below pH 5.8 and as a tetramer at physiological pH with identical components. Each 
component has a binding subunit for the cooperative accommodation of two divalent 
metal ions and appropriately configured carbohydrates with terminals such as mannose, 
glucose or fructose (Benzeval, Bowyer and Hubble, 2012; Kaushik, Mohanty and 
Surolia, 2009). Admixtures of lectin in solution with polysaccharides that are effectively 
multivalent form precipitates and gels. 
The gel which formed part of a implantable insulin delivery device used in the in vivo 
pig studies was a partially polymerised product of dextran methacrylate (dex-MA) and 
con A methacrylamide (con A-MA) that create large molecular structures with covalent 
bonds but not a solid hydrogel. Both simple mixtures (dex and con A) and the 
polymerised counterpart, form gels that produce a reversible change in consistency on 
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contact with glucose to modulate insulin transport and thus act as a self-adjusting 
system (Taylor, Tanna and Sahota, 2010a)(refer to Figure 2-4). 
 
Figure 2-4: Overview of the gel action contained in insulin delivery device 
 
Figure 2-5 shows a comparison of the polymerised and mixture systems with interstitial 
areas which become free when free glucose is introduced and allow insulin monomer 
transport. In the device the polymerised gel was retained between two porous 
membranes (~ MWCO 100kDa) which allows the ingress of glucose (180Da) and the 
delivery of insulin as the monomer (~6kDa) but prevents ingress of bacteria (0.2 -30 
µm), enzymes and other proteins larger than the pore size of the retaining membranes, 
such as those present in the peritoneum or other relevant implant site fluids as shown in 
Figure 2-4. A stability study conducted within the INsmart group, has shown that in the 
presence of chymotrypsin (25kDa), a tryptic enzyme present in the peritoneum, the 
polymerised acrylic gels maintained stability when encased in dialysis membrane 
MWCO 50kDa for over 500 days. Other biochemicals that may be present in the 
peritoneum include alkaline phosphatise (89kDa), aspartate aminotransferase (dimer; 
94kDa), albumin (66kDa), bilirubin (585Da), cholesterol (387Da) and urea (60.05Da) 
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Figure 2-5: Sol-gel transition of glucose-sensitive dextran and conA gel. Key- Large 
circles represent cross-section of conA, small closed blue circle represent dextran chain 
terminal glucose and open blue circle represent glucose.  
 
2.1.3 Insulin formulation 
The insulin solution contained in the device reservoir is another essential part of the 
device system. Commercially available high concentration insulin formulations which 
have been stabilised with phenol or m-cresol are required to minimise the device 
refilling cycles. 
 
A different working device type designed with double the surface area called the 
“modified works-like” (double sided device design) was used for the pig experiments 
to increase the amount of insulin delivered. It was difficult to predict if the initial 
prototype (interim working prototype as described earlier) would output enough 
insulin for a diabetic pig even with the maximum concentration commercially available 
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(500 IU/mL) insulin preparation. The difficulty in prediction was because of the 
following reasons;  
 Previous in vitro simulations suggested that output would be suitable but the 
bulk receptor fluid conditions are inevitably different from the peritoneum in 
which the device is in contact with fluid but not immersed. Delivery in vivo was 
lower than the in vitro output suggested. 
 Insulin solubility: At high concentrations of 500 IU/mL, the formulation is 
stabilised by phenol or m-cresol. The phenol is not merely present as a bacterial 
preservation but also as an agent which complexes with insulin molecule. This 
produces a stable hexamer that is soluble at higher concentrations than if phenol 
were not present. The phenol concentration could drop below the critical 
concentration over time through device material absorption or diffusion out of 
the reservoir.  
 Also, the physical and chemical stability of insulin could be compromised by 
even marginal pH fluctuations.  
 
A third prototype called the “advanced looks-like” was built to depict a clinically 
acceptable appearance (refer to Figure 2-6). The design conveys simplicity of shape, 
comfort, ease of sterilisation, suggests simpler surgery, the slot-in cartridge of gel, and 
the economy of the dual lumen refill plumbing that will interface with a standard but 
slim low-profile dual port such as the Bard type pictured below right. 
 





The interim working prototype and modified works-like models are the working 
models designed to be assembled and dissembled repeatedly for experiments, though a 
little bulky and less sleek than the future implantable advanced looks-like prototype.  
The interim working prototype was used in in vitro experiments presented in this thesis. 
The device was too bulky for use in in vivo because it has a substantial lid that fits a 
bespoke spanner and it has luer connections angled to the back for filling, all of which 
were later improved, however it is a good working prototype.  
 
In vitro testing with the device 
Some in vitro testing of the device have been performed in the past using tartrazine dye. 
Tartrazine was used because of its availability, its cost, its stability, its compatibility 
with the gel; and its ease of UV/Vis. assay for repeated readings. In these early studies a 
non-polymerised gel with a 3 mm path length and 10 mm diameter, was used. It was 
found to respond to a 1% glucose challenge with a prompt but sustained fourfold 
increased rate of dye delivery when tested in vitro. The pathlength and gel concentration 
influenced the magnitude of response with high gel concentrations producing osmotic 
gel swelling. 
 
2.2 In vivo performance in animal models 
 
In vivo study in rats 
A recent study in diabetic rats assessed the feasibility of a simple device version of the 
intraperitoneal (IP) implantable closed-loop insulin delivery device. The performance of 
the system was compared over time in diabetic rats with a control system. The protocol 
involved using oral glucose challenges and daily assessments of BG and body weight. 
The automated response regimen of the active system was quantified by comparison 
with IP multiple dose injection (MDI) results in the same rat model. Successful control 
was found for the device containing active gel when assessed daily and when 
challenged with large glucose doses in comparison with an inactive gel analogue as a 
36 
 
control. The device was well tolerated and was found to operate to further advantage 
when vascular omentum grew into the perforated front of the device. The response from 
the device was estimated at outputting approximately 0.5 IU/kg/h basal with 2 IU/kg 
boosts in order to match the demand of the challenges. The seemingly high response 
from the device could be attributed to a higher metabolic rate in rats than humans and 
hence requiring a higher wgt/wgt dose. The device eventually did exhaust and hence 
highlighted the need for a refill mechanism in future device models (Taylor, Tanna and 
Sahota, 2010b).  
 
In vivo study in pigs 
Following the study in rats, the next steps were to scale the device to be relevant for 
humans. To this end, the device engineered with filling circuit was surgically implanted 
in the domestic pig. For both rats and pigs, the diabetic model closely simulates human 
diabetes. The weight for weight insulin requirements for rodent is higher than humans 
but for pigs is the same. The study was approved by the respective ethical committees to 
be conducted on 10 pigs in two sites, Nottingham and Huntington. The study was 
conducted at the Nottingham site on ten animals in total, four were used to develop the 
surgery, two were used to implant single sided device design and check dose by 
injection and four received the double sided device design. Of the four that received the 
double sided device, one died of peritonitis, one did not become diabetic and two 
responded to the insulin, one perfectly and one sub-optimally. 
Surgery was developed and streptozotocin was used to induce diabetes in pigs and they 
were observed to ensure that blood glucose levels reached at least 33 mmol/L. The 
device was filled with insulin solution in situ using the subcutaneous port and the 
animal was observed for several weeks, during which time there was normal access to 
food and water. During this time the pig was given several oral glucose challenges.  
The study showed that blood glucose levels dropped from >33 to under 10 mmol/L five 
days after filling the device. Glucose challenge responses improved so that ultimately 
the blood glucose (BG) peak was 18 mmol/L and normalised about half an hour 
afterwards, contrasting with attempts to control the diabetes by intravenous insulin 
injections. The residual reservoir insulin solution was removed after 10 days of good 
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glycaemic control and diabetic BG levels >33mmol/L (>600 mg/dL ) occurred only 
after a further 24 days implying a depot of insulin had remained after removal of the 
reservoir solution. About 62.5 IU per 24 hours was needed to control the diabetes 
including the increased output needed to control the large oral glucose challenges 
implying the successful operation of the automatic bolus system, with no manual 
intervention needed. Using information from injected insulin and the observation that 
the pig ate its food about eight times daily, it was calculated that this translates to a 
basal dose of about 1.3 IU/h and boost doses of about 3.9 IU. The inference from the 
study was that the implantable device controlled the basal and bolus needs for more 
than four weeks without any manual insulin adjustment, including a period where 
residual insulin in the gel acted as a depot source. The implanted system eventually 
caused peritonitis (because of abrasion) after several uneventful weeks but 
improvements in how and where the device is located are planned to solve this. 
Another interesting finding from the pig experiment was with regards to the gel 
pathlength in the device. When the single sided device was initially used in vivo in the 
pig, there was almost no observed effect after filling the insulin reservoir; this could be 
due to a much longer in vivo lag time with the 3 mm gel path length. Hence, the 
delivery device was modified to a double sided system and the path length was reduced 
by half.  The gel path length is very important in the design of reservoir delivery devices 
because it affects both the lag time and the steady state flux. In the experiment where 
the path length was 1 mm the lag time was apparently 5.5 days, given that following the 
fill, the BG had settled to its lowest point by that time and that a steady-state BG plateau 
was established. In theory lag time is proportional to the square of the path length and 
this suggests that the lag time for a 1.5mm path would be (1.5)
2
 x 5.5 = 12.3 days. 
Interestingly, the effect of the extra dose in one of the pigs where the gel pathlength was 
1.5 mm started to have an effect about 12 days after its administration and supports this 
analysis. For the 3mm path used in the initial pig where no response was observed, the 




2.3 What are the next steps for this device? 
A recent survey was undertaken by the INsmart group to determine both positive and 
negative experiences of T1DM patients currently using open-loop continuous 
subcutaneous insulin infusion (CSII) pumps to ascertain their interest in and to define 
the desirable performance characteristics from the implantable closed loop insulin 
pump, INsmart. Most respondents with T1DM diabetes with well controlled blood 
glucose, based on self-reported HbA1c results reported a reduction in this value after 
transferring to CSII from multi-dose injections. However, 70% of pump users 
experienced more than three hypoglycaemic episodes per week. 80% reported self-
measured BG values above 10mmol/L three or more times per month. The majority of 
respondents felt that the current external insulin pumps had a number of disadvantages 
such as their constant visible presence, rotation of insertion sites and skin inflammation. 
The INsmart pump is implanted in the peritoneal cavity and works on instant feedback 
mechanism for controlling insulin release just like a normal pancreas would, hence 
could easily overcome the highlighted limitations of an external pump (Taylor et al., 
2014) and there clearly is a interest and willingness from T1DM sufferers to accept an 
implantable closed-loop device as part of their treatment strategy.  
The animal studies have highlighted the need to understand the design capabilities of 
the device with respect to insulin delivery mechanism and kinetics to gain confidence in 
the performance of the device. The aim of this work was to investigate and understand 
some key device reliability and performance related aspects.  
 
Reliability and Performance 
The INsmart implantable insulin delivery device aims to mimic pancreas, by monitoring 
the change in BG levels and achieving real-time responses and coping with the BG 
variations with basal and bolus doses. The next goal in the development of the INsmart 
device is human clinical trials. The following device reliability and performance related 
aspects were investigated in this work; 
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Insulin formulation stability and compatibility with device materials  
As discussed in Chapter 1, Section 1.3.2, insulin is inherently quite unstable, given to 
degradation mediated by both chemical and enzymatic means. In addition, the physical 
stability of solutions is a problem so that although phenols, surfactants and other 
stabilisers are used, the tendency to aggregate, precipitate and crystallise is a problem 
that limits the use of insulin formulations for purposes such as pumps. Though 
commercially available insulin formulation was used within the implantable device, its 
stability will be subjected to some of the deleterious influences mentioned above.  
Aggregation of aqueous insulin solutions is still a serious obstacle in the development of 
stable formulations for delivery devices (Florence, 2010).  A number of factors have 
been implicated as having an effect on insulin aggregation which lead to plugging of the 
devices namely, abrupt changes in flow path, motion, elevated temperatures, metal ion 
contamination, impure insulin formulations, CO2 diffusion, pH drop, dissimilar metal 
pump components, salt concentration, inappropriate diluents, refrigeration temperatures, 
processing, insulin heterogeneity, and buffering systems (Lougheed et al., 1980). A 
study  by Fiengold et al on the effect of contact material on vibration induced insulin 
aggregation tested a number of materials suitable for pump reservoirs which included 
metals (stainless steel, titanium and a titanium alloy) and various plastics 
(polypropylene, polytetrafluoroethylene, polyvinylchloride PVC, polyamide, cellulose 
butyrate and silicone elastomer) (Feingold, Jenkins and Kraegen, 1984). The study 
findings showed that insulin solution delivered through the PVC infusion set showed 
reduction in preservative content to less than 30% of initial content and an increased 
chemical transformation product formation. However, polyethylene PE infusion system 
showed a minor decrease in preservative content and no increase in chemical 
transformation. The study also highlighted the effect of the method of sterilization 
performed on PVC and PE catheters on the chemical stability of insulin solution. 
Gamma irradiated PVC catheters were markedly harmful to insulin solution (gamma 
irradiation could potentially break the polymer chains), while the ethylene oxide 
sterilization (which has the potential of absorbing into the material) did not affect the 
chemical stability of insulin. Silicone rubber has been found to be the most active in 
promoting insulin aggregation of all the medical grade materials likely to be used in 
pumps(Lougheed et al., 1983). These studies have highlighted the fact that careful 
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selection and combinations of insulin formulation and materials can minimise insulin 
aggregation and denaturation, it also highlighted the need for testing of the proposed 
reservoir components and insulin formulations with an aim to detect denaturation in 
solution and precipitation of insulin. 
Chapter 3 covers a study performed to understand the stability of insulin formulation 
and compatibility with each of the material used in the device over a period of a month. 
This was done by monitoring the loss of insulin and formation of degradants by reverse 
phase high performance liquid chromatography (RP-HPLC) over a period of a month.  
 
Insulin delivery mechanism and kinetics 
For the in vitro diffusion experiments performed to understand insulin delivery 
mechanism and release profiles from the device, insulin was fluorescently labelled with 
fluorescein isothiocyanate (FITC) to improve its detection and for quick quantification 
purposes. The details of the synthesis and identification of the FITC-insulin conjugates 
produced are presented in Chapter 4. Clinically used insulin analogue formulations 
were also fluorescently labelled and conjugate species produced were identified.  
The aim of the device is to mimic the real-time response in human. Based on the design 
of the INsmart device (interim working prototype) the various factors that could be 





Table 2-1: Factors affecting insulin delivery from the device.  
Factors responsible for inappropriate insulin delivery affect 
Factor Affects 
Device wrong place  Correct positioning of the implanted device is vital for the 
performance. Device needs to be in contact with an 
appropriate fluid and facing a permeable membrane. 
Device leak This would result in insulin overdose. 
Device blockage This would result in insufficient insulin dose. 
Gel Thickness Thicker gel means increased pathlength which will result 
in greater lag time before insulin is released from device. 
Very thin layer of gel can alter the uniformity of the gel 
thickness and thus affect the release kinetics. 
Insufficient insulin in 
reservoir 
This will affect the diffusion kinetics and hence affect the 
delivery rates. 
Area  Based on Fick’s law of diffusion, the rate of diffusion is 
directly proportional to the area available for insulin to 
diffuse through. 
Gel polymer content  Polymer content inversely affects the diffusion coefficient 
of insulin. Higher polymer content will result in lower 
diffusivity and lower polymer content will result in higher 
diffusivity. 
Gel response time  The response time is affected by gel characteristics or 
polymer content. 
 
One of the main factors affecting the insulin delivery from the device is the response of 
the gel to glucose levels. The intensity and the duration of the glucose trigger also 
influence the recovery of the gel. This highlighted the need to understand the insulin 
release kinetics from the device. The diffusion of insulin and glucose through the gel 
was determined. This was achieved by using model dyes and gel initially to develop an 
experimental protocol for selection of an appropriate mathematical model for measuring 
diffusion. The development of the experimental protocol for measuring diffusion is 
presented in Chapter 5.  
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The design of the INsmart device for the management of diabetes is based on the small 
changes occurring in the glucose responsive gel in response to the diabetic 
physiological glucose levels and its corresponding ability to modulate the diffusion of 
insulin through the material. Glucose sensitivity of the gel which forms the basis of the 
insulin delivery mechanism of the gel was assessed by rheological testing of the gel 
which is presented in Chapter 6.  
The diffusion kinetics of FITC-insulin conjugate through the gel and its response to 
glucose triggers are presented in Chapter 7.  
 
Predicting the performance of the INsmart device 
The importance of knowing the mechanism and kinetics lies in getting the dose right for 
each challenge but also in predicting the service intervals and what affects these. The 
service intervals apply to the gel and the insulin in the reservoir, the intervals at which 
the gel would need to be replaced and the insulin solution replenished. 
Long term stability studies have been performed on the biomaterial within the INsmart 
group which has given confidence in the long term performance capability of the gel 
(Sahota and Taylor, 2013). Acrylic polymerised gels and also dextran and concanavalin 
A at 20 and 37°C when stored with and without 0.1%w/w glucose have shown by 
rheological characterisation to have a stable complex viscosity for over 730 days 
indicating that over time they do not undergo degradation. Gel integrity in presence of 
chymotrypsin contained in dialysis membranes of 50kDa were found to be resistant to 
degradation over long term (>500 days). Thus giving confidence in the gel stability and 
integrity for use in the INsmart device. 
When considering the use of device in humans, one of the fundamental questions that 
needs to be answered is how long the insulin in the reservoir will last and how 
frequently it will need to be replaced. The service intervals for the insulin formulation in 
the reservoir would depend on the insulin concentration and volume in reservoir. The 
depletion of the insulin in the reservoir and replacement strategies depends on daily 
insulin consumption by the individual with diabetes. This consumption depends on a 
number of factors such as onset, peak and duration of action, patient factors such as 
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individual variations in insulin absorption affecting the basal dose required, levels of 
exercise and types of meals consumed. An idealised insulin release profile from the 
device should mimic the natural pattern of insulin release from a normal pancreas in the 
human body. Chapter 8 focuses on using the insulin diffusion kinetic data to make so 
theoretical estimations regarding the performance of the INsmart device. 
 
The following key questions with respect to reliability and performance of the device 
are investigated in this work; 
1. What are the factors that affect the stability of insulin in the device? 
2. How stable is the insulin formulation with the materials used in the device? 
3. What is the mechanism (pharmacokinetics) of insulin delivery from the INsmart 
device? 
4. What are the diffusion coefficient values of insulin through the glucose responsive 
gel? 
5. Does the gel respond to glucose triggers? 
6. How does gel pathlength affect insulin release rates? 
7. Is the device capable of delivering the daily insulin requirement (basal insulin 
amounts)? 
8. Can the device deliver post-prandial insulin doses (bolus amounts) and how fast? 
9. Should alternative device geometries be explored? 






Chapter 3.Insulin solution stability and 
compatibility with current and potential 
INsmart device materials 
 
3.1 Introduction 
The stability of insulin in solution is essential for the efficacy of therapeutic 
preparations used in continuous pumps and controlled release polymeric devices. The 
efficacy of insulin solution can be significantly reduced by a number of chemical 
changes of its primary structure yielding insulin derivatives and physical modifications 
of the secondary and quaternary structures resulting in denaturation, aggregation and 
precipitation. These chemical and physical changes lead to drastic reduction of 
biological potency and obstruction of delivery routes, creating serious problems for 
drug delivery systems (Brange and Langkjaer, 1993). The general modes of physical 
and chemical instabilities of insulin in solution and the factors that promote them have 
been discussed in detail in Chapter 1. 
The importance of investigating insulin aggregation in an environment which is relevant 
to the implantable delivery system has been discussed in Chapter 2. The most relevant 
factors for investigation include; effect of body temperature, vibration and contact with 
the reservoirs’ material. Undesirable aggregation of aqueous insulin solutions is still a 
serious obstacle in the development of stable formulations for delivery devices. Careful 
selection and combinations of insulin formulation and materials have been shown to 
minimise insulin aggregation and subsequent precipitation. This further highlights the 
need for testing the proposed reservoir components and insulin formulations with an 
aim to detect insulin precipitation in solution (Sluzky, Klibanov and Langer, 1992; 
Melberg et al., 1988; Feingold, Jenkins and Kraegen, 1984; Lougheed et al., 1983). In 
order to design and develop the implantable artificial pancreas, INsmart device, its 
materials need to be biocompatible not only with the surrounding tissue but also 
internally they need to be compatible with the novel glucose responsive gel and insulin.  
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Presented below is a brief description of insulin and its degradants and the analytical 
methods investigated to determine them. 
 
3.1.1 Stability of insulin in solution 
Insulin like many other proteins is not very stable in solution and is liable to 
modification by chemical reactions with molecules in its vicinity; chemical stability for 
insulin has been discussed in Chapter 1. During storage and use, insulin in  
pharmaceutical preparations deteriorate by two main chemical reactions; deamidation 
due to hydrolytic reactions and polymerisation due to formation of intermolecular 
covalent bonding with other insulin molecules to form higher molecular weight 
transformation products (Fisher and Porter, 1981; Oliva, Fariña and Llabrés, 1996). 
Both mechanisms accelerate at higher temperatures. Here, insulin deterioration due to 
the chemical transformation mechanism of deamidation was investigated. 
Deamidation of Asn residues is one of the most common protein degradation pathways, 
and has been used as a marker for the stability of protein drugs (Bischoff and Kolbe, 
1995). Deamidation, the most prominent nonenzymatic degradation reaction of insulin, 
occurs due to loss of the amide –NH2 groups. Insulin has six residues that are potential 












 (glutamine (Gln) 
residues at positions A5, A15, B4 and asparagine (Asn) residues at A18, A21 and B3). 
The Asn residues are more prone to deamidation than the glutamine residues. These 
positions do not play any part in the immunogenicity of the insulin molecule; hence 
formation of desamido insulin does not affect the potency of insulin (Fisher and Porter, 
1981).  
In acid solutions, pH <2, direct hydrolysis of the side chain amide leading to 
deamidation at residue Asn 
A21
 (Sundby, 1962), generates aspartate as the sole product 




This changes charge and hydrophilic/hydrophobic properties of insulin which are the 
key forces controlling its tertiary structure and responsible for its biological activity. 
In neutral solutions, deamidation primarily occurs at residue Asn
B3
 but at a reduced rate. 
Deamidation of Asn
B3
 and hydrolysis of the peptide bond between residues A8 and A9 
leads to the formation of a mixture of isoAsp and Asp derivatives (B3 desamido insulin) 
(Brange et al., 1992b; Nilsson and Dobson, 2003).  
This deamidation mechanism (beta-aspartyl shift mechanism) primarily occurs through 
intramolecular rearrangement as shown in Figure 3-1. Whereby an intermediate five-
membered cyclic succinimide (A) is formed due to the peptide bond nitrogen (reactive 
anion) of the N+1 amino acid attacks the carbonyl carbon of the asparagines or asparate 
side chain. The succinimide is then rapidly hydrolysed to yield iso-asparate (beta-
asparate) and asparate in a ratio of approximately 3:1 (Yomota et al., 1996).  
 
Figure 3-1:  Mechanism of deamidation of insulin residue Asn
B3
 under neutral 
conditions (taken from http://www.ionsource.com/Card/Deamidation/deamidation.htm). 
 
The rate limiting step for formation of B3 desamido insulin is the rate of cyclic 
succinimide intermediate formation; which is highly temperature dependent and pH 
dependent, more alkaline pH increases deprotenation of peptide bond hydrogen and rate 
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of succinimide formation. However, the ratios at which the two B3 derivatives 
(isoAsp/Asp) are formed are independent of time and temperature but vary with the type 
of formulation e.g. whether the formulation is a neutral suspension of crystals, or 
amorphous insulin, or neutral solution containing phenol or cresol. Thus the maximum 
stability against deamidation is at around pH 6, where reaction is 5 to 10-fold slower 
than at pH 7.4. The physical and chemical deterioration of insulin is almost entirely 
governed by the capacity of the B-chain terminals to undergo the structural changes 
necessary for these reactions to take place. By careful formulation e.g. addition of 
phenol or zinc ions the insulin molecules can be constrained (by forming hexamers) and 
their flexibility and tendency to disassemble reduced thus making them less prone to 
fibrillation and chemical degradation, these formulations are neutral hexameric 
solutions that dissociate into monomers on injection and are rapidly absorbed, hence the 
peritoneal pH of approximately 7.6 do not aid deamidation. 
 
3.1.2 Determination of insulin and its degradants 
A review of the literature highlights several immunoassay and non-biological analytical 
methods for the determination of human insulin in in vivo and in vitro conditions. 
Immunoassays reported include enzyme (Bürgi et al., 1988), electrochemiluminescence 
(Sloan et al., 2012; Cassidy et al., 2012), gravimetric and radiolabel immunoassay 
(Dezier et al., 1987) just to name a few.  Other than these, capillary electrophoresis 
(Staub et al., 2010; Yeh et al., 2010), high performance liquid chromatography (Mohd 
Hafiz et al., 2013; AbuHeshmeh et al., 2013), liquid chromatography-tandem mass 
spectrometry (Chen et al., 2013), size exclusion chromatography (Tantipolphan et al., 
2010) have also been widely used for determination of human insulin. 
Oliva et al have discussed reverse phase high performance liquid chromatography (RP-
HPLC) and size exclusion chromatography (SEC) HPLC methods for the analysis and 
characterisation of insulin and its degradation products in pharmaceutical preparations. 
The results of the validation procedure showed that their methods were specific, precise, 
reproducible and robust. The RP-HPLC method used by them for the determination of 
both A21 and B3 desamido insulin degradants however was able to detect these 
degradants only in samples stored under stress conditions of high temperatures (60°C 
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with shaking or in suspension samples at 50°C without shaking)(Oliva, Fariña and 
Llabrés, 2000).  
RP-HPLC is now a technique of choice used to separate proteins based on their 
hydrophobicity, where the hydrophobic interactions between the column packing and 
the hydrophobic regions of the protein are exploited (Aguilar, 2004). RP-HPLC is the 
most used analytical method for separation and determination of peptides and proteins 
in an extensive range of applications and is considered to be the most suitable method 
for meeting most of the criteria for quantitative analysis within the pharmaceutical 
industry (Crowther, 2001). This analytical technique has been widely used to develop 
and validate simple, rapid, accurate and specific method with short run times for 
determination of insulin in both artificial and biological environments (Mohd Hafiz et 
al., 2013; Rajan et al., 2006; AbuHeshmeh et al., 2013; Sarmento et al., 2006). Most of 
these determinations of insulin control the degree of ionisation on insulin by using a 
mobile phase with low pH or high salinity.  
The official monographs (USP 26 and BP 2014, Ph. Eur. Monograph 0854) detail 
HPLC methods for the assay of insulin for “Insulin preparations”. They provide 
information about potency (evaluated by assay by comparison with certified standard), 
purity (quantification of related proteins) and presence of covalent aggregation products 
(with molecular masses greater than that of insulin). The Pharmacopoeia limits and 
specifications for the insulin preparations are: A21 desamido insulin is not greater than 
5% of total area of peaks, sum of area of other peaks apart from those due to insulin and 
A21 desamido insulin is not greater than 6% of the total peak areas. Impurities with 
molecular masses greater than that of insulin: not greater than 2% of total area of peaks 
(British Pharmacopoeia Volume III, 2014). The liquid chromatography method 
described in the official BP for the assay of human insulin and detection of its A21 
desamido human insulin is a gradient method and has a run time of 50 min while the 
official USP HPLC method for analysis of human insulin has even longer run time of 90 
min. 
For the purposes of the present project it is important to determine the loss of insulin 
and also detect formation of degradants in an environment which is relevant to the 
49 
 
implantable device, therefore sensitive methods which can detect insulin and the two 
desamido insulin are required. 
An isocratic HPLC method used by Moslemi et al (Moslemi, Najafabadi and 
Tajerzadeh, 2003) uses an ion-pairing reagent, tetraalkylammoniumhydroxide to acquire 
peaks with better resolution. However it was found that in the reported method A21 
desamido was prepared by storing human insulin in 0.01MHCl at 40°C for 48 hours in 
order to detect it and also the peak appeared very close to the human insulin peak.  
The RP-HPLC acidic analytical method validated and used in this project for 
determination of insulin and A21 desamido insulin is an isocratic method with a short 
analysis time (30 mins) and sensitive to detect small amounts of A21 desamido insulin. 
The usual reported acidic HPLC method (like the ones discussed above) allows the A21 
peak to be well separated, but the B3 desamido peak is usually included in the main 
insulin peak. Contrasting with acidic analytical methods, Yomota et al have developed a 
HPLC method for separation of B3 desamido insulin by using pH stable octadecylsilyl 
(C18) column and an alkaline eluent (0.1M phosphate buffer pH 9.0 containing 26% 
acetonitrile), by which two peaks corresponding to B3 desamido insulin derivatives 
(isoAsp/Asp) were eluted in front of the insulin peak. These results were in agreement 
with capillary zone electrophoresis method used to separate human insulin and A21 and 
B3 desamido insulin (Yomota et al., 1996). The RP-HPLC neutral analytical method 
used for this project was based on this study. A C18 column from Phenomenex and an 
alkaline mobile phase at pH 7.4 was used for the determination of insulin and B3 
desamido insulin. 
Thus two RP-HPLC methods, the acidic and neutral analytical methods were used for 
the determination of insulin and its desamido insulin degradants. 
A RP-HPLC method for the determination of fluorescently labelled insulin (FITC-
insulin) was also investigated for identification of the synthesised FITC-insulin 
conjugates and for material compatibility studies using FITC-insulin. The FITC-insulin 
method used for the determination of FITC-insulin conjugates was as described in the 
published paper by Hentz et al (Hentz et al., 1997).  
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Thus the following three RP-HPLC methods were developed; 
1. Acidic analytical method for determination of insulin and A21 desamido insulin 
2. Neutral analytical method for determination of insulin and B3 desamido insulin  
3. FITC-insulin method for determination of FITC-insulin conjugates 
 
This chapter has two sections; the first presents the validation results for the three 
methods and demonstrates the suitability of these methods for determination of insulin 
and its degradants and FITC-insulin conjugates. The second section presents the results 
from compatibility studies of insulin with various device materials that were used for 
the in vitro studies and was used/or have a potential to be used as part of an in vivo 
device. 
 
3.2 Materials and Methods  
 
3.2.1 Chemicals and reagents 
Humulin® R (Hum R) 500 IU manufactured by Eli Lilly and Co was used. Diluting 
fluid manufactured by Novo Nordisk was used. HPLC grade acetonitrile, sodium 
dihydrogen phosphate, disodium hydrogen phosphate, ortho-phosphoric acid and 
ethanolamine were purchased from Fischer Chemicals, Loughborough, UK. Nylon 
membrane filters, 0.45µm, 47 mm were purchased from Whatman International Ltd, 
England. Distilled water was used. FITC-insulin synthesised in-house (synthesis as 
discussed in Chapter 4) was used. 
 
3.2.2 Preparation of Humulin R standards 
The Hum R standard solutions from 50 to 500 IU/mL (50, 100, 150, 200, 250, 300, 350, 
400, 450, 500 IU/mL) were prepared by dilution of the standard stock solution with 
diluting fluid. A calibration graph was constructed in the range of 50 to 500 IU/mL for 




3.2.3 Preparation of FITC-insulin standards 
A standard stock solution containing FITC-insulin was prepared in distilled water at a 
concentration of 5 mg/mL and pH was adjusted to 7.6. The standard solutions from 
0.025 to 5 mg/mL (0.025, 0.05, 0.10, 0.15, 0.20, 0.25, 0.50, 1, 3, 5 mg/mL) were 
prepared by dilution of the standard stock solution with distilled water (pH 7.6). A 
calibration graph was constructed in the range of 0.025 to 5 mg/mL for FITC- insulin 
(n=6).  
 
3.2.4 RP-HPLC Chromatographic system  
The chromatographic analyses were performed using a Shimadzu Prominence HPLC 
system consisting of an in-line DGU-20AS Prominence degasser, LC-20AD 
Prominence quaternary pump, SIL-20A Prominence auto sampler, CTO-20AC 
Prominence column oven, SPD-M20A Prominence diode array detector and RF-10AXL 
Fluorescence Detector for detection of fluorescent peaks. 
 
3.2.5 Acidic analytical method for determination of insulin and A21 
desamido insulin degradant. 
A Jupiter 5 µ C18 300 Å, 250 × 4.6 mm column from Phenomenex, Cheshire UK was 
used for the separation preceded by a 0.5mm in-line filter and a widepore C18 4 × 3 mm 
guard column. For detection of insulin and degradant Asn 
A21 
desamido insulin an acidic 
mobile phase was used. The mobile phase consisted of 74:26 (v/v) aqueous sodium 
sulphate pH 2.3: acetonitrile. The aqueous sodium sulphate solution was prepared by 
dissolving 28.4 g/L sodium sulphate in distilled water. 2.7 ml ortho-phosphoric acid was 
then added and the pH adjusted to 2.3 with ethanolamine. The aqueous solution was 
filtered through nylon membrane of 0.45 µm pore size. Elution was isocratic with a 
flow rate of 1.5 mL/min, a column temperature of 40 °C and sample injection of 20 µl. 
The detector was set to scan from 190 to 400 nm and had a channel set at 215 nm to 




3.2.6 Neutral analytical method for the determination of insulin and B3 
desamido insulin degradant. 
A  Jupiter 5 µ C18 300 Å, 250 × 4.6 mm column from Phenomenex, Cheshire UK was 
used for the separation preceded by a 0.5 mm in-line filter and a widepore C18 4 × 3 
mm guard column. The mobile phase consisted of 73:27 (v/v) 0.1 M sodium phosphate 
buffer pH 7.4: acetonitrile. 0.1 M sodium phosphate buffer was prepared by dissolving 
3.5 g/L of sodium dihydrogen phosphate and 13.8 g/L of disodium hydrogen phosphate 
in distilled water and pH adjusted to pH 7.4. The buffer was filtered through nylon 
membrane of 0.45 µm pore size. Elution was isocratic with a flow rate of 1.5 mL/min, a 
column temperature of 40°C and sample injection of 20 µl. The detector was set to scan 
from 190 to 400 nm and had a channel set at 215 nm to detect insulin and its 
degradation product. 
 
3.2.7 FITC-insulin method for determination of FITC-insulin conjugates. 
A Luna (3 µ) C18 (2) 100 Å, 150x4.60 mm column from Phenomenex, Cheshire UK 
was used for the separation preceded by a 0.5mm in-line filter and a widepore C18 4 × 3 
mm guard column. Elution was using a gradient method using mobile phase A; 0.1% 
trifluoroacetic acid (TFA) in water and mobile phase B; 90% acetonitrile and 10% water 
containing 0.1% TFA with a flow rate of 1.0 mL/min, a column temperature of 40°C 
and sample injection of 20 µl. The following gradient was used: 0-15 min (85% to 
65%A), 15-25 min (65% to 35%A), and 25-32 min (35%A).  
The peaks were monitored by fluorescence detection where the excitation and emission 
wavelengths were set at 494 and 518 nm, respectively. The photo diode array detector 
(PDA) was also set to scan from 190 to 400 nm and had a channel set at 215 nm to 




3.3 Validation  
 
3.3.1 Method validation parameters 
The three methods were subjected to an assessment of validation capabilities and was 
based on the FDA guidance document – ‘Guidance for Industry, Q2B Validation of 
Analytical Procedures: Methodology’ ( FDA Guideline for Industry Q2B Validation of 
Analytical Procedures: MethodologyID - 1524 1997). This Guidance was developed 
within the Expert Working Group (Quality) of the International Conference on 
Harmonisation of Technical Requirements for Registration of Pharmaceuticals for 
Human Use (ICH) and has been subject to consultation by the regulatory parties in 
accordance with the ICH process. The guidance document is complementary to the ICH 
guidance entitled ‘Text on Validation of Analytical Procedures (ICH Q2A)’. The 
objective of validation of these three analytical methods is to demonstrate their 
suitability for the intended purpose. In accordance with the ICH guidelines a design of 
experiment approach was utilised in order to provide a sound, overall knowledge of the 
validation capabilities. 
Validation capabilities such as Selectivity, System suitability, Linearity, Range, 
Accuracy, Precision and Detection and Quantitation limits, as detailed in the FDA 
guidance, for the three RP-HPLC methods were determined and are presented below. 
For detailed FDA guidance acceptance criteria and details for each parameter, refer to 
Appendix 1.  
 
Selectivity 
To demonstrate selectivity of the RP-HPLC methods a diluting fluid which contained 
the same excipients as those present in HumR without human insulin was used.  
Diluting fluid and HumR were injected into the HPLC system under the optimised test 
conditions and corresponding chromatograms were recorded. Representative 
chromatograms were generated to show that excipients present in the diluting fluid were 





The system (integral system which comprises of the equipment, electronics, analytical 
operations and samples to be analysed) suitability for the three methods was assessed by 
six replicate analyses of HumR and FITC-insulin at a selected concentration. The 
acceptance criterion from the guidance referred to above was ±2% for percent relative 




A series of standard solutions containing 50-500 IU/mL of HumR (10 concentrations) 
and 0.025-5.0 mg/mL of FITC-insulin (10 concentrations), sample volume of 20 µl each 
were analysed using the method-specific chromatographic conditions described in 
Section 3.2. Calibration plots from six replicate experiments were constructed for 
HumR standard solutions and FITC-insulin solutions by plotting the concentration of 
compounds versus peak area response (area under peaks, AUP). The regression equation 
was calculated from the calibration curves, along with the standard deviations of the 
slope and intercept on the ordinate. 
 
Range 
The concentration range, within or at the extremes of which the three analytical methods 




Accuracy is defined as the closeness of the agreement between a test result and the 




Accuracy of the methods was determined by injecting four different concentrations, 
with three replicate each, of HumR and FITC-insulin into the HPLC system. The same 
procedure as described for linearity was followed. AUP for each insulin solution was 




Precision of an analytical method expresses the closeness of agreement between a series 
of measurements obtained from multiple sampling of the same homogenous sample 
under the prescribed conditions (Crowther, 2001). 
Precision of the assay was determined by repeatability (intra-day) and intermediate 
precision (inter-day) by injecting four different concentrations, with three replicate each, 
of HumR and FITC-insulin into the HPLC system. Repeatability which refers to the use 
of the analytical procedure within a laboratory over a short period of time was evaluated 
by assaying the samples the same day. Intermediate precision was assessed by 
comparing the assays on different days using different insulin standards, using freshly 
prepared mobile phase. The AUPs were recorded and RSD % was calculated. 
 
Detection and Quantitation limits (Sensitivity) 
Limits of detection (LOD) and quantitation (LOQ) were calculated based on standard 
deviation of the analytical response represented by AUP (for the lowest concentration 
used) and slope of the calibration curve. The following equations Equation 3-1 and 
Equation 3-2 were used;  
         
 
 
 Equation 3-1 
 
        
 
 
 Equation 3-2 
Where σ is the standard deviation of the response and S is the slope of the calibration 




3.3.2 Results and Discussion 
Validation capabilities; selectivity, system suitability, linearity, range, accuracy, 
precision and detection and quantitation limits for the three RP-HPLC methods were 
assessed and results are as discussed below. For the FITC-insulin method the validation 
results for only the di-labelled FITC-insulin conjugate are presented here, the mono and 
tri-labelled conjugates gave similar results. 
 
Selectivity 
The developed RP-HPLC acidic analytical method, under the chromatographic 
conditions, achieved a run time of 30 minutes with elution of HumR insulin at Rt of 
13.3 min, m-cresol at Rt 5.6 min and degradation product A21 desamido insulin at Rt 
24.1 min. The comparison of the chromatograms of the placebo and HumR revealed 
that there were no additional peaks co-eluting with the peaks of insulin and A21 






                
Figure 3-2: RP-HPLC chromatogram using the acidic analytical method of (1) Placebo 
(diluting fluid), a: m-cresol peak at Rt 5.6 min and (2) HumR (400 IU/mL), a: m-cresol 
































































The developed RP-HPLC neutral analytical method, under the chromatographic 
conditions, achieved a run time of 30 minutes with elution of HumR insulin at Rt of 
16.6 min, m-cresol at Rt 5.4 min and degradation product B3 desamido insulin at Rt 
12.6 min and Rt 13.4 min. The comparison of the chromatograms of the placebo and 
HumR revealed that there were no additional peaks co-eluting with the peaks of insulin 
and B3 desamido insulins, refer to Figure 3-3.  
 
 
Figure 3-3: RP-HPLC chromatogram using the neutral analytical method of (1) Placebo 
(diluting fluid), a: m-cresol peak at Rt 5.4 min and (2) HumR (400 IU/mL), a: m-cresol 
peak at Rt 5.4 min, b: B3 desamido insulin peaks at Rt 12.6 and 13.4 min, c: insulin 













































The RP-HPLC FITC-insulin method has shown that FITC-insulin had mono-labelled 
FITC-insulin conjugate peak with Rt of 21.8 min, di-labelled FITC-insulin conjugate 
peak with Rt 22.5 min and tri-labelled FITC-insulin conjugate peak with Rt 23.5 min 
(refer to Figure 3-4). This has been determined and confirmed using RP-HPLC and MS 
as discussed in Chapter 4.  
 
 
Figure 3-4: RP-HPLC chromatogram of FITC-insulin (5 mg/mL) using the FITC-
insulin method, a: mono-labelled at Rt 21.8 min, b: di-labelled at Rt 22.5 min, c: tri-
labelled FITC-insulin conjugate at Rt 23.5 min. 
 
System suitability 
The system suitability results for the acidic, neutral and FITC-insulin methods are as 





























Table 3-1: System suitability study of HumR (concentration 200 IU/mL) using acidic 
analytical method for determination of insulin and its A21 desamido insulin degradant. 
System suitability 
parameters 
Rt in min Peak Area 
Mean (n=6) 13.3 114,382,890 
SD 0.05 473811 
% RSD 0.41 0.41 
 
Table 3-2: System suitability study of HumR (concentration 250 IU/mL) using neutral 
analytical method for determination of insulin and its B3 desamido insulin degradant. 
System suitability 
parameters 
Rt in min Peak Area 
Mean (n=6) 16.6 92,426,999 
SD 0.25 419828 
% RSD 1.49 0.45 
 
Table 3-3: System suitability study of di-labelled FITC-insulin conjugate (concentration 
0.25 mg/mL) using FITC-insulin method for determination of FITC-insulin conjugates. 
System suitability 
parameters 
Rt in min Peak Area 
Mean (n=6) 22.5 19,111 
SD 0.01 279 
% RSD 0.06 1.46 
 
The % RSD of peak area and Rt for HumR using the acidic and neutral analytical 
methods and for di-labelled FITC-insulin using the FITC-insulin method are within 
±2% (acceptance criteria) indicating the suitability of the corresponding systems. 
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System suitability results thus suggest that the chromatographic system and conditions 
used in the three methods are suitable for the samples analysed. 
 
Linearity 
Figure 3-5 and Figure 3-6 show the linear relationship between AUP and insulin 
concentration over the concentration range 50-500 IU/mL for the acidic and neutral 
analytical methods, respectively. Figure 3-7 shows the linear relationship between AUP 
and FITC-insulin concentration over the concentration range 0.025-5.0 mg/mL for the 
FITC-insulin method. The calibration curves constructed for the six replicate 
experiments were evaluated by their correlation coefficient.  
The calibration equation for the acidic analytical method from six replicate calibration 
curves, y=387,831x + 2,089,296 (R
2
 = 0.9966), demonstrated the linearity of the 
method. Standard deviations of the slope and intercept for the calibration curves were 
8,986 and 1,506,488, respectively. The regression equation with all the linearity 
parameters for the acidic analytical method from six replicate calibration curves is as 
presented below in Figure 3-5, where R
2
 is correlation coefficient, r is Pearson 





Figure 3-5: Parameters of regression equation, relating HumR concentration to 
analytical response (AUP) using acidic analytical method. 
 
The regression equation with all the linearity parameters for the neutral analytical 
method from six replicate calibration curves is as presented below in Figure 3-6; 
y = 387,831(±8,986)x + 2,089,296(±1,506,488) 
R² = 0.9966, r = 0.9983 
95% CI of slope: 380,641 - 395,021 






































Figure 3-6: Parameters of regression equation, relating HumR concentration to 
analytical response (AUP) using neutral analytical method. 
 
The regression equation with all the linearity parameters for the FITC-insulin method 
from six replicate calibration curves is as presented below in Figure 3-7; 
y = 379,847(±1,620)x + 4,513,995(±423,999) 
R² = 0.9956, r =0.9978 
95% CI of slope: 378,551 - 381,143 









































Figure 3-7: Parameters of regression equation, relating di-labelled FITC-insulin 
conjugate concentration to analytical response (AUP) using FITC-insulin method. 
 
Linearity studies have shown a linear relationship between AUP and concentration of 
HumR across the concentration range 50 – 500 IU/mL as indicated by the correlation 
coefficient using both the acidic and neutral analytical methods. Also, linear relationship 
was shown for di-labelled FITC-insulin across the concentration range of 0.025-5.0 
mg/mL (correlation coefficient was 1) using the FITC-insulin method. 
 
Range 
The linearity ranges studied using the acidic, neutral and FITC-insulin methods are as 
shown in Figure 3-5, Figure 3-6 and Figure 3-7, respectively. The linearity results 
suggest that all three analytical methods provide an acceptable degree of linearity 
within, and at the extremes of the concentration ranges studied.  
 
y = 79040(±2692)x - 558(±494) 
R² = 1.00, r = 1.00 
95% CI of slope: 76886 to 81193 







































The accuracy results for the acidic, neutral and FITC-insulin methods are shown as in 
Table 3-4, Table 3-5 and Table 3-6, respectively.  
The AUPs corresponding to insulin concentrations were used to calculate the recovery 
percent of insulin using the regression equation. The recovery was 100.48 ± 0.63% and 
101.27 ± 1.46% for HumR using the acidic and neutral analytical method, respectively 
and was 100.02 ± 0.26% for di-labelled FITC-insulin conjugate using the FITC-insulin 
method.  
 
Table 3-4: Accuracy of the acidic analytical method for determination HumR.  
Std conc. 
IU/mL 





150 59,082,209±519,203 0.88 150.50±3.14 100.33 
200 81,130,312±321,212 0.40 202.74±0.89 101.37 
350 136,853,506±1,181,152 0.86 351.11±4.33 100.32 
500 197,502,242±1,337,885 0.68 499.43±2.52 99.89 






Table 3-5: Accuracy of the neutral analytical method for determination HumR.  
Std conc. 
IU/mL 
AUP Mean ±SD RSD % Cal. conc.±SD 
IU/mL 
Recovery % 
150 64,732,780±149.388 0.23 150.62±0.34 100.41 
200 82,944,396±184,091 0.22 206.79±0.09 103.39 
300 124,611,907±190,231 0.15 303.12±0.46 101.04 
400 156,927,295±1,166,927 0.74 400.91±1.43 100.23 













0.05 3,483±29 0.82 0.0500±0.00 99.92 
0.20 15,216±160 1.06 0.2000±0.00 100.00 
0.50 39,393±470 1.19 0.5019±0.01 100.38 
1.00 79,149±339 0.43 0.9978±0.00 99.78 




Accuracy results demonstrate the suitability of the methods for quantitative 




Precision calculated for the HumR samples during the intra- and inter-day run using 
acidic and neutral analytical methods are presented in Table 3-7 and Table 3-8, 
respectively. Precision calculated for the FITC-insulin samples using FITC-insulin 
method are given in Table 3-9. The % RSD value for intra-day precision was ≤ 1.01 and 
for inter-day precision was ≤ 0.75.for acidic analytical method, intra-day precision was 
≤ 0.74 and for inter-day precision was ≤ 0.30 for neutral analytical method and intra-day 
precision was ≤ 1.05 and for inter-day precision was ≤ 0.83 for FITC-insulin method. 
Thus all three methods show suitable repeatability and intermediate precision.  
 













200 80,511,102±8,10,141 1.01 81,130,312±321,212 0.40 0.80 
300 114,116,991±502,655 0.44 114,648,789±310,602 0.27 0.41 
500 197,502,242±1,337,885 0.68 197,061,936±1,478,956 0.75 0.65 
 













100 45,340,751±79,090 0.17 44,156,436±133,078 0.30 1.47 
200 82,944,396±184,091 0.22 86,743,903±37,292 0.04 2.46 
400 156,927,295±1,166,927 0.74 162,635,381±141,610 0.09 2.01 
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Intra-day Inter-day Overall RSD 
mg/mL AUP Mean±SD RSD % AUP Mean±SD RSD % % 
0.05 3,483±29 0.82 3,493±29 0.83 0.75 
0.20 15,216±160 1.05 15,806±84 0.53 2.21 
1.00 79,149±339 0.43 80,421±238 0.30 0.93 
 
Precision studies have demonstrated the repeatability and intermediate precision of the 
three analytical methods with respect to the chromatographic conditions under which 
they are intended to be used.  
 
Detection and Quantitation limits (Sensitivity) 
LOD and LOQ were calculated based on standard deviation of the analytical response 
represented by AUP for the lowest concentration used in linearity studies and slope of 
the calibration curve. The LOD and LOQ for HumR using acidic analytical method 
were 0.79 and 2.41 IU/mL, respectively. The LOD and LOQ for HumR using neutral 
analytical method were 0.98 and 2.97 IU/mL, respectively. The LOD and LOQ for di-
labelled FITC-insulin conjugate using FITC-insulin method were 0.0013 and 0.0039 
mg/mL, respectively. The results thus demonstrate the sensitivity of the three methods. 
 
3.4 Compatibility with device materials results and discussion 
 
3.4.1 Background  
The objective of the compatibility studies was to investigate insulin stability and 
compatibility with materials that formed part of the implantable closed-loop insulin 
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delivery device, INsmart, or have a potential to be considered for use in future device 
designs. 
Insulin has a tendency to come out of solution in several forms, possibly even when the 
formulations are optimised for stability in the product as presented for sale (containing 
additives such as pH adjusters, phenol and zinc). Some precipitated and/or aggregated 
forms are permanently inactivated whereas some are reversible, but in precipitated 
form, all cause problems for the working of devices with membranes and fine tubes. 
Some preliminary work was performed by the INsmart group at National Physical 
Laboratory (Teddington) to understand the effect of formulation adjuncts and the 
conditions relevant to the INsmart device that could have an effect on insulin stability. A 
design of experiment approach (power analysis -Taguchi approach) was employed to 
select key influential factors. The following were selected;  
 Formulations (insulin 0.4% and 2%),  
 Temperature (20°C and 37°C),  
 Glucose concentrations (0 and5%),  
 Phenol concentrations (0 and 0.4%),  
 2 different shear rates achieved using different tube diameter  
 Stirring using orbital motion at 20 rpm. 
These were studied over a period of 21 days. The study has found that the most 
significant factors were phenol, insulin concentration, temperature and the combination 
of phenol and temperature. The worst case conditions were 0% phenol, 2% (500 IU/mL, 
the top commercial concentration) insulin and 20°C. The effect of agitation seemed 
much less significant and the passage of the solutions through fine tubing (shear) was 
not found to be significant under the conditions. Agitation and shear are known to be 
factors that can cause insulin to come out of solution but here the movement may have 
been gentler than needed to produce the effect and the single passage of insulin through 
tubing may be an insignificant insult, though representative of the in vivo refilling 
condition (and also of pump-delivered insulin).  
As an extension of this work material compatibility studies were performed and are 
presented here. This chapter describes experiments conducted to look at the potential 
adverse effects of material type on insulin stability. Five materials were investigated of 
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which polycarbonate (a thermoplastic polymer containing monomer bisphenol A) and 
stainless steel (Grade 316) are present in current device design, polyurethane (a long 
chain thermoplastic polymer made up of polyol and isocyanate mixed) and titanium 
(99.99% purity) are potential future materials of interest and resin (a polyurethane two 
part thermosetting resin made of polyol and isocyanate mixed) was a material which 
was used in very early designs which might have potential future use.  
HumR 500 IU/mL concentration was used in in vivo pig experiments as described in 
Chapter 2. It was therefore important to simulate these in vivo conditions where 
compatibility could be assessed using a similar concentration and with each of the 
material used to fabricate the device. The material compatibility study was therefore 
conducted with HumR (500 IU/mL) which it was reasoned would give valuable 
information with regard to selection of material for future design. FITC-insulin was 
used in all in vitro diffusion studies discussed in this thesis. Therefore material 
compatibility study was also conducted with FITC-insulin which would provide 
understanding of solution stability for the duration of in vitro experiments. The material 
compatibility was assessed by measuring insulin recovery and degradation products 
formed over the study period using the three validated RP-HPLC methods discussed in 
the previous section. 
 
3.4.2 Experimental set-up 
 
3.4.2.1 Materials 
HumR 500 IU/mL manufactured by Eli Lilly and Co was used. It has a composition of 
500 IU/mL insulin, 2.5 mg/mL meta-cresol, and 16 mg/mL glycerine, zinc oxide to 
supplement the endogenous zinc to obtain a total zinc content of 0.017 mg /100 units, 
and water for injection. The pH (reported as between 7.0 and 7.8) was adjusted to 7.4.  
FITC-insulin solution (5mg/mL, pH 7.6) was prepared by dissolving FITC-insulin 
(synthesised in-house) in distilled water and then adjusting the pH (refer to Chapter 4 
for details on synthesis of FITC-insulin). The FITC-insulin solution was prepared 
immediately before use. 
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Sample bottles were acquired from Fisher Scientific, Loughborough. These were clear 
1.8 mL Vial (E-C sample Wheaton 33 low extractable borosilicate glass 12 x 35 mm 
dia. x ht (cap on) 8-425 screw cap size) with septum top, rubber lined black cap. 
Machined material samples of polycarbonate (a thermoplastic polymer containing 
monomer bisphenol A) (PC), polyurethane (a long chain thermoplastic polymer made 
up of polyol and isocyanate mixed) (PU), resin (a polyurethane two part thermosetting 
resin made of polyol and isocyanate mixed) (R) and stainless steel (Grade 316) (SS) 
were acquired from Renfrew Group. These were rounded rods, dia.: 2.8±0.2 mm, ht: 
44±1 mm with polish and finish matching those on the device. Titanium wire (Ti) 
manufactured by Sigma Aldrich, 0.5 mm diameter, 99.99%, 50cm wire was used. These 
were cut to size to fit the sample bottles.  
 
3.4.2.2 Experimental set-up and method 
The material rods were secured in the sample bottles by inserting in the sample bottle 
lids through the septum as shown in Figure 3-8 below; 
 
 
Figure 3-8: Sample bottles with material rods secured in the lid. 
 
1mL of the insulin solution was placed in the 2 mL test sample bottles each with PC, 
PU, R, SS rod and Ti wire. In addition, insulin solutions placed in sample bottles 
without any test materials and stored at 20°C were used as control standards. The test 
sample bottles were stored at 20°C and 37°C. Three sets of sample bottles with material 
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rods (3x10 sample bottles) were set up to provide for the three RP-HPLC methods. Two 
sets had HumR solution and one set had FITC-insulin solution. Sampling was 
performed after 0.083 (2hr), 1, 3, 7, 11, 21 and 31 days and analysed by RP-HPLC. The 
sample bottles with FITC-insulin solutions were placed in a dark container and 
protected from light. 
For the HumR samples RP-HPLC the acidic analytical method was used in order to 
determine the amount of insulin remaining in the sample and to assess the amount of 
A21 desamido insulin degradant. The RP-HPLC neutral analytical method was used to 
determine the amount of insulin remaining in the sample and to assess the amount of B3 
desamido insulin degradant. In addition the recovery of meta- cresol (m-cresol) in the 
HumR samples was determined. Insulin and m-cresol recovery were determined by 
comparison with control samples stored at 20°C but without the test material rods. A 
calibration curve using the control samples was generated at each time point. 
The FITC-insulin method was used for the determination of the amount of FITC-insulin 
conjugates remaining in the FITC-insulin samples. FITC-insulin recovery was 
determined by comparison with control samples stored at 20°C but without the test 
materials (rods). A calibration curve using the control samples was generated at each 
time point. 






Figure 3-9: Experimental set-up of the study sample bottles with test materials. 
 
3.4.3 Results and discussion 
The compatibility study results for HumR samples with test materials using the RP-
HPLC acidic and neutral analytical methods are presented together followed by the 
results for FITC-insulin samples. 
 
3.4.3.1 Compatibility study results for HumR with device materials at 20°C and 
37°C using the RP-HPLC acidic and neutral analytical methods 
The visual observation results for the HumR samples for both analytical methods, acidic 
and neutral, are presented in Table 3-10. Same visual observations were noted for both 
sample sets as the visual observations are independent of the HPLC methods used and 






Table 3-10: Visual observation table for material compatibility study from both sets 
(acidic and neutral analytical methods). 
20°C Test material 
Time 
(days) 
Control PC PU R SS Ti 
0.08 clear clear clear clear clear clear 
1 clear clear clear fine suspended 
particles 
clear clear 















21 clear clear white sediment increased 
suspended particles 
clear clear 
31 clear clear white sediment increased 
suspended particles 
clear clear 
37°C Test material 
Time 
(days) 
Control PC PU R SS Ti 
0.08 clear clear clear clear clear clear 















11 clear clear white sediment increased fine 
suspended particles 
clear clear 
21 clear clear white sediment increased 
suspended particles 
clear clear 




The control HumR solution stored at 20°C without any material remained clear over the 
entire study period, it can be concluded that the effects observed were due to the device 
materials present. Solutions with PC, SS and Ti remained clear throughout the study as 
shown in Table 3-10. From 1 day onwards, R seems to initiate aggregation and/or 
precipitation at 20°C and 37°C. PU initiating aggregation and/or precipitation from 1 
day onwards at 37°C and from 3 days at 20°C. Time limitations prevented analysing the 




3.4.3.1.1 Effect on insulin recovery over time 
The insulin recovery values were normalised over the entire time period based on values 
observed at initial time point. The insulin recovery results using the acidic and neutral 
analytical methods are presented below in Figure 3-10 and Figure 3-11, respectively; 
 
Figure 3-10: Insulin recovery over time for each test material at 20°C and 37°C using 
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Figure 3-11: Insulin recovery over time for each test material at 20°C and 37°C using 
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Using the acidic analytical method, as shown in Figure 3-10, solutions in contact with 
PC, R, SS and Ti show negligible loss of insulin after 31 days at 20°C. However, PU 
showed a loss of ~74% after 31 days at 20°C. At 37°C, solutions in contact with Ti 
showed negligible loss of insulin, with SS showing a loss of ~7%, R showing ~16%, PC 
showing ~ 67% and PU showing complete loss of insulin after 31 days. 
Using the neutral analytical method, as shown in Figure 3-11, solutions in contact with 
PC and Ti show negligible loss of insulin after 31 days at 20°C. However, R showed a 
loss of ~25%, SS showed a loss of ~ 15% and PU showed a loss of ~82% after 31 days 
at 20°C. At 37°C, solutions in contact with PC and Ti showed negligible loss of insulin, 
with SS and R showing a loss of ~22% and PU showing complete loss of insulin after 
31 days. 
The insulin recovery results suggest that at 20°C HumR solution is compatible with PC 
and Ti for up to 31 days and with R and SS up to 21 days. At 37°C HumR solution is 
compatible with Ti for up to 31 days, with SS for up to 21 days and PC and R up to 11 
days. The results show that PU looks like the least compatible of all the materials. 
 
3.4.3.1.2 Formation of A21 and B3 desamido insulin over time 
A21 desamido insulin 
The levels of A21 desamido insulin formed in the insulin solutions with the test 
materials over 31 days at 20°C and 37°C are as presented in Figure 3-12.  
Low levels of A21 desamido insulin were observed over time for all materials at 20°C 
and 37°C, the maximum values observed were well below Pharmacopoeia specified 
limits for insulin preparations of not more than 5% of total area of peaks. 
The maximum levels observed over 31 days at 20°C was with R (0.34%) and the 




Figure 3-12: A21 desamido insulin formed over time at 20°C and 37°C as a percentage 
of the total insulin peak area using acidic analytical method. 
 
B3 desamido insulin 
The levels of B3 desamido insulin formed are as presented in Figure 3-13. Formation of 
B3 desamido insulin is largely unaffected by any of the materials at 20°C and 37°C 
except for R, which shows an increase after 3 days. Polycarbonate seems to contribute 
to the formation of B3 desamido insulin after 21 days at 37°C. For all materials, except 



















































Time points (days) 




Pharmacopoeia specified limit which states that all other peaks (other than A21and 
insulin peak) should not be more than 6%. 
 
 
Figure 3-13: Total B3 desamido insulin (isoAsp and Asp) formed over time at 20°C and 
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3.4.3.1.3 Effect on m-cresol recovery over time 
The m-cresol recovery values were normalised over the entire time period based on 
values observed at initial time point. The m-cresol recovery levels from the insulin 





Figure 3-14: m – cresol recovery over time for each test material at 20°C and 37°C 
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Insulin solutions in contact with all five materials show loss of m-cresol over the 31 day 
test period at 20°C and 37°C. At 20°C, solution with Ti showed the least loss of m-
cresol, with PU and R showing a loss of ~56% and SS and PC showing a loss of ~28% 
after 31 days. 
At 37°C, solution with Ti showed least loss of m-cresol, with PC, PU and R showing a 
loss of ~74% and SS showing a loss of ~45% after 31 days. 
Comparison of the insulin and m-cresol recovery trends reveal that recovery of m-cresol 
decreases with increase in loss of insulin at 20°C and 37°C. 
 
Combining all findings from the visual observations, insulin recovery, m-cresol 
recovery, formation of A21 and B3 desamido insulin the following conclusions can be 
made for the materials tested; 
PC – HumR is found to be compatible with PC at 20°C with negligible loss of insulin 
and very low levels of desamido insulin degradants formed though there is some loss of 
m-cresol observed. At 37°C there appears to be insulin loss after 11days (using the 
acidic method) which is proportional to m-cresol loss observed after 11 days, here the 
insulin loss can be linked to the loss of protection of the insulin molecule by m- cresol 
and not formation of degradants. 
SS and Ti – At 20°C  and 37°C , the HumR solutions were compatible over 31 days 
with no aggregation observed, low levels of  desamido insulin degradants observed and 
some loss in insulin observed for SS at 37°C after 21 d can be linked to loss in m- cresol 
observed. 
PU – Aggregation of the HumR solutions were observed at 20°C and 37°C which can 
be linked to insulin loss from 11d at 20°C and 3d at 37°C. This loss in insulin was due 
to loss of protection by m-cresol observed and not due to formation of the desamido 
insulin degradants as very low levels of these were observed. 
 R – Aggregation of the HumR solutions were observed at 20°C and 37°C after 1d and 
increased over 31 days, insulin loss was less compared to other materials. The m-cresol 
loss is linked to higher levels of B3 (>7%) formed. Here aggregation observed is not 
linked to insulin loss, but loss of m-cresol (which could have been absorbed by Resin) 
and formation of B3 desamido insulin instead.  
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3.4.3.2 Compatibility studies for FITC-insulin with device materials at 20°C and 
37°C using the RP-HPLC FITC-insulin method 
Observation table for material compatibility study for FITC-insulin method are 
presented in Table 3-11. FITC-insulin control solutions stored at 20°C without any 
material remained clear for up to 7 days. Solutions with PC, SS and Ti showed signs of 
precipitation from 3 days onwards at 20°C and 37°C. Solution with PU showed signs of 
precipitation from 3 days at 20°C and from 1 day at 37°C, whereas R seems to initiate 
precipitation from 1 day onwards at 20°C and 37°C. 
The visual observations indicate that precipitation occurs in FITC-insulin solution 
between 7 and 14 days when stored alone in glass and with the test materials it starts 
much sooner. A point to be noted here is that the FITC-insulin solution has no 
formulation additives or stabilisers. For the purposes of the diffusion in vitro 
experiments, FITC-insulin solutions were always freshly prepared just before use. 
 
Table 3-11: Observation table for material compatibility study for FITC-insulin method. 
20°C Test material 
Time 
(days) 
Control PC PU R SS Ti 
0.08 clear clear clear clear clear clear 
1 clear clear clear fine suspended 
particles 
clear clear 








14 hazy hazy hazy hazy hazy hazy 
36 hazy hazy hazy hazy hazy hazy 
37°C Test material 
Time 
(days) 
Control PC PU R SS Ti 
0.08 clear clear clear clear clear clear 





3 clear hazy hazy hazy hazy clear 
7 clear hazy hazy hazy hazy hazy 
14 hazy hazy hazy hazy hazy hazy 
36 hazy hazy hazy hazy hazy hazy 
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3.4.3.2.1 Effect on FITC-insulin recovery over time 
The percent FITC-insulin conjugates were determined for each sample solution at each 
time point by comparing to the same solution stored at 20°C with no materials using the 
FITC-insulin method, the results are as presented in Figure 3-15 and Figure 3-16.  
 
 
Figure 3-15: Percentage recovery of FITC-insulin conjugates at 20°C over time 
compared to the same solution stored without material at initial time point using FITC-
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Figure 3-16: Percentage recovery of FITC-insulin conjugates at 37°C over time 
compared to the same solution stored without material at initial time point using FITC-
insulin method (data presented is normalised against control). 
 
The percentage recovery of FITC-insulin conjugates over time indicate the loss of the 
conjugates from 3 day time point at 20°C and 37°C as shown in Figure 3-15 and 
Figure 3-16, respectively for all the materials tested. The results suggest that the FITC-
insulin solution would need some formulation adjuncts and stabilisers if the solution is 
to be used with the device for a longer period. 
 
3.5 Chapter summary 
 The validation capabilities; selectivity, system suitability, linearity, range, accuracy, 
precision and detection and quantitation limits determined for the three RP-HPLC 
methods were assessed based on the FDA guidelines. The RP-HPLC acidic and 
neutral analytical methods can be used to detect and quantify insulin and two of its 
main deamidation degradants. The RP-HPLC FITC-insulin method enables 
quantification of the FITC-insulin conjugates in samples. 
 The validation studies have demonstrated the suitability of the three methods for the 
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analysis times and with accuracy across the concentration ranges intended to be 
studied for the INsmart device material compatibility studies.  
 The objective of the compatibility studies was to investigate insulin stability and 
compatibility with materials that formed part of the device or have a potential to be 
considered for use in future device designs. The main conclusions from the material 
compatibility studies are as follows; 
 HumR was found to be compatible with PC, SS and Ti for up to 31 days at 20°C 
showing no visible aggregation, negligible loss of insulin, low levels of desamido 
insulin degradants and some loss of m-cresol. At 37°C, similar observations were 
made for SS and Ti, except for some loss in insulin observed for SS at 37°C after 
21 d which can be linked to loss in m-cresol observed. At 37°C for PC there 
appears to be insulin loss after 11days (using the acidic method) which can be 
linked to loss of protection of the insulin molecule by m- cresol and not to the 
formation of degradants. 
 With PU, visual aggregation of HumR solutions were observed at 20°C and 37°C 
which can be linked to insulin loss from 11d at 20°C and 3d at 37°C. This loss in 
insulin was due to loss of protection by m-cresol observed and not due to 
formation of the desamido insulin degradants as very low levels of these were 
observed. 
 With R, aggregation of the HumR solutions were observed at 20°C and 37°C after 
1d and increased over 31 days, insulin loss was less compared to other materials. 
The m-cresol loss is linked to higher levels of B3 (>7%) formed. Here aggregation 
observed is not linked to insulin loss, but loss of m-cresol (which could have been 
absorbed by Resin) and formation of B3 desamido insulin instead.  
  The material compatibility results suggest that the current device materials, SS 
and PC are suitable for in-vivo use with HumR for up to 11 days, but after that PC 
could contribute towards loss of insulin at 37°C. SS is compatible for up to 21 
days at 37°C. Ti showed negligible loss of insulin for the entire duration of the 
study suggesting that it is a good material to consider in future device designs. R 
might not be the best material to consider and PU is definitely the least compatible 
and hence not suitable for future device designs.  
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 In comparison to the conclusions from the experiments performed at NPL which 
concluded that the worst case conditions were 0% phenol, 2% (500 IU/mL, the 
top commercial concentration) insulin and 20°C, the material compatibility study 
conclusions here confirm the necessity for presence of phenolic compound (m-
cresol) for maintaining the stability of insulin solution but in contrast highlighted 
greater loss in insulin recovery at 37°C. 
 FITC-insulin which is being used as a tool in in vitro experiments, the solution 
was found to be compatible with the device materials up to only 3 days. The 
control FITC-insulin solution showed signs of precipitation between 7 and 14 
days and with materials it started much sooner, with PC, SS and Ti showing visual 
signs of precipitation from 3 days onwards at 20°C and 37°C while PU and R 
showing signs 1 day onwards. These visual observations matched the FITC-
insulin conjugate recovery results.  
 This did not pose a problem for the in vitro studies as such as FITC-insulin 
solutions were always freshly prepared just before use and the same solution was 
never used for periods greater than 3days. However, it has highlighted the fact that 
FITC-insulin solution needs formulation adjuncts and stabilisers, which should be 
assessed for stability if it is intended to be used in experiments with the device 




Chapter 4 Synthesis and identification of 
FITC-insulin conjugates  
 
4.1 Introduction 
Several immunoassay and non-biological analytical methods, especially high 
performance liquid chromatography (HPLC) are available for assay and determination 
of human insulin in in vivo and in vitro conditions. Though these methods are suitable 
for routine assay measurements, they are time consuming and not suitable for quick real 
time experimental measurements. This shortfall was overcome by the use of 
fluorescently labelled insulin for quick minute by minute quantification of insulin 
delivered from the INsmart device. Fluorescently labelled insulin was synthesised for 
use in in vitro experiments to monitor and understand insulin delivery mechanism from 
the INsmart device. 
In this chapter the synthesis of FITC-insulin conjugates (Fluorescein isothiocyanate 
insulin conjugates) using native human insulin will be described. FITC-insulin 
conjugates produced at various reaction times and in the presence of phenol or meta 
cresol (m-cresol) which are known to promote stability of insulin solution are 
investigated. FITC-insulin conjugate species synthesised using various clinically used 
insulin injection preparations are also presented.  Further, conjugate species present in 
FITC-insulin products (synthesised by Sigma Aldrich) were examined and are 
presented. 
 
4.1.1 Fluorescent probes 
Fluorescence technologies are widely used in bioanalytical applications for detection 
purposes and have often superseded radiolabeling. Small molecule - based fluorescent 
probes have been extensively used in biological sciences over the last several decades 
(Lavis and Raines, 2008; Jameson and Ross, 2010). They have been routinely used by 
researchers to tag non fluorescent molecules of interest for detection purposes 
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(Giepmans et al., 2006).  In addition to aiding in visualization, functional fluorescent 
probes have become indispensable tools in modern biology because they provide 
dynamic information concerning the localization and quantity of molecules of interest 
(Ueno and Nagano, 2011). The small size of a fluorophore in comparison to a 
protein/peptide is advantages with respect to potentially low impact on the protein’s 
biological activity and at the same time can impart high detection sensitivity.  
Fluorescein isothiocyanate isomer I (Fluorescein 5-isothiocyanate, FITC) (empirical 
formula: C21H11NO5S, molecular weight: 389.38 Da) is yellow-orange in colour and is 
widely used to fluorescently label proteins via the amine group in various biological 
applications. The isothiocyanate group reacts with terminal amine residues and primary 
amines in proteins. FITC isomer I has the thiocyanate group on the 4 carbon of the 
benzene ring, whereas isomer II has the thiocyanate on the 5 carbon (Figure 4-1). The 
two isomers are indistinguishable spectrally, by wavelength or intensity. Isomer I is the 
commonly used isomer due to the fact that it more easily isolated in pure form and 






FITC isomer I 
[Fluorescein-5-isothiocyanate] 
FITC isomer II 
[Fluorescein-6-isothiocyanate] 
Figure 4-1: Structure of fluorescein isothiocyanate isomers.   
 
Biological applications of this amine-reactive fluorescent probe include fluorescent 
labelling of proteins, fluorescent reagent for protein tracing, microsequencing of 
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proteins and a reagent in the fluorescent antibody technique for the rapid identification 
of pathogens (Choi et al., 2013; Shelma and Sharma, 2013; Rodríguez-Sáinz et al., 
2013). FITC is a fluorophore of choice due to its high molar absorptivity and quantum 
yield. It is soluble in acetone at 1 mg/mL, in anhydrous dimethyl sulfoxide (DMSO) at 5 
mg/mL, in water at less than 0.1 mg/mL in water. An organic solvent is normally used 
for stock solutions which can be diluted in basic buffer for coupling procedures 
immediately prior to use, displaying absorption maximum excitation at 495 nm and 
emission at 525 nm in the visible range of the spectrum. FITC (isomer 1) was used to 
fluorescently label insulin to synthesise FITC-insulin conjugates for in vitro use. 
 
4.1.2 Insulin, insulin receptor structure and binding mechanism 
Despite more than three decades of investigation, the details of the mechanism of 
insulin–insulin receptor binding has still not been fully understood, this is partly due to 
the fact that the three-dimensional structure of the insulin–insulin receptor complex has 
proved elusive aggravated by the complexity of producing the receptor protein (Menting 
et al., 2013; Vashisth, 2014). Here, information highlighting the importance of certain 
regions of insulin residue involved in insulin-receptor recognition and binding are 
presented. This is important with respect to understanding the impact of fluorescent 
labelling on certain sites on the insulin molecule. 
 Studies of insulin analogues have allowed mapping of the interactive residues on the 
surface of the molecule and have demonstrated how activity depends on the integrity of 
the insulin fold. Two surfaces of insulin are understood to interact with the insulin- 
receptor (De Meyts, 2004; Schaffer, 1994), as shown in Figure 4-2. It appears that both 
these regions are involved in binding; the classical binding site is labelled as 'binding-
site 1' and binding site on the hexamer surface as 'binding site 2'(Schaffer, 1994). The 
classical binding site is usually considered to comprise a number of residues in the 
dimer-forming surface (B12, B24, B25) and probably also some of the hydrophobic 





Figure 4-2: Model of human insulin showing binding sites 1 and 2. Note that binding-
site 1 is partially covered by the C-terminus of the B chain (Schaffer, 1994). 
 
The insulin receptor is a cell surface receptor for insulin, comprising a tetramer of two 
alpha (α) and 2 beta (β) subunits derived from cleavage of a single precursor protein. It 
is a disulphide-linked (αβ)2 homodimer; the extracellular portion of each αβ protomer 
contains six domains (L1, CR, L2, FnIII-1, FnIII-2 and FnIII-3) and an insert domain 












Figure 4-3: Three dimensional structure of the insulin receptor system with the dashed 
ellipses showing the primary and secondary insulin-binding sites (Menting et al., 2013). 
 
The homodimer has a two-fold symmetric inverted “V” conformation, with the L1-CR-
L2 module of one insulin receptor monomer packed against the FnIII-1,-2,-3 module of 
the alternate insulin receptor monomer. The tandem L1-β2 / αCT element forms site 1, 
the primary insulin-binding site (dashed ellipse). Site 2, the secondary insulin-binding 
site, is formed by residues at the junction of the FnIII-1 and FnIII-2 domains of the 
opposite α-chain to that contributing the L1 domain to site 1 (Menting et al., 2013; 
Hubbard, 2013; Ward and Lawrence, 2012; Ward and Lawrence, 2011).  
Menting et al have studied and presented the interaction of insulin with the insulin-
receptor binding sites. The insulin-binding sites 1 and 2 interact with the primary and 
secondary receptor binding sites. It has been proposed that at the receptor primary 
binding site insulin rearranges itself by displacing the C-terminal B chain residues B20-
B30 from its helical core upon receptor engagement (Menting et al., 2013; Whittaker et 
al., 2008). The receptor contains an intrinsic tryrosine kinase domain that is located 
within the β subunit which upon activation by insulin results in numerous changes 
including uptake of glucose into the liver, muscle and adipose tissue (Kido, Nakae and 
Accili, 2001; Saltiel and Kahn, 2001). 
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4.1.3 Clinically used insulin injection preparations  
Variant forms of insulin, known as insulin analogues, with modified amino-acid 
sequences and improved pharmacokinetic properties have been produced since human 
insulin was successfully made using recombinant-DNA (rDNA) technology in the early 
1980s. Design of insulin analogues are based on general principles of protein folding 
and assembly (Berenson et al., 2011). Short acting insulin analogues, present in 
commercially available injections Humulin
®
 R and Actrapid
®
, have been produced using 
rDNA technology with same structure as natural human insulin which show absorption 
similar to natural human insulin. After subcutaneous injection, the maximal effect is at 
approx. 3 hrs (range: 20 min to 7 hrs) and terminates after approx. 8 hrs (range: 3 to 14 
hrs).   







 respectively, have been produced with reduced 
self-association properties or accelerated hexamer dissociation properties to achieve 
rapid absorption than regular insulin (Brange, 1997; DeFelippis, Chance and Frank, 
2001),(Weiss, 2013). Following subcutaneous injection, the time to maximum 
concentration is 40 – 60 min and duration of action is about 3 - 5 hrs. 





 respectively, have been synthesised either by introducing amino-acid 
changes that increase the isoelectric point of insulin whereby reducing its solubility at 
physiological pH, or by covalent acylation. After subcutaneous injection, insulin levels 
rise slowly to a plateau within 6–8 hrs and remain essentially unchanged for up to 24 
hrs, suitable for once-daily administration (Owens, 2002). The differences between the 
insulin analogues are as presented in Figure 4-4 and Table 4-1 to Table 4-3, the 
information was largely derived from manufacturers’ data and product monographs. It is 
important to know the differences between the insulin analogues in terms of amino-acid 
substitutions and formulation details to understand the impact of fluorescent labelling 











Table 4-1: Types of short - acting insulin preparations commercially available with description of insulin present.  
 
  
Insulin, Brand & 
Manufacturer 
Difference from Human Insulin and 
mode of action 
Molecular 






 R U-500 
Eli Lilly 
Structurally identical to natural human 





Humulin® R U-500 is a sterile, clear, aqueous and colourless 
solution that contains human insulin (produced by rDNA 
technology in a special non-disease-producing laboratory strain 
of Escherichia coli bacteria) 500 units/mL, 16 mg/mL glycerine, 
2.5 mg/mL metacresol  and 0.005 mg/mL zinc oxide and water 
for injection (WFI). The pH is 7.0 to 7.8. HCl and/or NaOH may 
be added during manufacture to adjust the pH. Also available as 
Humulin R U-100. 






Structurally identical to natural human 
insulin. 




Actrapid® is a neutral, clear and colourless solution of human 
insulin (rys).  
One IU (International Unit) of human insulin corresponds to 
0.035 mg of anhydrous human insulin (rys) (produced by rDNA 
technology using Saccharomyces cerevisiae).Also contains: 
glycerol, meta-cresol, zinc chloride and WFI. HCl and/or NaOH 




Table 4-2: Types of rapid - acting insulin preparations commercially available with description of insulin present. 
Insulin, Brand & 
Manufacturer 
Difference from Human Insulin and mode of action Molecular 










Human insulin analogue in which proline has been 
replaced by aspartic acid in the B-chain position 28, 
which creates charge repulsion and steric hindrance 
due to a local conformational change at the carboxyl 
terminus of the B chain.  
Reduced tendency to self-associate into hexamers due 
to electrostatic repulsion at the dimer interface 
resulting in rapid absorption leading to an earlier peak 





 100 U/mL, is a sterile, aqueous, clear, 
and colourless solution, that contains insulin aspart 
(produced by r DNA technology in Saccharomyces 
cerevisiae) 100 Units/mL (3.5mg), 16 mg/mL 
glycerin,  1.50 mg/mL phenol, 1.72 mg/mL 
metacresol, 19.6 mcg/mL zinc, 1.25 mg/mL 
disodium phosphate dihydrate, 0.58 mg/mL sodium 
chloride and WFI. The pH is 7.2-7.6, HCl 10% 






Human insulin analogue in which the amino acid 
asparagine at position B3 is replaced by lysine and the 
lysine in position B29 is replaced by glutamic acid. 
The glucose lowering activities of Apidra® and of 
regular human insulin are equipotent when 
administered by the intravenous route, however after 
subcutaneous administration; the effect of Apidra® is 
more rapid in onset and of shorter duration compared 
to regular human insulin. 
C258H384N64O78S6 
5823 Da 
Apidra® is a sterile, aqueous, clear, colourless 
solution in vials or cartridges for use as an 
injection. Each millilitre of Apidra® contains 100 
units (3.49 mg) insulin glulisine (produced by 
rDNA technology utilising a non-pathogenic 
laboratory strain of Escherichia coli (K12),3.15 mg 
m-cresol, 6 mg tromethamine, 5 mg sodium 
chloride, 0.01 mg polysorbate 20, and WFI. The pH 
is adjusted to approx. 7.3 by addition of aqueous 









Human insulin analogue in which the amino acid 
proline at position B28 is replaced by lysine and the 
lysine in position B29 is replaced by proline.  
Mode of action same as regular insulin, however the 
change in amino acid sequence creates steric hindrance 
and a reduced ability to self-associate, as a result is 
absorbed more rapidly than regular soluble insulin 
from subcutaneous injection sites and also has a 




Humalog® is a sterile, aqueous, clear, and 
colourless solution. Each millilitre of Humalog® 
contains insulin lispro (produced by rDNA 
technology utilising a non-pathogenic laboratory 
strain of Escherichia coli) 100 units, 16 mg 
glycerine, 1.88 mg dibasic sodium phosphate, 3.15 
mg m-cresol, zinc oxide content adjusted to provide 
0.0197 mg zinc ion, trace amounts of phenol, and 
WFI. Insulin lispro has a pH of 7.0 to 7.8. The pH 
is adjusted by addition of aqueous solutions of HCl 





Table 4-3: Types of long - acting insulin preparations commercially available with description of insulin present. 
Insulin, Brand & 
Manufacturer 
Difference from Human Insulin and mode of action Molecular 





Insulin detemir differs from human insulin in that threonine 
in position B30 has been omitted and acylation of a C14 
fatty acid chain (myristic acid) to the lysine residue at B29.  
This modification results in delayed absorption due to  
increased self-association into hexameric form at  injection 
site and high degree of reversible albumin binding (by fatty 
acid chain), thereby delaying its absorption from the 
subcutaneous tissue and transport across the capillary 





Levemir® is a clear, colourless, aqueous, neutral 
sterile solution. Each mL of Levemir® contains 
100units(14.2mg/mL) insulin detemir (produced 
by rDNA expression in Saccharomyces cerevisiae 
followed by chemical modification.), 65.4mcg 
zinc,2.06mg m-cresol,16.0mg glycerol, 1.80mg 
phenol,0.89mg disodiumphosphatedihydrate, 
1.17mg NaCL and WFI. HCl and/or NaOH added 






Insulin glargine differs from human insulin in that A21 
asparagine is replaced by glycine (to stabilise the molecule) 
and two arginines are added to the B-chain C-terminus 
resulting in a shift of isoelectric point to neutrality. After 
subcutaneous injection, the insulin glargine acidic solution 
(pH 4) is neutralised; leading to formation of 
microprecipitates from which insulin glargine is slowly 
released, resulting in a relatively constant conc./time profile 
over 24 hrs with no pronounced peak. This profile allows 





Lantus® is a clear aqueous fluid. Each millilitre of 
Lantus® injection contains 100 IU (3.6378 mg) 
insulin glargine (produced by rDNA technology 
utilising a non-pathogenic laboratory strain of 
Escherichia coli (K12)). 10mL vials contain the 
following inactive ingredients per mL: 30 mcg 
zinc, 2.7 mg m-cresol, 20 mg glycerol 85%, 20 
mcg polysorbate 20, and WFI. The pH is adjusted 
by addition of aqueous solutions of HCl and/or 




4.1.4 Background and outline 
From previous work carried out within the INsmart group with labelling bovine insulin 
it was understood that labelled insulin can be produced which display higher aqueous 
solubility than native human insulin. Thus, for the in vitro experiments higher 
concentrations could be used in the insulin reservoir without the risk of precipitation. 
Also, synthesis of stable (in solution) biologically active labelled insulin in-house could 
be useful in wider biological and in vitro applications. Human FITC-insulin and bovine 
FITC-insulin synthesised by Sigma Aldrich are available but are very expensive (~£240 
per 5 mg). Therefore a method to fluorescently label insulin was further developed to 
produce the material in house. 
FITC-insulin complexes have been produced in the past but they have yielded mixtures 
with reduced biological activities (Maggi, 1966; Tietze, Mortimore and Lomax, 1962; 
Ciencialová et al., 2004). Fluoresceinthiocarbamyl insulin derivatives of bovine insulin 
prepared by Bromer et al (Bromer, Sheehan et al. 1967) under aqueous conditions have 
yielded mixtures of monosubstituted, disubstituted and tri substituted species with the 
monosubstituted fraction retaining only 40% of the native activity. 
The FITC-insulin synthesis method used here was based on the work carried out by 
Hentz et al (Hentz et al., 1997). The method described by Hentz et al is the only 
exhaustive method described in literature for synthesis of FITC-insulin and has been 
repeatedly used by researchers. Although there is a much recent work done by Liu et al 
(Liu, Kohn and Mayer, 2012) where a N-trifluoroacetyl- based protecting group scheme 
is used to selectively label human insulin at positions A1, B1 and/or B29. In Hentz’s 
work, human insulin was labelled with FITC to produce four distinct FITC-insulin 
conjugates by changing the reaction conditions (i.e. pH, reaction time, buffer and 
FITC/insulin ratio) which alter the selectivity of the fluorescein conjugation. The four 
isolated  FITC-insulin conjugates were labelled at the following residues; A1(Gly), 






Figure 4-5: Diagram showing primary structure of human insulin with red stars 
indicating reactive primary amine sites for FITC conjugation (diagram modified from 
Shutterstock). 
 
The characterisation of the conjugates shows that the degree and position of substitution 
affects the structural conformation and thus the biological activity of the FITC labelled 
insulin.  Hentz found that FITC-insulin conjugates labelled at the A1 or B1 positions 
exhibited similar binding toward anti-insulin antibodies. Biological activity was 
measured using a tryrosine kinase phosphorylation assay for all four FITC-insulin 
conjugates. Refer to Section 4.1.2 where insulin-insulin receptor binding was discussed 
highlighting the importance of certain sites on insulin molecule in insulin receptor 
recognition, receptor compatibility and biological activity in vivo. Based on biological 
activity results for FITC-insulin conjugates from the Hentz paper, the FITC-labelled 
insulin conjugate at B1 had equivalent activity as native insulin thus confirming that B1 
position was not significantly involved in the binding to the insulin receptor, as can be 
understood from the discussion in Section 4.1.2. The A1 and the A1B1 FITC-insulin 




involvement of the A1 site in binding with the insulin receptor which can be understood 
as it forms part of the classical binding site for the receptor. The A1B1B29 showed 
almost ~100 fold decrease in biological activity indicating the importance of the B29 
residue in receptor binding as discussed in Section 4.1.2. The proposed detachment of 
the C-terminal B-chain residues B20-B30 from the helical core of insulin upon receptor 
binding is understood to be crucial for the hormone–receptor recognition mechanism. 
The labelling of the insulin molecule at B29 could affect the conformation of the FITC-
insulin conjugate and render it unrecognisable by the receptor and thus is likely to 
significantly reduce its biological activity.  
The synthesis protocol detailing the various factors considered and different starting 
materials used are discussed below. The work described here is an extension of Hentz’s 
work.  
 
Synthesis of FITC-insulin conjugates using human insulin  
FITC-insulin conjugate was synthesised using native human insulin and the synthesised 
conjugate species were identified using reversed phase high performance liquid 
chromatography (RP-HPLC).Mass spectrometry (MS) was used as an additional 
analytical tool to confirm the identity of the conjugate species produced. The effect of 
varying reaction time and adding phenolic compounds on the conjugates produced was 
assessed.  
Effect of reaction time  
In this study human insulin from Sigma Aldrich was labelled with FITC using the 
method described by Hentz et al and effect of varying reaction time on the FITC-insulin 
conjugate species produced was investigated.  
Effect of phenol or m-cresol 
Phenolic compounds are commonly used in insulin pharmaceutical preparations for dual 
purposes as anti-microbial preservatives and allosteric effectors due to their stabilising 
effect on the hexamer conformation of insulin (Berenson et al., 2011). Phenol promotes 
formation of an additional helical segment from B1-B8 and induces a structural change 




R-state formed has less tendency to dissociate, the B1-B8 α-helices are stabilised at the 
dimer-dimer interface and its position restricts zinc-ion diffusion out of the hexamer.  
This structural transition is induced by phenol in the presence of zinc ions and thus is a 
property of the hexamer. (Brange and Langkjaer, 1993).  
The FITC-insulin conjugation method has zinc removed by chelating with EDTA, 
which dissociates the hexamer structure, and also does not include any phenolic 
compounds. Phenol or m-cresol was included in the reaction solution to study effect of 
phenolic compounds on the FITC-insulin conjugates produced in the absence of zinc. 
This will further give an insight into the conjugates produced using clinically used 
insulin injection preparations which always contain either phenol or m-cresol. 
 
Synthesis of FITC-insulin conjugates using clinically used insulin injections 
Different starting materials such as clinically used insulin injections which were either 
monomeric or hexameric were used to obtain conjugates which were then identified. 




), rapid-acting insulin 
analogues which are monomeric [NovoRapid
®










 (insulin glargine)] which are hexameric were labelled with 
FITC to obtain mono-labelled active FITC-insulin conjugates with future biological and 
in vitro applications for tracing and relevant specific receptor binding studies. 
 
Comparison to FITC-insulin products (synthesised by Sigma Aldrich) 
Fluorescently labelled insulin products, FITC-bovine insulin and FITC-human insulin 
from Sigma Aldrich were analysed to compare with the FITC-insulin conjugate species 
synthesised in-house. FITC-insulin conjugate using bovine insulin was also synthesised 
in-house as it was required for comparison with the Sigma Aldrich commercial product. 
As shown in Figure 4-6 bovine insulin differs from human insulin at the following 
positions: alanine for threonine at A8, valine for isoleucine at A10, and alanine for 
threonine at the carboxyl terminal of the B-chain (B30). Bovine insulin 





Figure 4-6: Primary structure of bovine insulin (Berg, Tymoczko and Stryer, 2002). 
 
4.2 Materials and Methods 
4.2.1 Chemicals and reagents 
Human insulin, recombinant, expressed in yeast (12643, Pcode 1001188651, CAS: 
11061-68-0), insulin from bovine pancreas (15500, CAS: 11070-73-8), fluorescein 
isothiocyanate isomer I (F-7250, CAS: 3326-32-7) were purchased from Sigma-Aldrich 






 manufactured by Novo 
Nordisk, Apidra
®
 and  Lantus
®
 by Sanofi-Aventis, Humalog
®
  and  Humulin
®
 R 
manufactured by Eli Lilly were used. HPLC grade acetonitrile, trifluoroacetic acid, 
acetone, NaOH, HCl and buffer salts were purchased from Fischer Chemicals 
(Loughborough, UK). Ethylenediaminetetra-acetic acid disodium salt was from 
Hopkins & Williams and phenol, m-cresol were purchased from Sigma Aldrich. 
Distilled water was used throughout.  
 
4.2.2 Synthesis of FITC-insulin conjugates 
The FITC-insulin conjugate synthesis protocol was as presented below;  
 
4.2.2.1 Preparation of 0.1M potassium phosphate buffer with 0.2M EDTA  
1.07g dipotassium hydrogen phosphate (K2HPO4) and 0.52g of potassium dihydrogen 
phosphate (KH2PO4) were dissolved in ~50 mL distilled water and 0.2M EDTA was 
added. After dissolution of EDTA the volume was made up to 100 mL with distilled 




For FITC-insulin conjugate synthesis in the presence of phenol or m-cresol, 0.4% w/v 
phenol or 0.25% w/v m-cresol were added to the 0.1M potassium phosphate buffer with 
0.2M EDTA and the pH of the buffer was adjusted to 7.0 with either 0.1M NaOH or 
0.1M HCl. 
 
4.2.2.2 Preparation of human insulin/bovine insulin solution 
A 10mg/mL human insulin/bovine insulin solution (5 mL) was prepared. Human 
insulin/bovine insulin was dissolved in hydrochloric acid (50mg in 10 drops of 0.1M 
HCl). About 4 mL of 0.1M phosphate buffer containing 0.2M EDTA was added 
resulting in a cloudy solution, followed by drops of 1M NaOH using a 1mL syringe 
until a clear solution was obtained. Buffer was added to just below the 5 mL mark and 
the pH was adjusted to 7.0 with acid or alkali. 
 
4.2.2.3 Preparation of FITC solution 
A 5 mg/mL solution of FITC in acetone was prepared just before use and protected from 
light, by covering in foil and kept in dark until use.  
 
4.2.2.4 Method for FITC-insulin conjugation 
Insulin solutions/ clinically used insulin preparations volume equivalent to 50 mg 
human insulin/ bovine insulin/insulin analogue was labelled with FITC using a 3 moles 
to 1 mole(FITC: insulin) ratio. Based on insulin/insulin analogue molecular weight and 
FITC molecular weight (389.39 Da), for a 3:1 molar FITC: insulin ratio, the quantity of 
FITC required was calculated. The calculated quantity of FITC solution (5 mg/mL) was 
added drop wise to the human insulin solution/insulin preparation, the pH of the 
solution was adjusted to 7.0, and the solution was protected from light and allowed to 
mix on a magnetic stirrer at room temperature for required reaction time. The quantities 






Human insulin solution 
Based on human insulin (5807.57 Da) and FITC (389.39 Da) molecular weight, 10.06 
mg of FITC (2.01 mL of 5 mg/ml solution) was required for 5 mL (10mg/mL) human 
insulin solution. 
Bovine insulin solution 
Based on bovine insulin (5733.5 Da) and FITC (389.39 Da) molecular weight, 10.19 mg 






R U-500 and Actrapid
® 
U-100  
Based on human insulin (5807.57 Da) and FITC (389.39 Da) molecular weight, 
10.06 mg of FITC (2.01 mL of 5 mg/ml solution) was required for 2.87 ml of 
Humulin
®








Based on insulin aspart (5825.8 Da) and FITC (389.39 Da) molecular weight, 10.03 mg 







Based on insulin glulisine (5823 Da) and FITC (389.39 Da) molecular weight, 10.03 mg 






Based on insulin lispro (5808 Da) and FITC (389.39 Da) molecular weight, 10.06 mg of 











Based on insulin determir (5916.9 Da) and FITC (389.39 Da) molecular weight, 






 U-100  
Based on insulin glargine (6063 Da) and FITC (389.39 Da) molecular weight, 9.63 mg 




4.2.3 Separation of FITC-Insulin conjugate produced: 
The FITC-insulin conjugate synthesised was separated by gel permeation 
chromatography (GPC) using Buchii apparatus chromatography pump B-688, peak 
detector B-686, fraction collector B-684 and a gel permeation column. The GPC column 
was a borosilicate plastic-glass column containing Sephadex 
TM
 G25 (bead size: dry 50-
150 µm and wet 86-258 µm). Sephadex 
TM
 G25 is a cross-linked dextran which 
minimises nonspecific adsorption and gives high recoveries when used in group 
separations to remove small molecules or free labels from larger protein molecules.  
Sephadex 
TM
 G25 which was supplied as a dry powder was first swollen before use by 
adding sufficient distilled water to cover the surface of the powder and then allowed to 
stand at room temperature for 3 hrs. The Sephadex 
TM
 G25 slurry was resuspended and 
poured into the column in one continuous motion to prevent introduction of any air 
bubbles. Sephadex 
TM
 G25 was packed by passing distilled water at 10 mL/min until the 
bed had reached a constant height. The column adapter was locked in position on the gel 
bed surface and packing was continued until the gel bed was stable. The column was 
equilibrated first with distilled water for at least 2 hrs before use. A sample volume of 
up to 20 was injected for separation. The flow rate for elution was maintained at 10 
mL/min. Between separation runs, the column was rinsed with 0.1M acetic acid and 




After the required reaction time, the FITC-insulin conjugation mixture was injected into 
the gel permeation column and the fractions separated were collected. As shown in  
Figure 4-7 two distinct bands visible on the column were collected separately. The first 
band collected should be the larger molecules of FITC-insulin conjugates and second 
band should be the smaller unreacted FITC molecules. 
 
 
Figure 4-7: Figure showing bands (corresponding to FITC-insulin conjugates and FITC 
molecules) separated using gel permeation chromatography.  
 
4.2.4 Analytical procedures for identification of FITC-insulin conjugates 
synthesised 
The FITC-Insulin conjugate bands collected following GPC were analysed using 
reversed phase high performance liquid chromatography (RP-HPLC) and mass 
spectrometry (MS) to identify the species produced and confirm the absence of any 
unreacted FITC in the FITC-insulin conjugate band. 
RP-HPLC chromatographic analyses 
The RP-HPLC chromatographic analyses were performed using a Shimadzu 




LC-20AD Prominence quaternary pump, SIL-20A Prominence auto sampler, CTO-
20AC Prominence column oven and SPD-M20A Prominence diode array detector. A  
Luna (3 µ) C18(2), 150 x 4.60 mm column from Phenomenex, Cheshire UK was used 
for the separation preceded by a 0.5mm in-line filter and a widepore C18, 4 × 3 mm 
guard column. Elution was achieved using a gradient method with a flow rate of 1.0 
mL/min, a column temperature of 40°C and sample injection of 20µl. The following 
gradient was used in HPLC determinations: 0-15 min (85% to 65%A), 15-25 min (65% 
to 35%A), and 25-32 min (35%A) where A was mobile phase A: 0.1% trifluoroacetic 
acid (TFA) in distilled water and B was mobile phase B: 90% acetonitrile/ 10% 
water/0.1% TFA. 
The sampling was performed by SIL-20A Prominence autosampler and the sample 
volume used throughout was 20µL. The peaks were monitored by fluorescence 
detection where the excitation and emission wavelengths were set at 494 and 518nm, 
respectively. The Photo Diode Array (PDA) detector was also set to scan from 190 to 
400nm and had a channel set at 215 nm to detect presence of unlabelled native insulin. 
This RP-HPLC method for identification of FITC-insulin conjugates has been validated 
and the results are as presented in Chapter 3. 
MS analyses 
MS to determine the mass of the FITC-insulin conjugates produced was performed 
using a Thermofisher LTQ Orbitrap XL (a high resolution instrument giving accurate 
mass measurement over the mass range: m/z 50–2000 or m/z 200–4000) using the 
nanospray ionisation mode (NSI) at the EPSRC National Mass Spectrometry Facility, 
Swansea University.  
The NSI mode is a low energy process creating very few fragments  and yields positive 
and negative mass spectra with typical positive ions [M + H]
 +
, [M + Na]
 +
, [M + nH]
 n+
 
and negative ions [M - H]
-
, [M + X]
 –
 produced. The solvent used for sample 
preparation was a mixture of water/1:1 water: methanol + 0.1% formic acid. Hence the 
ions being produced may contain sodium (Na, m wt: 22.99 Da, formic acid (CH2O2, 
46.03 Da) or methanol (MeOH, CH4O, 32.04 Da). Samples were infused into the source 




were performed in the positive ion detection mode. Scans were acquired over a range of 
m/z 50–2000 or m/z 200–4000. 
 
4.3 Results and discussion 
 
4.3.1 Synthesis of FITC-insulin conjugates using human insulin  
As discussed in Section 4.1.2 the insulin binding sites involving residues A1,A13, 
A21,B12, B17 and B-chain residues B20-B30 play a crucial role in the binding of 
insulin to insulin receptors. The objective of the synthesis was to produce the B1 mono-
labelled FITC-insulin conjugate, which has an equivalent biological activity to native 
insulin. Human insulin from Sigma Aldrich was thus labelled with FITC using the 
synthesis method described in Section 4.2.2.  
The RP-HPLC chromatogram for FITC, Figure 4-8, show the peaks at retention times 
(Rt) 13 min, 16 min, 24 min and 28 min. The absence of these peaks in a synthesised 






Figure 4-8: RP-HPLC fluorescence chromatogram of FITC showing peaks at Rt 13 
min, 16 min, 24 min and 28 min. 
 
The HPLC fluorescence chromatograms were checked for no unreacted FITC present. 
The PDA chromatograms were checked for any unlabelled native insulin, insulin peak 


































Figure 4-9: RP- HPLC fluorescence chromatogram and PDA UV chromatogram 
(showing peak at Rt 20.5 min) for Human insulin solution. 
 
4.3.1.1 Effect of reaction time 
The FITC-insulin conjugation reactions were monitored at different time intervals by 
RP-HPLC over a 45-hrs period. As shown in Table 4-4 and Figure 4-10 reaction time 
of 1 hr and 2 hrs produced predominantly mono-labelled conjugate (Rt 21.8 min) and as 
the reaction time increased over 45 hrs more di-labelled FITC- insulin conjugate 
(second peak, Rt 22.5 min) was produced with the appearance of tri-labelled conjugate 
(a third peak, Rt 23.5 min) after 20 hrs reaction time. The switch in ratio in favour of 
more di-labelled FITC-insulin conjugate produced occurs between reaction times 9 and 
20 hrs. There was unlabelled native insulin present up to 5 hrs, suggesting that it is not 
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Table 4-4: RP-HPLC area % of FITC-insulin conjugates formed at retention times over 




Area (%) Unlabelled native 
insulin 
(Rt 20.5 min on 
PDA) 
Mono-labelled 
(Rt 21.8 min) 
Di-labelled      
(Rt 22.5 min) 
Tri-labelled       
(Rt 23.5 min) 
1 89 9 none yes 
2 57 36 none yes 
5 77 23 none yes 
9 61 39 none no 
20 36 62 none no 
22 22 74 3 no 
25 11 80 5 no 
45 6 79 9 no 
Note: Instances where area % is not equal to 100% are due to small unresolved peaks present 






































Using the mass spectra for the reaction times 1 hr and 45 hrs where predominantly one 
conjugate species (recognised by retention time) was produced it is possible to identify 
the conjugates. The RP-HPLC fluorescence and PDA chromatograms for FITC-insulin 
conjugates produced after reaction times of 1 hr and 45 hr are presented in Figure 4-11 
and Figure 4-12. The mass spectra and corresponding molecular mass for conjugates 
produced were compared against the theoretical molecular mass for FITC-insulin 
conjugate species as presented in Table 4-5 and their identities ascertained. Figure 4-
13, Figure 4-14 and Figure 4-15 show the mass spectra (full scan) for reaction times 1 
hr, 5hrs and 45 hrs. Raw MS data is available from EPSRC UK National Mass 
Spectrometry Facility, Swansea University. The molecular mass of the conjugates 
produced after reaction times 1 hr, 5 hrs and 45 hrs are as presented in Table 4-6.  
 
 
Figure 4-11: RP- HPLC fluorescence chromatogram (showing peaks with Rt (%Area)) 
and PDA UV chromatogram (showing peak at Rt 20.5 min) for FITC-insulin conjugates 















































Retention Time Rt (min) 











Figure 4-12: RP- HPLC fluorescence chromatogram (showing peaks with Rt(%Area)) 
and PDA detector UV chromatogram (no peak at Rt 20.5 min showing absence of 
unlabelled native insulin) for FITC-insulin conjugates produced after a reaction time of 
45 hrs. 
 
Table 4-5: Theoretical molecular mass of FITC-insulin conjugate species and their 
identity. 
No of FITC labels Theoretical mass 
M (Da) 
Identity of conjugate 
0 5807.6 Insulin 
1 6197.0 A1 or B1 FITC-insulin conjugate 
(Mono-labelled) 
2 6586.3 A1B1 FITC-insulin conjugate 
(Di-labelled) 
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Figure 4-13: Mass spectra data for FITC-insulin conjugates produced after reaction 
time of 1 hr (peaks present in raw data at m/z 1317.7478, z5 corresponding to di-
labelled conjugate not labelled in spectra)  
 
Figure 4-14: Mass spectra data for FITC-insulin conjugates produced after reaction 
time of 5 hr (peaks present in raw data at m/z 1162.5338 z5 and 1452.6644 z4 
corresponding to unlabelled human insulin; peak at m/z 1098.6242 z6 corresponding to 






Figure 4-15: Mass spectra data for FITC-insulin conjugates produced after reaction 
time of 45 hrs (peak present in raw data at m/z 1549.9247 z4 corresponding to mono-
labelled conjugate; peaks at m/z 1395.9559 z5 and 1750.1864 z4 corresponding to tri-





Table 4-6: Fluorescence chromatogram peaks, corresponding mass spectra data and 
identification of FITC-insulin conjugates produced after reaction times of 1 hr, 5 hrs and 
45 hrs (key: M - mass, H - hydrogen, MeOH – methanol, Na - sodium, PDA – Photo 




peaks Rt (min) 
(Area %) 
Theoretical 
mass M       
(Da)(# 
FITC) 
Molecular mass of 


































- 6975.7 (3) - - 
5 hrs 




























- 6975.7 (3) - - 
45 hrs - 5807.6 (0) - - 




























As shown in Table 4-6, from the chromatogram peaks and corresponding mass spectra 
for the reaction times 1 hr, 5 hrs and 45 hrs it was possible to identity the FITC-Insulin 
conjugate species produced. The chromatogram and mass spectra for the product 
produced after reaction time of 1 hr shows that predominantly mono-labelled conjugate 
(89%) was produced with very little di-labelled (9%), it also contained unlabelled native 
insulin. At a reaction time of 5hrs mono-labelled (77%) and di-labelled (23%) 
conjugates and trace unlabelled native insulin were present. At 45 hrs reaction time very 




of tri-labelled conjugate (9%) (absent in the previous reactions) was produced. No 
unlabelled native insulin was observed. Thus the chromatogram peaks with retention 
time of Rt 21.8 min shows presence of mono-labelled conjugates, Rt 22.5 min shows 
presence of di-labelled and retention time of Rt 23.5 min shows presence of tri-labelled 
FITC-insulin conjugates and PDA peak at Rt 20.5 min shows presence of unlabelled 
native insulin. 
It was observed that it was possible to produce predominantly mono-labelled insulin 
with short reaction times, however there always was unlabelled native insulin present. 
Also, from the chromatogram and mass spectra it couldn’t be ascertained if the mono-
labelled conjugate was A1 or B1 substituted. In order to locate the exact positions where 
FITC were attached, a Staphylococcus aureous digestion of the separated/isolated 
conjugates as described by Hentz et al would need to be employed.  Also, a biological 
test, an autophosphorylation assay using insulin receptor would aid in confirming the   
activity of the conjugates produced. These are however outside the remit of the work 
carried out here. 
For the purposes of the in vitro experiments it was more important to know the size of 
the FITC-insulin conjugate produced and the presence of any undesired unlabelled 
native insulin. Reaction time of 25 hrs was selected for production of FITC-insulin; 
refer to Figure 4-16 and Table 4-7; here predominantly di-labelled FITC-insulin 
conjugate (over 75%) was produced with the absence of any unlabelled native insulin. 
Increasing the reaction time over this period showed no change in the amount of di-








Figure 4-16: A: RP- HPLC fluorescence chromatogram (showing peaks with 
Rt (%Area) and PDA detector UV chromatogram (no peak at Rt 20.5 min showing 
absence of unlabelled native insulin) and B: mass spectrum of FITC-insulin conjugates 
produced after a reaction time of 25 hrs (peak present in raw data at m/z 1550.1785 z4 
corresponding to mono-labelled conjugate; peak at m/z 1163.4662 z6 corresponding to 













































Retention Time Rt (min) 














Table 4-7: Fluorescence chromatogram peaks, corresponding mass spectra data and 
identification of FITC-insulin conjugates produced after a reaction period of 25 hrs. 



































4.3.1.2 Effect of phenol and m-cresol 
In order to understand the effect of phenolic compounds on the FITC-insulin conjugates 
produced in the absence of zinc, phenol or m-cresol was included in the reaction 
solution and the FITC-insulin conjugates produced were investigated. Table 4-8 
presents the FITC-insulin conjugates synthesised with and without phenol or m-cresol at 
reaction time of 2 hrs. 
 
Table 4-8: FITC-insulin conjugates produced with and without phenol or m-cresol.  
Reaction time (2 
hrs) 
Without 
Rt (min) (Area %) 
With 




20.5 (PDA) 20.5 (PDA) 
Unlabelled native 
insulin 
21.8 (57) 21.8 (47) Mono-labelled 
22.5 (36) 22.5 (53) Di-labelled 
22.7(8%) - - 
m-cresol 
20.5 (PDA) 20.5 (PDA) 
Unlabelled native 
insulin 
21.8 (57) 21.8 (46) Mono-labelled 
22.5 (36) 22.5 (54) Di-labelled 
22.7(8%) - - 
 
There appears to be a 10% decrease in the amount of mono-labelled conjugate and an 
increase in di-labelled conjugate produced in presence of phenol or m-cresol. The 
presence of phenolic compounds, which aid the stable R-state of insulin monomer 




extended position, seems to have contributed to the increase in the di-labelled conjugate 
produced.  
In the FITC-insulin synthesis method used for synthesising FITC-insulin conjugates, 
zinc was removed by chelating with EDTA, thus dissociating the hexamer structure and 
the method does not include any phenolic compounds. These results thus show that in 
the presence of phenol or m-cresol, where the zinc ions have been removed, as would be 
in the case with all the conjugates produced using commercially available insulin 
preparations as well, there is an expectation of a small noticeable decrease in mono-
labelled FITC-insulin conjugate produced in comparison to if phenol or m-cresol were 
absent. 
 
4.3.2 Synthesis of FITC-insulin conjugates using clinically used insulin 
injections 
A set of commercially available insulin preparations, containing different insulin 
analogues were fluorescently labelled using the synthesis method described in Section 





monomeric insulin analogues [NovoRapid
®
 (insulin aspart), Apidra
®
 (insulin glulisine), 
Humalog
®





 (insulin glargine)] were labelled with FITC and the 
conjugates produced identified. 
 
 Short-acting insulin 
The FITC-insulin conjugates synthesised using  Humulin
®
 R and Actrapid
®
 after 2 hrs 
and 20 hrs reaction times are as presented in Table 4-9. The corresponding mass spectra 
are presented in Appendix 2 Figure A2-1 to Figure A2-4. The short-acting insulin 
analogues in Humulin® R and Actrapid® are structurally similar to natural human 
insulin (and the human insulin used) hence similar conjugates are expected to be 
produced, however here the effect of the various formulation excipients present in the 
commercial preparation (as described in Table 4-1) on the FITC-insulin conjugates 




produced using Humulin® R and Actrapid® as with human insulin (refer to Table 4-4). 
For Humulin® R after 2 hrs reaction (no EDTA was added), 82% mono-labelled FITC-
insulin conjugate and at 20 hrs similar amounts were produced compared to when 
human insulin was used, the formulation excipients present namely, glycerine, m-cresol 
and zinc oxide (though EDTA was added) suggest to play a role in aiding more mono-
labelled conjugate synthesis at 2 hrs reaction time. Actrapid® however shows increased 
amounts of mono-labelled conjugate synthesised at 2 hrs (95%) and 20hr (59%) 
compared to when human insulin was used. The increased amounts of mono-labelled 
conjugates produced using Actrapid even in comparison to Humulin® R where similar 
formulation excipients were present suggest that the factor contributing to this could be 
that the human insulin (rys) in Actrapid is synthesised using a yeast species 





Table 4-9: Fluorescence chromatogram peaks, corresponding mass spectra data and 
identification of FITC-insulin conjugates synthesised using commercially available 









Molecular mass of 





 R (human insulin) 
2 hrs
* 






































- 6975.7 (3) - - 
20 hrs 
- 5807.6 (0) - - 



























Actrapid® (human insulin(rys)) 
2 hrs 



























22.5 (4) 6586.3 (2) 20048.5[3(4Na+M)+13H]
10+
 Di-labelled 
- 6975.7 (3) - - 
20 hrs 
- 5807.6 (0) - - 




















23.6 (0.9) 6975.7 (3) - Tri-labelled 






The rapid-acting insulin, NovoRapid
®
 (insulin aspart), Apidra
®
 (insulin glulisine), 
Humalog
®
 (insulin lispro) have amino acid replacements at B28, B3 & B29 and B28 & 
B29 respectively aimed at accelerating hexamer disassembly and thus facilitating rapid 
absorption. The method used here for fluorescent labelling of insulin produces 
fluorescent conjugates labelled at amino acid residues at A1, B1 and B29 sites, therefore 
it was of interest to see which conjugates are produced here especially for insulin 
glulisine and insulin lispro where the amino acid at B29, lysine has been replaced by 
glutamic acid and proline respectively. Though, lysine is still present at B3 and B28 for 
insulin glulisine and insulin lispro, respectively. 







2 hrs and 20 hrs reaction times are as presented in Table 4-10. The corresponding mass 
spectra are presented in Appendix 2 Figure A2-5 to Figure A2-9. The FITC-insulin 
conjugates produced using NovoRapid
®
 show that similar conjugates as when human 
insulin was used were synthesised and the presence of unlabelled insulin aspart (for 2 hr 
reaction time). However, it shows increased amounts, 77% at 2 hrs and 47% at 20 hrs of 
mono-labelled FITC-insulin aspart conjugate compared to when human insulin was 
used. Insulin aspart has B28 proline replaced by aspartic acid, to achieve electrostatic 
repulsion at the dimer interface to weaken the tendency to associate into dimers and 
hexamers. Comparison of crystal structures with native insulin have shown a local 
distortion of the dimer interface associated with absence of B28 proline, thus 
highlighting the importance of its absence (Berenson et al., 2011). The increased 
amounts of mono-labelled conjugate observed when insulin aspart was used could be 
associated with change in conformation of insulin aspart monomer which results in it 
reduced ability to associate into dimers and hexamers. 
Insulin glulisine in Apidra
® 
has decreased zinc-free self-association tendency achieved 
by B3 asparagine substitution by lysine and B29 lysine substitution by glutamic acid. It 
shows similar conjugates synthesised as those obtained with human insulin (refer to 
Table 4-4) and the presence of unlabelled insulin glulisine (for 2 hr reaction time). The 
substitutions seem to promote the synthesis of more mono-labelled FITC-insulin 




The FITC-insulin lispro conjugates produced using Humalog
®
 after 2 hr and 20 hr 
reaction times are same and in similar amounts as those obtained with human insulin 
(refer to Table 4-4), this could be because the amino acid sequence at B28 (lysine) and 
B29 (proline) for insulin lispro has not been replaced but just swapped. 
 
Table 4-10: Fluorescence chromatogram peaks, corresponding mass spectra data and 
identification of FITC-insulin conjugates synthesised using commercially available 










Molecular mass of 
conjugates (Da) 
[ions] 
Identity of conjugates 
NovoRapid
®
 (insulin aspart) 
2 hrs 












22.5 (14) 6604.6 (2) 6608.7 [M+5H]
5+ 
Di-labelled 
- 6993.9 (3) - - 
20 hrs 
- 5825.8 (0) - - 
















- 6993.9 (3) - - 
APIDRA
®
 (insulin glulisine) 
2 hrs 
20.5 (PDA) 5823 (0) 5828.7 [M+5H]
5+ Unlabelled insulin 
glulisine 








22.4 (9) 6601.8 (2) - Di-labelled* 
- 6991.1 (3) - - 
20 hrs 
- 5823 (0) - - 






























20.5 (PDA) 5807.6 (0) 5811.7 [M+5H]
5+ Unlabelled insulin 
lispro 



















23.4 (0.5) 6975.8 (3) None detected Trace tri-labelled 
20 hrs" 
- 5807.6 (0) - - 
21.8 (27) 6197 (1) - Mono-labelled 
22.5 (67) 6586.4 (2) - Di-labelled 
- 6975.8 (3) - - 
Note: * APIDRA
®
 2hrs reaction time di-labelled conjugate identified based on chromatogram peak Rt. " 
HUMALOG
®
 20 hrs reaction time – no mass spectra available, hence conjugates identified based on 
chromatogram peak Rt. 
 
Long-acting insulin 
The FITC-insulin conjugates synthesised using Levemir
®
 (insulin determir) and Lantus
®
 
(insulin glargine) after 20 hrs reaction time are as presented in Table 4-11. The 
corresponding mass spectra for FITC-insulin conjugates synthesised using Levemir
®
 
after 20 hrs reaction time is presented in Appendix 2 Figure A2-10. Both these insulin 
analogues have modifications to their B chain B29 and B30 region to impart their long-
acting effects and as described earlier this region plays a very important role in receptor 
binding and hence its biological activity.  
Insulin determir contains a fatty acyl group on B29 Lysine which has reversible albumin 
binding tendency thereby providing a circulating depot and enhances the stability of the 
modified insulin hexamers (Havelund et al., 2004), (Whittingham et al., 2004). FITC-
insulin determir conjugates produced after 20hrs reaction time were mono-labelled 
(15%) and di-labelled (82%) conjugates species based on their mass spectra results; 
their retention times seemed to have shifted by 5min. There was no tri-labelled 
conjugate species produced as expected due to the fatty acyl group substitution at B29.  
Insulin glargine molecule differs from human insulin in that the A21 asparagine is 
replaced with glycine and has 2 arginines attached to the C-terminus of the B-chain that 
results in the isoelectric point shift of the solution to neutrality thus resulting in 






 preparation is at pH 4 and it has very low solubility at neutral pH. It was very 
difficult to follow the synthesis method where the reaction needed to be carried out at 
pH 7; hence the reaction was carried out at a higher pH much above its neutral 
isoelectric point where the reaction solution was clear. The chromatogram results for 
reaction time of 20 hrs show two peaks which could be mono-labelled conjugate with a 
combined 92% and very low (2%) of di-labelled conjugate. 
 
Table 4-11: Fluorescence chromatogram peaks, corresponding mass spectra data and 
identification of FITC-insulin conjugates synthesised using commercially available 




peaks Rt (min) 
(area %) 
Theoretical 
mass         
(Da) (#FITC) 







 (insulin determir) 
20 hrs 













 - 7085 (3) - - 
LANTUS
®
 (insulin glargine) 
20 hrs* 
- 6063 (0) - - 
21.3 (33%) 
21.8 (59%) 
6452.4 (1) - Mono-labelled 
22.3 (~1%) 6841.8 (2) - - 
22.7 (2%) 7231.1 (3) - Di-labelled 
Note: * LANTUS
®
 20 hrs reaction time – no mass spectra available, conjugates identified 
based on chromatogram peak Rt. 
 
4.3.3  Comparison to FITC-insulin products (synthesised by Sigma Aldrich) 
FITC-bovine insulin and FITC-human insulin synthesised by Sigma Aldrich were 
analysed to determine the conjugates present. Their RP-HPLC chromatograms and mass 
spectra are as presented in Figure 4-17 and Figure 4-18 and their corresponding mass 







Figure 4-17: RP- HPLC fluorescence chromatogram (showing peaks with Rt(%Area)) 
and PDA detector UV chromatogram (showing presence of a peak at Rt 20.5 min) for 
Sigma FITC- bovine insulin.  
 
 
Figure 4-18: RP- HPLC fluorescence chromatogram (showing peaks with Rt(%Area)) 
and PDA detector UV chromatogram (showing absence of a peak at Rt 20.5 min) for 





















































Retention Time Rt (min) 















































Retention Time Rt (min) 

















Table 4-12: Fluorescence chromatogram peaks, corresponding mass spectra data and 
identification of FITC-insulin conjugates present in commercially available FITC-
insulin products.  
 
FITC-bovine insulin (synthesised by Sigma Aldrich) show that a number of different 
conjugates are present. Table with all the chromatographic peaks are presented in 
Appendix 2 Table A2-1. The conjugates present were compared with FITC-bovine 
insulin conjugates synthesised in-house with a reaction time of 20 hrs. The 
corresponding chromatogram peaks and mass spectra data are presented in Figure 4-19, 
and Table 4-13, respectively. The FITC-bovine insulin (synthesised in-house) showed 
the usual number of peaks and absence of any unlabelled bovine insulin. The FITC-
bovine insulin conjugates (synthesised by Sigma Aldrich) were identified based on their 
Rt and mass spectra results. The Rt for these peaks were found to be slightly higher than 
the in-house synthesised conjugates. The product also shows presence of unlabelled 
bovine insulin and a number of unidentified peaks. Mass spectra for FITC-bovine 
insulin (synthesised by Sigma Aldrich) and FITC-bovine insulin (synthesised in-house) 
are presented in Appendix 2 Figure A2-11 and Figure A2-13, respectively. 
  
Chromatogram 
peaks Rt (min) 
(Area %) 
Theoretical mass 
(Da) (#  FITC) 





FITC-bovine insulin (Sigma) 






















- 6901.6 (3) - - 
FITC-human insulin (Sigma) 
- 5807.6 (0) - - 
- 6197 (1) - - 



















Chromatogram for FITC-human insulin product (synthesised by Sigma Aldrich) show a 
number of small peaks, the peaks associated with Rt 12.9 min, 24.1 min and 27.9 min 
indicate presence of unreacted FITC in the product. The product shows one 
predominant peak at 23.4 min (90%) which can be confirmed as tri-labelled FITC-
insulin conjugate (which is the most biologically inactive species as studied by Hentz et 
al) based on its corresponding mass spectra data. It shows presence of di-labelled 
conjugate about 3%. The product did not contain any unlabelled human insulin. Table 
with all the chromatographic peaks and mass spectra for Sigma FITC-human insulin 
product are presented in Appendix 2 Table A2-2 and Figure A2-12. 
 
 
Figure 4-19: RP- HPLC fluorescence chromatogram (showing peaks with Rt (%Area)) 
and PDA detector UV chromatogram (showing absence of a peak at Rt 20.5 min) for 














































Retention Time Rt (min) 










Table 4-13: Fluorescence chromatogram peaks, corresponding mass spectra data and 
identification of FITC-insulin conjugates synthesised using bovine insulin (Note: the 
small chromatogram peak associated with Rt 23.4 (3.8%) is most probably Tri-labelled 
conjugate, this was not picked up by the mass spectra). 
Chromatogram 
peaks Rt (min) 
(Area %) 
Theoretical mass   
(Da) (# FITC) 





- 5733.5 (0) - - 





















23.4 (3.8) 6901.6 (3) - - 
 
4.4 Chapter summary 
In this project FITC-labelled insulin was used for in vitro diffusion experiments as a 
tool to improve analytical quantification and detection to understand release profiles 
from the closed loop insulin delivery device. Commercially available FITC-insulin 
products are very expensive and as substantial amounts were needed for experiments it 
was synthesized in-house. 
The synthesis protocol based on work by Hentz et al was used to produce the B1 mono-
labelled FITC-insulin conjugate, which has been shown by them to have equivalent 
biological activity as native unlabelled insulin. The following are the findings and 
achievements; 
 Mono-labelled FITC-insulin conjugate (A1 or B1) was successfully produced using 
human insulin at short reaction times (up to 5 hrs) however the product always 
contained some unlabelled native human insulin. This suggested that 5hrs wasn’t 
long enough for labelling all the insulin molecules. 
 As the reaction time was increased over a period of 45 hrs more di-labelled FITC-
insulin conjugate (A1B1) was produced than mono-labelled conjugate with the 
appearance of tri-labelled conjugate (A1B1B29) after 20 hrs reaction time. The 
quantities switch from mono-labelled to di-labelled FITC-insulin conjugate between 




 For the purposes of the in-vitro experiments it was more important to know the size 
of the FITC-insulin conjugate produced and presence of any unlabelled native insulin 
was undesirable. Hence, reaction time of 25 hrs was selected for production of FITC-
insulin where predominantly di-labelled FITC-insulin conjugate (over 75%) was 
produced with the absence of any unlabelled native insulin. Increasing the reaction 
time over this period showed no change in the amount of di-labelled conjugate 
produced. 
 To determine the identity of the mono-labelled FITC-insulin conjugate (A1 or B1 
labelled) produced at short reaction times further biological studies to separate and 
isolate the conjugates and confirm their biological activity would be needed. These 
are however outside the remit of the work carried out here. 
 In the presence of phenol or m-cresol, there appears to be a 10% decrease in the 
amount of mono-labelled conjugate and an increase in di-labelled conjugate 
produced. This observation could be attributed to the fact that phenolic compounds 
aid the stable R-state of insulin monomer in which the B1 residue is in an extended 
form and is more readily available for labelling. Thus in commercially available 
insulin preparations which usually contain phenolic compounds, there is an 
expectation of a small noticeable decrease in mono-labelled FITC-insulin conjugate 
produced in comparison to if phenol or m-cresol were absent. 
 Clinically used insulin analogues present in commercially available preparations 
were successfully fluorescently labelled for future biological and in vitro applications 
in tracing and receptor binding studies. 
─ The short-acting insulin analogues in Humulin® R and Actrapid®, which are 
structurally similar to native human insulin after 2 hrs and 20 hrs reaction times 
produced similar conjugates as with human insulin as expected. Humulin® R 
after 2 hrs reaction produced higher amount, 82%, mono-labelled FITC-insulin 
conjugate compared to when human insulin (57%) was used and at 20 hrs 
similar amounts to human insulin (36%) were produced. The formulation 
excipients present namely, glycerine, m-cresol and zinc oxide (though EDTA 
was added) suggest to play a role in aiding more mono-labelled conjugate 
synthesised at the 2 hrs reaction time. Actrapid® however shows increased 




(59%) compared to when human insulin was used, the increased amounts in 
comparison to Humulin® R where similar formulation excipients are present, 
suggest that the factor contributing to this could be that the human insulin (rys) 
in Actrapid® is synthesised using a yeast species Saccharomyces cerevisiae 
instead of Escherichia coli bacteria (used for Humulin® R). 
─ The rapid-acting insulin analogues in NovoRapid® (insulin aspart), Apidra® 
(insulin glulisine) and Humalog® (insulin lispro) all produced similar 
conjugates as with human insulin at 2hr and 20hr reaction times and had 
unlabelled insulin analogues present for 2hr reaction time. At 2hrs and 20hrs 
reaction times, insulin aspart and insulin glulisine showed increased amounts 
of mono-labelled FITC-insulin analogue conjugates produced compared to 
human insulin which could be due to the amino acid replacements at B28 and 
B3 & B29 respectively. Insulin lispro where the amino acid sequence at B28 
and B29 has not been replaced but just swapped, produced similar amounts of 
conjugates after 2hrs and 20 hrs as those obtained with human insulin. 
─ The long-acting insulin analogues in Levemir® (insulin determir) and 
Lantus®( insulin glargine), both having modifications to their B chain B29 and 
B30 region were fluorescently labelled with 20 hrs reaction time. FITC-insulin 
determir conjugates synthesised at 20hrs reaction time were mono-labelled 
(15%) and di-labelled conjugates (82%). No tri-labelled conjugate was 
produced as expected due to the fatty acyl group substitution at B29. FITC-
insulin glargine conjugates synthesised at 20hrs reaction time carried out at a 
higher pH than 7 produced two peaks which could be mono-labelled 
conjugates with a combined 92% and very low (2%) di-labelled conjugate. 
 FITC-bovine insulin (synthesised by Sigma Aldrich) show that a number of different 
conjugates were present, including mono-labelled and di-labelled conjugate and also 
had unlabelled native bovine insulin which was undesirable. 
 FITC-human insulin (synthesised by Sigma Aldrich) was found to contain some 
unreacted FITC, predominantly tri-labelled conjugate (which is biological inactive as 
studied by Hentz et al) and some di-labelled conjugate. It was thus hugely 
advantageous to synthesise FITC-insulin in-house with predominantly di-labelled 




Chapter 5 Development of an 
experimental protocol for measuring 
diffusion. 
5.1 Introduction 
The study of molecular transport in solutions and across artificial or biological barriers 
ranging from simple diffusion and dissolution to complex in vivo pharmacokinetic 
investigations contributes towards understanding drug release mechanisms. This 
movement of molecules can be mathematically modelled and these descriptions can aid 
in the design of experiments and interpretation of data. In this chapter concepts of 
diffusion and drug transport relevant to the INsmart device are presented and the 
process followed in developing an experimental protocol to ultimately measure 




Movement of molecules in solution or molecular transport across barriers can be caused 
by migration or diffusion. Migration is caused by an external force, such as gravity, 
electrical fields or hydrodynamic flow that acts on each of the solute molecules. 
Diffusion is defined as a process of mass transfer of individual molecules of a solute, 
from one part of a system to another brought about by random thermal movement in 
solution in the presence of a concentration gradient. Transport by simple diffusion can 
be measured as flux (Brodin, Steffansen and Nielsen, 2009). The passage of molecules 
through a polymeric membrane may occur by simple molecular diffusion involving 
dissolution of the drug in the matrix of the membrane or also by the process of passage 
through solvent-filled pores or channels available between polymeric chains of a 




of the pores. Molecular diffusion is a particularly convenient way of studying the 
diffusion process (Martin, 1993). 
The study of simple diffusion or passive transport of solute molecules through liquids, 
solids and membranes is of considerable importance in pharmaceutical sciences and 
applies to a number of processes that form part of drug delivery such as dissolution of 
drugs from tablets, powders and granules; release from ointments and suppository 
bases; lyophilisation; ultra filtration and other mechanical processes. It also applies to 
passage of water vapour, gases, drugs and dosage form additives through coatings, 
packaging, films, plastic container walls, seals and caps, and permeation and 
distribution of drug molecules in living tissues (Martin, 1993). The most common 
biopharmaceutical use of diffusion flux studies is transport investigations of drug 
candidates across a barrier tissue, such as intestinal cell culture models or tissue models. 
It can also be advantageous in determining screening and selection criteria for candidate 
drug compound or to predict in vivo bioavailability of a given drug substance (Brodin, 
Steffansen and Nielsen, 2009). 
 
5.1.2 The diffusion equations 
The mathematical equation of heat conduction derived by Fourier in 1822 was adopted 
by Fick (1855) to put forward a quantitative basis for diffusion. The mathematical 
theory of diffusion is based on the hypothesis that the rate of transfer of diffusing 
molecules through a unit area of a section is proportional to the concentration gradient, 
as shown in Equation 5-1. 











, C is the concentration of a diffusing molecules in g/cm
3
, x is the space 
coordinate measured normal to the section in cm, and D denotes the diffusion 
coefficient (also called diffusivity) in cm
2
/sec. D is defined as a constant that describes 
the velocity of diffusion and is related to the properties of a given molecule in a given 
solvent. The SI units of kilogram and meter are sometimes used and time may be given 




occurs in a direction opposite to that of increasing concentration. Equation 5-1 is 
known as Fick’s first law (Crank, 1975). In some cases as in dilute solutions, D can 
reasonably be taken as being constant, while in others such as high molecular weight 
polymers; it depends very markedly on concentration. D is also affected by temperature, 
pressure, solvent properties and the chemical nature of the diffusing solute.  
Fick’s second law emphasizes the mass transport, change in concentration with time at a 
definite location rather than the mass diffusing across a unit area of barrier in unit time 
(Martin, 1993). Fick’s second law states that the change in concentration with time in a 
particular region is proportional to the change in the concentration gradient at that point 





   




Equation 5-2 represents diffusion only in the x direction. Fick's second law of diffusion 
represents solute concentration changes in three dimensions and can be expressed in the 




   
   
   
  
   
   
 
   
   
   
Equation 5-3 
 
Where C is the concentration of the diffusing solute; t denotes time, D is the diffusion 
coefficient and x, y and z are the three spatial (Cartesian) coordinates. This expression is 
not usually needed in pharmaceutical problems of diffusion, where movement in one 
direction is sufficient to describe most cases (Martin, 1993). 
Steady State is an important condition in diffusion. Fick’s first law, Equation 5-1 gives 
the rates of diffusion through unit area i.e. flux in the steady state of flow. The second 
law, Equation 5-3 on the other hand gives the change in solute concentration with time, 
at any distance i.e. a steady and nonsteady state of flow.  
A number of different experimental methods have been used to measure diffusion 
coefficients with reasonable accuracy; however it is essential to understand and decide 
how these measurements will be made. Takeru Higuchi who is considered as the “father 
of mathematical modelling of drug release” derived his classical equation using the 




(from one layer, if only one side of the film is exposed to the receptor medium; from 
two layers, if both sides of the film are exposed to the receptor medium) upon water 
penetration into the system. Initially the rate controlling membrane is completely free of 
drug. After an initial period of drug diffusing into the membrane, drug concentration 
gradients are built up within the membrane during early phase drug release. Based on 
maximum concentration gradient at the inner and outer membrane surface, steady state 
is reached where the release rate is constant and the cumulative amount of drug released 
can be calculated as a function of time. The extrapolation of the steady state straight line 
on the time-axis at t =“l²/ (6D)” gives lag-time which depends on the thickness of the 
release rate controlling barrier membrane and on the mobility of the drug within the 
membrane. The experimental measurement of these lag-times can be used to 
experimentally determine the diffusion coefficient of a drug in a specific barrier 
membrane (knowing the thickness of the membrane) (Siepmann and Peppas, 2011). 
The Stokes diaphragm cell developed by Stokes et al in 1950 is considered as one of the 
best tools to understand diffusion in liquids or across membranes (Cussler, 2009). It 
consists of two compartments separated by either a glass frit or a porous membrane and 
is similar to the diffusion cell as shown in Figure 5-1. Figure 5-1 shows a simple 
diffusion cell where the solute dissolved in solvent is present in left hand compartment 
of the cell i.e. donor compartment and solvent alone is placed on the right hand side of 
the barrier i.e. receptor compartment and the solute diffuses from the donor 
compartment through the central barrier or membrane to the receptor compartment. This 
is shown schematically in  
Figure 5-2. In diffusion experiments, sink conditions i.e. very low solute concentration 
is maintained in the receptor compartment so that the concentration gradient driving 











Figure 5-2: Schematic diagram showing concentration gradient of diffusing solute 


















      
  












    









The solute concentration will fall in the donor compartment of Figure 5-1 and rise in 
the receptor compartment until the system comes to an equilibrium, based on the rate of 
removal of solute molecules from the sink and the nature of the barrier. If sink 
conditions are maintained wherein the solute concentration in the donor compartment is 
so high that the concentration gradient is equivalent to the solute concentration, then the 
concentration gradient across the two compartments remains constant over long periods 
of time sufficient to cover experimental measurements. Then within each diffusional 
slice perpendicular to the direction of flow, the rate of change of concentration, ∂C/∂t, 






   
   
   Equation 5-4 
 





0. This means that the concentration gradient across barrier is constant, signifying a 
linear relationship between concentration and distance as shown by Figure 5-2. The 
concentration will not be rigidly constant but rather is likely to vary slightly with time 
i.e. when ∂C/∂t is not equal to 0. The conditions are referred to as “quasi-stationary” or 
“quasi-steady state” (QSS) with little error introduced by assuming steady state.  
Calculating diffusion coefficient using a diffusion cell requires an accurate chemical 
analysis method, total area available for diffusion, type and thickness of diaphragm used 
(Cussler, 1997). Taking into account the cross-sectional area available for diffusion, 
Fick’s first law for a simple diffusional cell set-up in which a polymer membrane of 
cross-sectional area A and thickness x separates the two compartments may be written 
as Equation 5-5, where the concentrations on the donor and receptor sides are CA and 
CB,  
  
    
  
   
   








Where (CA – CB)/x approximates dC/dx, this gradient within the polymer membrane 
must be assumed to be constant for the quasi-steady state to exist. Equation 5-5 
assumes that the aqueous boundary layer, which is the unstirred and static aqueous 
layers on both sides of the membrane do not significantly affect the total transport 
process. Unit activity ensures constant release of the drug at a rate that depends on the 
membrane permeability and the geometry of the dosage form (Martin, 1993). 
 
5.1.3 Mathematical models for diffusion 
General solutions for the diffusion equation can be obtained by means of mathematical 
modelling for a variety of initial and boundary conditions provided the diffusion 
coefficient is constant. The importance of in silico optimization of advanced drug 
delivery systems is expected to significantly increase in the future due to the advances 
in information technology (Siepmann and Siepmann, 2012). Mathematical modelling of 
drug release which uses mechanistic realistic mathematical description of mass transport 
(Siepmann and Siepmann, 2008; Siepmann and Peppas, 2001; Siepmann and Göpferich, 
2001; Siepmann, Siepmann and Florence, 2006), can be highly beneficial in 
understanding the mechanisms controlling drug release (Glaessl et al., 2010; Marucci et 
al., 2008; Brandl et al., 2010) and for quantitative predictions of the effects of 
formulation and design parameters on the resulting drug release kinetics (Siepmann et 
al., 1998; Siepmann, Lecomte and Bodmeier, 1999; Siepmann et al., 2010)(Siepmann 
and Siepmann, 2012). Relatively simple mathematical equations can be used to 
quantitatively describe drug release from predominantly diffusion controlled delivery 
systems (Siepmann and Siepmann, 2012). Drug product development could be 
accelerated and experimentation time and cost reduced by using in silico simulations to 
optimise composition and design of drug delivery systems in order to provide the 
desired drug release profiles. In addition, they can provide deeper insight into the 
underlying drug release mechanisms. 
Drug release from dosage forms can be controlled by different types of mass transport 
processes (Marucci et al., 2011; Yin and Li, 2011; Herrmann et al., 2007a; Kreye, 
Siepmann and Siepmann, 2011a; Kreye et al., 2011b). Processes involved could be 




polymer swelling, matrix former erosion, osmotic effects and various other phenomena 
(Lee, 2011; Lao et al., 2011; Sackett and Narasimhan, 2011; Frenning and Strømme, 
2003; Narasimhan, 2001). If several of these processes occur in sequence, the slowest 
process can be considered as the rate-limiting step for the entire sequence for a 
simplified mathematical description of drug release from the system (Siepmann and 
Peppas, 2012). Diffusional mass transport is the most common process involved in 
controlling drug release from a dosage form (Herrmann et al., 2007b; Zhou et al., 2005; 
Helbling et al., 2010b; Helbling et al., 2010a). In numerous cases drug diffusion is the 
predominant step (Seidenberger et al., 2011; D’Aurizio et al., 2011; Siepmann and 
Siepmann, 2011). In some cases drug diffusion could play a major role in combination 
with polymer swelling (Siepmann and Peppas, 2000; Siepmann, Streubel and Peppas, 
2002; Faisant, Siepmann and Benoit, 2002) or in combination with polymer 
degradation/matrix erosion. Also, in certain cases drug diffusion could even play a 
minor role (Siepmann and Göpferich, 2001). Diffusional mass transport is generally 
quantified by Fick’s law as described by Equation 5-1 and Equation 5-2.  
For the type of drug delivery system and type of release conditions, the following 
conditions including the so-called “initial and boundary” conditions need to be 
considered. 
 The “initial conditions” concern the initial distribution of the diffusing solute 
molecules in the system. The mathematical treatment is much simpler if this 
distribution is homogeneous.  
 The “boundary conditions” concern the conditions for diffusion at the boundaries 
of the drug delivery system. The boundary conditions are called “stationary” if the 
device dimensions are constant with time (no significant swelling or 
dissolution/erosion), are called “moving” in case of time-dependent device 
dimensions. If the device swells significantly, the boundaries are moving outwards; 
if the system dissolves/erodes significantly, they move inwards. 
 In case of “perfect sink conditions” the drug concentration in the surrounding 
bulk fluid can be considered negligible. Furthermore, if the receptor medium is well 
stirred, the liquid unstirred boundary layer surrounding the device is generally thin. 




much higher than the mass transfer resistance in this liquid boundary layer, the 
latter can generally be neglected.  
 Whether or not the diffusion coefficient (D) of the diffusing species is constant is a 
very important aspect when solving Fick's law of diffusion. The mathematical 
treatment is much simpler if D is constant which is the case in a purely diffusion 
controlled drug release system where matrix erosion or polymer swelling is not an 
issue and hence mathematical modelling is very simple. Reasons for time and 
position dependent diffusion coefficients might include matrix erosion, polymer 
swelling and/or degradation (Verhoeven et al., 2009; Lin and Metters, 2006), where 
generally no “ exact analytical solutions” of Fick's law can be derived (solutions 
quantifying the amount of drug released as a function of time), but “ approximate 
numerical solutions” can be used (Frenning, 2011; Perale et al., 2009).  
General solutions for the diffusion equation can be obtained by means of mathematical 
modelling for a variety of initial and boundary conditions provided the diffusion 
coefficient is constant. For the appropriate selection of the mathematical equation, that 
is valid for a particular type of diffusion controlled dosage form, the following 
information is crucial; 
1. Type of the system – in a reservoir system the drug and the release rate controlling 
barrier material (polymers) are physically separated (here the drug may be located at the 
centre of the dosage form whereas the polymer forms a membrane surrounding this drug 
depot). In a matrix system, also called “monolithic system” the drug and the release rate 
controlling material (polymers or lipids) are homogeneously distributed throughout the 
device. 
2. Drug concentration – A high initial drug concentration in the reservoir medium is 
preferred to maintain steady state for a longer time. The exact solubility of the drug in 
the wetted device might be difficult to ascertain. Here a rough estimate of the drug 
solubility in the receptor medium at 37 °C might be used, taking into account presence 
of other dissolved compounds which might significantly affect drug solubility. 
3. Geometry of the drug delivery system – diffusional mass transport determinations 
through thin films are simpler compared to other geometries (Siegel, 2000; Helbling, 





Understanding the mass transfer behaviour of insulin through the gel is essential for the 
modelling, design, optimisation and application of the closed loop implantable INsmart 
device, a reservoir system. Measuring the diffusion coefficients of drug molecules is 
important for theoretical predictions of the drug bioavailability in terms of drug release. 
Determination of diffusion of drug molecules in aqueous media can be complicated 
where avoiding disturbance is not easy. Diffusion coefficient measurements can be done 
in a variety of ways and estimates made in many systems for a range of drugs from 
small to large molecules. The approach presented here shows progression adopted in 
selecting a suitable method and mathematical model with the use of a model dye 
(tartrazine) in a model gel (agarose) media initially for determining diffusivity.  
Based on the type, geometry and design of the closed loop insulin delivery device, 
INsmart the following mathematical models and methods were considered for 
measurement of diffusion coefficient. The mathematical methods presented in detail 
below are based on general solution for the diffusion equation, Fick’s law, taking into 
account the initial and boundary conditions and assuming that the diffusion coefficient 
is constant.  
 The Laplace transform method  
 The diffusion cell quasi-steady state (QSS) method 
 The diffusion cell time-lag (TL) method 
-The TL Intercept method (TL intercept) 
-The TL Slope method (TL slope) 
These have been discussed individually in detail below.    
 
5.1.3.1 The Laplace transform method  
The solutions for diffusion usually take two standard forms. It comprises a series of 
error functions which are suitable for numerical evaluations at early stages of diffusion 
or is in the form of trigonometrically derived series which cover large values of time. 




replaced by a series of Bessel functions which are used in the Laplace transform 
equation which is essentially an operator method and is most powerful for complicated 
problems. Application of the Laplace transform to the diffusion equation removes the 
time variable, leaving an ordinary differential equation; the solution of which yields the 
transform of the concentration in terms of x, y, z and time, satisfying the initial and 
boundary condition. 
Consider the problem of diffusion in a semi-infinite medium, x > 0, when the boundary 
is kept at a constant concentration C0, the initial concentration being zero throughout the 
medium. 







   





Satisfying the boundary condition; 
C = C0, x = 0, t > 0 
And the initial condition; 
C = 0, x > 0, t = 0 
And is given by; 
 
           
 





Where, erfc z = 1 – erf z 
Equation 5-7 can be used as a solution for a diffusion problem, provided Equation 5-6 




The cylinder experimental setup is such that the two solutions, one with diffusing dye 
and the other without are separated by a membrane or gel (in this case). The 
concentration profile with distance in this setup over time changes at the junction and 
assumes a half Gaussian curve (or one half of a normal distribution). At this time the 
concentrations at the two ends of the cylinder are assumed to be as they were at the start 
(i.e. full solute concentration at the lower end and zero concentration at the upper end). 
Eventually the dye reaches the same concentration throughout. The integral for the 
Gaussian curve is also known as the complementary error function (erfc) and it is equal 
to (1-error function) or (1-erf). The error function is actually the inverse curve and 
values can be found tabulated like log tables. 
 
5.1.3.2 The diffusion cell technique – Quassi steady state (QSS) method 
The measurement of effective diffusivities (De) for substrates within gel matrices in the 
form of beads or large membranes has been reported extensively, Klein,J (1985), 
Vanancio,A (1997), Tanaka,H (1984), Bassi,A.S. (1987), Axelsson,A (1988) and 
Teixeira,J.A. (1994)) as cited by (Zhang and Furusaki, 2001). The most common 
techniques for determining diffusivities are the non-steady state technique (Tanaka, 
Matsumura and Veliky, 1984) and the diaphragm diffusion cell technique (Axelsson and 
Persson, 1988). The diffusion cell technique, modified particularly for determining De 
within the gel, is recognized as reliable, rapid and accurate technique (Axelsson and 
Persson, 1988).  
The diffusion cell technique uses a diaphragm diffusion cell that consists of two 
identical chambers separated by a gel membrane in which the diffusivity will be 
measured. In both chambers, sufficient mixing will ensure negligible external mass 
transfer resistance. Initially, one chamber (A) is filled with a solution that contains the 
solute and the other (B) with pure solvent. As the solute diffuse through the membrane, 
the concentrations in both chambers are measured as a function of time. After an initial 
period of time (time-lag), a quasi steady state of solute flux is attained. The diffusivity 
can be estimated by either the QSS or TL method that has been treated mathematically 




The diffusion coefficient D as defined by Fick’s first law is based on the average 
concentration of solute in the whole gel. The effective diffusion coefficient, De , is based 
on the average concentration of solute in liquid phase in equilibrium with the average 
concentration of solute in the whole gel (CL) and is represented by, 
 
       






The relationship between diffusion coefficient, D, and the effective diffusion coefficient, 
De in gels has been discussed by Zhang (Zhang and Franco, 1999; Zhang and Furusaki, 
2001) and is represented by Equation 5-9 
 
 




Where, K is the equilibrium partition coefficient. 
The QSS method assumes that a QSS is attained, resulting in a linear concentration 
profile of the solute in the gel membrane after an initial period of time (t0).  
The molar flow, N can be obtained by integrating Equation 5-8 to obtain Equation 
5-10; 
 
         






Under QSS, the flux of the solute leaving chamber A equals the flux of the solute 






           
  
   






Another condition that needs to be satisfied is that the volumes VA and VB of the two 
chambers separated by the gel are constant. 
By combining Equation 5-10 and Equation 5-11, De can be calculated from the slope 
of the line obtained by plotting the left-hand side of Equation 5-12 against time t: 
 
   
              
         
   
  
 










The essential condition to apply Equation 5-12 is that the QSS must be fulfilled, i.e. 
‘the solute flux in’ has to equal ‘the solute flux out’ of the gel, mathematically checking 
whether Equation 5-11 is satisfied.  
 
5.1.3.3 The diffusion cell technique - The time lag (TL) method 
The diffusion cell technique, where the diffusion mass transfer process occurs through 
the gel membrane, has been used to estimate diffusivity using the TL method that has 
been treated mathematically previously (Crank, 1975; Cussler, 1997). 
Here, the basic conditions assumed are the two chambers are well mixed, that both 
chambers are large enough so that changes in concentration are negligible and that 
initially solute is only present in chamber A. Upon satisfaction of these conditions, 
Fick’s law can be solved to give the total amount of solute transferred through the 
membrane (Qt), Equation 5-13: 
 
                
       
 










To estimate the diffusivity, the TL method uses a plot of the total amount of solute 
transferred through the gel membrane (Qt), the left-hand side of Equation 5-13 vs. time 
(t) as represented in Figure 5-3.  
 
Figure 5-3 : Total solute mass transferred through the gel membrane (Qt) as function of 
time in through-diffusion tests. The slope of linear part (steady state) gives D and its 
intercept gives lag time. 
 
The TL Intercept method  
 The intercept of the linear part of the curve is known as the ‘lag time’, that physically 
corresponds to the time point when the solute appears in downstream chamber B and is 
given by Equation 5-14, 
 










































Time (t)     
Transient state 




In literature, the diffusion coefficients (D) for solute molecules have been calculated 
exclusively from the lag time using the TL method (Frisch and Prager, 2003; Venâncio 
and Teixeira, 1997; Chen, Loo and Wang, 2012; Oztan and Mutlu, 2005). 
 
The TL Slope method  
Alternatively, D can also be estimated from the plot slope. It, however, remains 
unresolved as to which of the two estimations produces the correct result. Zhang and 
Furusaki (2001) have discussed and compared the QSS method with widely used 
methods, the TL method and the variant-quasi- steady- state (VQSS) method in order to 
assess their applicability. The VQSS method as developed by Converti et al (Converti et 
al., 1996)  evaluates De from a diffusion cell experiment by rearranging the QSS 
Equation 5-12 for mass balance for the receptor chamber and by estimated point by 
point and then averaging to give a global De value. They concluded that in their 
experiments it was observed consistently that diffusivities estimated by the TL intercept 
method were substantially lower than those estimated by the TL slope method. 
However, the estimation by the TL slope method produced similar value as that by the 
QSS and VQSS method when a QSS is established. They concluded that the TL method 
using the intercept, which has been extensively used in literature, generates erroneous 
estimations of diffusivity in most cases and should not be relied upon. 
 
5.2 Outline of experiments 
Diffusion coefficient measurements were performed using a custom made experimental 
test rig which mimics the peritoneal cavity and data was recorded using UV or 
fluorescence spectroscopy. Initially model dyes such as tartrazine and fluorescein 
sodium and model gel such as agarose were used for technique development and 
mathematical model selection. The primary aim for using model dyes and gels was for 
understanding the diffusion kinetics of small solute molecules, to develop an 
appropriate experimental technique and for selecting appropriate mathematical models 




The experimental results presented here provide a good platform for understanding the 
drug release mechanism of insulin from the formulation held within the device and the 
performance window for the device, which are discussed in Chapter 7 and Chapter 8. 
The following assumptions and consideration were made for the INsmart device set-up 
used later on in the experiments (conditions considered for applicability of the 
diffusional equations) for determining insulin diffusivity; 
• The INsmart device set-up is considered to have “perfect sink conditions” during the 
entire experimental time period, here the drug concentration in the donor compartment 
is high and in the surrounding bulk receptor compartment fluid is considered negligible. 
• Diffusional drug mass transport is release-rate limiting in the gel. 
• The diffusion coefficient of the drug (within the gel ‘film’) is constant and does not 
depend on its time or position within the device. 
• The device (gel) is not significantly swelling (or swells very rapidly upon contact with 
receptor medium and then reaches an equilibrium state) or dissolve during drug release. 
• The device (gel) is not significantly eroding during drug release or losing its 
constituents by some other process. 
• Mass transfer resistance due to liquid unstirred boundary layers on the surface of the 
system is negligible. As the receptor medium is well stirred, the liquid unstirred 
boundary layer surrounding the device is generally thin. The mass transfer resistance in 
this liquid boundary layer is much lower than that within the drug delivery system for 
drug diffusion and hence the former can be neglected. 
• The initial drug concentration in the gel film/slab is much higher than the solubility of 
the drug in the (wetted) system. 
• Gel placed in the device can be considered as a thin film with negligible edge effects, 
which means that diffusional mass transport through the edges of the film is negligible 
compared to diffusional mass transport through the film's main surface. The 





 The development of an experimental model and selection of an appropriate 
mathematical model with an aim of determining the diffusivity of insulin through the 
glucose-responsive gel in the INsmart device was performed in a sequential manner as 
shown in Figure 5-4. The left hand arrow describes each experimental stage with dye, 




Figure 5-4: Development of mathematical model for diffusion study 
 
A simple diffusion model (tube) was initially investigated to develop the experimental 
technique and to understand the diffusivity of a model dye, tartrazine through a model 
gel, agarose.  This experimental model allowed a quick, easy and efficient system to test 




•Experimental technique development with model dye and gel 
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•Understand diffusivity in NP gel with InSmart device 





•Understand diffusivity of fluorescent dye (smaller) in NP gel with InSmart 
device 
• Experimental technique development using fluorimeter 




Tartrazine, molar mass: 534.36 Da was selected as a model dye because of its small 
size, availability, stability, compatibility with gels, its non-staining properties as well as 
strong absorbance at 427 nm aiding easy UV/Vis assay. Tartrazine diffusivity in agarose 
gel was checked, taking into account factors possibly influencing the diffusion rates 
such as tartrazine concentration, gel thickness and agarose concentration. From various 
possible gels agarose was chosen because of its neutral structure (Foord and Atkins, 
1989). Diffusion in agarose, similar to diffusion in polymers, is regarded as diffusion in 
a porous solid matrix where pores are connected and filled with the solvent. Agarose 
forms a gel at very low concentrations and has been used to find the aqueous diffusion 
coefficient of small molecules in water as the water in these gels exists mainly as “free” 
water through which the solutes move unhindered –i.e. the micro-environment is not 
viscous whereas the macro-environment is.  
The four mathematical methods for determining the diffusion coefficient described in 
Section 5.1.3, namely: Laplace transform, diffusion cell-QSS, TL, slope and intercept 
analysis were assessed and compared for their applicability using the tube model and 
model dye and gel. 
 
Following tube diffusion, experiments were undertaken with the INsmart device using 
the model dye, tartrazine and gel, agarose held within the device.  Experimental 
technique improvement learnt from the tube set-up was applied to the device set-up.  
Selected agarose gels were used in these experiments. Further the applicability of the 
four mathematical models for determination of diffusion coefficient was assessed and 
suitable models selected for further experiments.  
The selected mathematical models were then taken forward to determine diffusivity of 
tartrazine in the non-polymerised dex2M-conA gel (NP gel) prepared using dextran 
(molecular weight 2 million daltons) and concanavalin A (conA) housed in the INsmart 
device. The NP gels were used instead of the cross-linked dex500MA-conAMA gels 
(CL gel) in order to study the underlying drug release mechanism. Refer to Chapter 2 
for the function of the gels and Section 5.3.3 and Chapter 6, Section 6.2.1 for 
preparation of the gels. Tartrazine diffusivity through NP gel was also determined in 




concentration of 0.1% w/w as used in the experiments corresponds to ~5.5 mmolL
-1 
the 
basal normal limit of fasting plasma glucose for most individuals, 0.2% w/w 
corresponds to ≥ 11.1 mmolL
-1
 which indicates diagnosis of diabetes and higher 
concentrations of 0.5% w/w (27.75 mmolL
-1
) and 1% w/w (54 mmolL
-1
) are levels that 
might be reached or threatened after food or glucose challenges. 
The next step in the experimental plan was to understand the diffusivity of glucose 
molecule itself in the NP gel to gain some idea of the responsiveness of the gel to 
glucose levels. However, it is difficult to determine the diffusion properties of glucose 
molecule itself in the NP gel as free glucose dismantles the gelatinous three- 
dimensional network of the gel by competitive displacement resulting in a fall in its 
viscosity. Fluorescein sodium was chosen as a glucose mimic as its molecular weight 
(376.28 Da) lies midway between glucose (180.2 Da) and tartrazine (534.3 Da). There 
were two advantages for using fluorescein sodium, firstly to provide some estimation of 
glucose diffusivity in the NP gel and secondly to aid with experimental technique 
development using the fluorimeter, which is required for diffusivity determination of 
fluorescently labelled insulin through the NP gel and CL gel as discussed in Chapter 7. 
Fluorescein sodium salt (Acid Yellow 73), C20H10Na2O5, molecular weight 376.28 Da 
has been extensively used as fluorescent tracer to study blood brain barrier (Oishi et al., 
1989), in permeability and perfusion studies due to its small molecular radius (De 
Bruyn et al., 2011; Kozler and Pokorny, 2003). Its excitation wavelength of 485 nm and 
emission wavelength of 515nm makes it suitable for fluorescent measurements. 
Each experimental stage has been discussed separately below along with details of the 
experiment system set-up and diffusivity results determined using the different 
mathematical models. 
 
5.3 Materials and methods 
5.3.1 Materials /Chemicals and reagents 
Agarose, batch no: 19843, gelation temperature (1.5% Gel) 32-40°C was purchased 
from Fisher Bioreagents, UK. Tartrazine No T-0388 (C.I.1914, Acid Yellow 23) Lot: 




Ltd. (Poole, Dorset, UK). Concanavalin A, from Canavalia ensiformis, lyophilised 
powder (Type VI) (conA) and dextran (produced by Leuconostoc mesenteroides, strain 
no. B512; average molecular weight 2000 kDa) (dex2m) were purchased from Sigma 
Aldrich Co. 3050, St Louis, M.O. 63103, USA 314-771-5765. Fluorescein sodium salt, 
molecular weight 376.28 Da, was obtained from BDH. 0.2 µm cellulose nitrate 
membrane filter was purchased from Whatman International Ltd, England. Dialysis 
membranes (molecular weight cut off: 100 kDa) were obtained from Spectrum Europe 
B. V. (4800 DG Breda, Netherlands). Metric 180 PVC tubing-FDA/USPVI (1mmID, 
2mmOD, 5mmWall) was purchased from Nalgene® Brand products,USA. All other 
chemicals were of analytical grade and distilled water was used throughout.  
 
5.3.2 Preparation of agarose gel  
Agarose gels, 0.5%, 0.7%, 1%, 1.5% and 2% w/w were prepared in glass beakers. Gels 
were prepared by dispersing agarose powder in distilled water using a magnetic stirrer 
and left for about 10 min to ensure sufficient hydration. The mixture was then heated to 
80°C with continuous stirring for approximately 10 minutes and cooled to 60°C prior to 
casting. For storage, it was mixed thoroughly and cooled at room temperature for 2-3 
hours and stored at 4°C until use. For casting purposes the stored gel was brought to a 
boil with continuous stirring and the solution was cooled to 60°C prior to casting. 
 
5.3.3 Preparation of NP gel  
1 g of conA was dissolved in 8 mL of distilled water containing 0.3% w/w sodium 
azide. 1g of dex2M was then added to the solution and stirred to form a viscous 
mixture. The mixture was stored at 4°C for at least 24 hours before use. 
For experiments with glucose, the relevant amount of glucose was added to the prepared 
NP gel and mixed and stored at 4°C for at least 24 hours before use. Prior to use the gels 
were allowed to equilibrate at room temperature for at least 2 hours. 
 




The absorbance data from diffusion experiments was first converted into concentration 
of tartrazine using a calibration curve. The data was then plotted as described below 
based on the mathematical methods for calculating diffusion coefficient; 
 
The Laplace transform method  
Here the solution for the diffusion problem as described in Section 5.1.3.1, Equation 
5-7 was used. 
 
           
 






The data was plotted as Cx/C0 over time as shown in Figure 5-5; 
Figure 5-5: Representative plot of the Laplace transform method: Evaluation of 

















Using the following solution for the equation, the erf function was calculated by reading 
the Cx/Co values at five different time points and solving for D at that particular time. 
The reported D was an average calculated at five different time points. 
 
   
  
  
      
 
      






   
 
 
       
  
  







Here the solution for diffusion problem as described in Section 5.1.3.2, Equation 5-12 
was used. 
   
              
         
   
  
 











De was calculated from the slope of the line obtained by plotting the left-hand side of 
Equation 5-12 against time t: 






Figure 5-6: Representative plot of the QSS method: Evaluation of diffusivities, De for 
tartrazine in 0.7% w/w agarose gel using the tube experiment.  
 
Using the slope of the curve at the QSS the Equation 5-12 was solved for De as shown 
in Equation 5-17, 
 
         
 











TL slope and TL intercept methods 
Here the solution for the diffusion problem as described in Section 5.1.3.3, Equation 
5-13 was used. 
                
       
 








y = -5.43x10-7x + 2.69x10-3 



































To estimate the diffusivity, the TL method uses a plot of the total amount of solute 
transferred through the gel membrane (Qt) vs. time (t) as shown in Figure 5-7; 
 
 
Figure 5-7: Representative plot of the total amount of tartrazine transferred through the 
gel, Q vs. time by the TL method: Evaluation of diffusivity, D for tartrazine in 0.7% 
w/w agarose gel using the tube experiment. 
 
For the TL slope method, D was estimated from the plot slope by solving Equation 
5-19. 
        








    
       





y = 9.45x10-11x - 4.63x10-7 

















For the TL intercept method, the intercept of the linear part of the curve which is known 
as the ‘lag time’, is determined from the plot and D is determined by solving Equation 
5-20. 




(Equation 5-14 repeated 
here for reference) 
 
 
   
  






5.4 Determination of diffusion coefficient of tartrazine in agarose using 
tube set-up  
A simple system using model dye, tartrazine and gel, agarose was investigated as a 
diffusion model with the ultimate aim to model insulin release through the glucose-
responsive gel in the INsmart. Here a tube set-up was used to test the feasibility of the 
system, to develop the experimental technique and to understand the diffusivity of a 
small molecule.  
The four mathematical methods for determining the diffusion coefficient described in 
Section 5.1.3, namely: Laplace transform, diffusion cell-QSS, TL, slope and intercept 
analysis were assessed and compared for their applicability using the tube set-up and 
model dye and gel. 
 
 
5.4.1 Experimental set-up and procedure of diffusion 
Polyethylene tubes (dimensions: ranging from 11 to 20 mm diameter) were used. The 
casting of agarose gel was performed by placing the cylindrical tube on a clean glass 
plate and agarose solution maintained at 60°C was decanted into the tube to produce 
hydrogels ranging from approximately 3 to 9 mm thick.  During this it was ensured that 




solution was allowed to cool and gel at room temperature for approximately 15 min. 
The tube was lifted slowly and gently from the glass plate and these agarose containing 
tubes were used immediately for experiments. 





Figure 5-8: Experimental set-up for diffusion in tube experiment. 
 
Figure 5-9: Photograph of set-up for tube measurements. 
 
Agarose gels – 0.5%, 0.7%, 1% and 2% w/w were prepared as described in Section 
5.3.2. Once the gel was cast within the tube the following steps were followed; 




2) The receptor beaker containing distilled water (approximately 25 to 35 mL) was 
stirred using a magnetic rod to ensure uniform concentration in the receptor and to 
reduce sampling errors.  
3) The tube cast with agarose gel was placed in a receptor beaker containing distilled 
water using a stand and clamp. The height of the tube in the beaker was adjusted 
so the level of water in the beaker matched the donor solution level to ensure no 
pressure differences. 
4) The donor tartrazine solution (approximately 1 mL of 1% w/w solution) carefully 
added onto the top of the gel in the tube and the exact volume was noted. 
5) 0.1 mL of sample was withdrawn every 15 min and diluted to 3 mL with distilled 
water to ensure measurement in the detection range and analysed using Perkin 
Elmer UV/Vis Spectrometer Lambda 40 at 427 nm.  
6) After each sampling, equivalent volume (0.1 mL) of water was added to the 
receptor to eliminate any errors due to volume difference. 
Sampling was performed over a period of minimum 5 hours. All experiments were 
performed at 20°C and in triplicate. The UV Winlab wavelength program software 
application provided by PerkinElmer, UK was used to measure the sample absorbance 
at 427 nm. Tartrazine shows strong absorbance at 427 nm as shown in Figure 5-10. The 
absorbance data was imported into Excel for the concentration time plots. The tartrazine 
absorbance intensity at 427nm wavelength was linear with respect to concentration thus 
enabling simple conversion of intensity data into concentration values observed for 






Figure 5-10: UV spectrum for tartrazine showing strong absorbance at 427 nm.  
 
Figure 5-11: Calibration graph for tartrazine (0 – 20 µg/mL) (using disposable cuvette). 
(Data represent mean±SD of six measurements, error bars present but may not be 




















y = 0.0448x + 0.0004 

























5.4.2 Results and Discussion 
The diffusivities of tartrazine in increasing agarose gel concentrations from 0.5% to 2% 
w/w were determined using the Laplace transform; QSS, TL slope and TL intercept 
methods. The results are as presented in Table 5-1.  
 
Table 5-1: Diffusion coefficient values (D and De) for tartrazine in increasing agarose 
gel concentration determined using different methods. The number of replicates for each 
experiment was 3. Where VA – volume of tartrazine solution above the gel, VB – volume 





QSS TL slope TL intercept 























0.5  1.04 ± 0.30 0.22 ± 0.07 4.13 ± 0.42 10.57 ± 2.50 
0.7  0.82 ± 0.24 0.24 ± 0.07 4.46 ± 0.47 8.37 ± 2.25 
1  0.75 ± 0.11 0.32 ± 0.11 5.47 ± 1.58 5.45 ± 3.37 
2  0.70 ± 0.07 0.20 ± 0.06 3.38 ± 0.68 6.34 ± 2.30 
2  
(where VA ~VB ) 
2.00 ± 0.74 3.40 ± 0.36 6.14 ± 2.20 11.92 ± 2.79 
 
Table 5-1 shows the D values determined using the Laplace transform and QSS 
methods for diffusion in tube are significantly different from the values determined 
using the TL slope and TL intercept methods for all agarose gel concentration. The data 
thus suggested that either the QSS state was not achieved or because VA and VB were not 
same (the second requirement for QSS method). By keeping VA and VB as close to each 
other as possible the tube set-up can be considered to be same as a diffusion cell. The 
results for 2% w/w where VA ~VB  (the tartrazine solution placed above the gel being VA 
and water in the beaker being VB) are as shown in the table, here the D values for the 
Laplace transform, QSS and TL slope method match, however the D obtained using the 




The experimental data are graphically presented in Appendix 3 the Laplace transform 
method data has been presented as Cx/C0 vs. Time (s), QSS method ln (CA(t)-CB(t)/CA(t0)-
CB(t0)) vs. Time (s) and the TL slope and TL intercept method Q(g) vs. Time (s). 
Representative data for 0.5% w/w, 0.7% w/w, 1.0% w/w , 2.0% w/w agarose gel and 
2.0%w/w agarose gel with matched donor and receptor volumes are presented in Figure 
A3-1, Figure A3-2, Figure A3-3, Figure A3-4 and Figure A3-5, respectively.  
 
Constraints and factors affecting the design of experimental protocol 
The simple tube experiments enabled to identify a number of key factors that need to be 
controlled and defined to progress with the experimental protocol for the next stage. For 
further experiments the test rig was changed to be very like the actual conditions for the 
INsmart device. Diffusivity was measured using the four mathematical methods in a 
glucose sensitive gel held within the INsmart device.  
 The following constraints and factors that need consideration were identified for 
refining the experimental protocol; 
 The “boundary conditions” needs to be constant which means that the glucose-
responsive gel should show no swelling or erosion. This was achieved by the 
INsmart design itself in which the glucose-responsive gel is housed within the 
device between two cellulose nitrate membranes supported by stainless steel mesh 
in such a way which restricts the gel from swelling or eroding. 
 “Perfect sink conditions” was achieved by using a high concentration of drug/dye in 
the donor compartment and ensuring that the receptor fluid is well stirred.  
 Understanding the geometry of the system is essential to design the experiment 
around the constraints imposed by the model used to interpret the data and ensure 
its suitability. The gel placed in the device can be considered as a thin film with 
negligible edge effects, the gel is contained within a stainless steel housing with the 
gel spacer surrounding the gel film, as the surface of the film exposed to the 
receptor medium is large compared to its thickness which means that diffusional 




main surface. The mathematical description of drug diffusion here can thus be 
restricted to one dimension. 
 Osmotic effects – Osmotic effects within the whole system can be kept constant if 
the boundary conditions as discussed above are kept stationary. For diffusivity 
experiments in presence of glucose, the osmotic effects due to presence of glucose 
are avoided by maintaining same glucose concentration throughout the system; 
donor side, in the gel and receptor side. 
 Detection limit – The detection limit for the detector used should be taken into 
account as very high drug/dye concentration on donor side coupled with low 
volumes on receptor side could lead to the detector getting saturated very quickly. 
This could result in inability to detect the lag time as well as the steady state. 
 Gel area and thickness – The diffusion rate of the drug depends on the gel 
permeability and the gel area and thickness (geometry of the device). Depending on 
the size and shape of the diffusing molecules, the gel pore sizes affect their simple 
diffusion. The total amount of the drug delivered from the device however depends 
on the surface area available to diffuse through, which in turn depends on the 
geometry of the device. The gel thickness affects the rate at which the diffusing 
drug is delivered; the flux is inversely proportional to the gel thickness, the thinner 
the gel quicker the drug is delivered.  
 Volume of receptor fluid – As was an outcome from the tube experiments in order 
to attain a QSS state in a diffusion cell type system, it is essential to maintain the 
donor and receptor volume same. Furthermore for detection purposes it is 
paramount to maintain an appropriate volume, if the volume is too high the diffused 
species will be detected after a considerably long time thereby increasing the 
overall experimentation time.  
 Gel concentration: The homogeneity of the gel affects the diffusivity of the 
diffusing species, unwetted areas lead to inconsistent diffusion coefficient values. A 
non-uniform gel will have uneven thickness across the surface of a thin film/ slab. 
Therefore special care is required in preparation of the gel. The presence of a 
significant meniscus could also affect the D value calculated especially when using 




INsmart device this should be less of a concern as a gel spacer is used and the 
weight of gel placed in it is always kept constant. 
 
5.5 Determination of diffusion coefficient of tartrazine in agarose in the 
INsmart device  
Following the tube diffusion measurements further experiments were untaken with the 
INsmart device using tartrazine and agarose gel held within the device.  From the tube 
experiments, it was understood that the models can be applied only when the volumes in 
the donor and receptor compartments are kept the same and that the TL intercept 
method might not give consistent results. The experimental set-up was designed to 
incorporate the learning from tube diffusion experiments. Diffusion of tartrazine was 
assessed in 2 and 1.5% w/w agarose gels, selected as model gel concentrations for use 
with the INsmart device. Here the applicability of the four mathematical models for 
diffusion coefficient determination was assessed for tartrazine in agarose gel held within 
the INsmart device.  
 
5.5.1 Experimental set-up and procedure of diffusion 
The design of the INsmart device has been explained in Chapter 2, Section 2.1. 
Assembling the device was crucial for the success of the experiment and its 







Figure 5-12: Figure showing the various components of the INsmart device. Key: A- 
polycarbonate base, B- parafilm, C-stainless steel screen, D- membrane (specific 
MWCO), E-stainless steel gel spacer, F- stainless steel mesh, G-stainless steel top with 
O-ring, H-mould for holding device whilst assembly. 
 
The device was assembled, ensuring that components were placed sequentially as 
shown in Figure 5-12 and PTFE (Polytetrafluoroethylene) grease, (Magnalube®-G) 
applied between metal components. The polycarbonate base which has the luer 
connections was placed on a specially designed mould to keep it flat. A 0.2 µm cellulose 
nitrate membrane was placed in between two stainless steel screens with parafilm rings 
in between for a tight seal, ensuring that they are placed flush. The stainless steel gel 
spacer was placed with a parafilm ring over the screen. The agarose gel solution at 60°C 
A B C 
F B D B E 
B 
C 







was poured into the gel spacer, 3 mm thick and left to set at room temperature for 
approximately 15 minutes. After the agarose gel had formed a 0.2 µm cellulose nitrate 
membrane and stainless steel mesh were placed on top with parafilm rings in between to 
ensure a good seal is formed. The stainless steel top which holds the O-ring was 
screwed on and tightened, initially by hand and then using a specially designed wrench. 
This was to ensure that there were no gaps in between components which could lead to 
leak in the device.  
After the device was assembled as described above, the experiment test rig was set up as 
shown in Figure 5-13. The receptor compartment circuit is a closed circuit; with 
receptor reservoir to ensure equal volumes in both receptor and donor sides and to 
eliminate any air bubbles generated. As shown in Figure 5-13 and Figure 5-14, the 
polycarbonate base (donor compartment) of INsmart device was used as part of the 
receptor in this setting while the donor compartment was on the outside. This receptor 
compartment plumbed with tubing was made closed circuit by emptying and drawing 
from a receptor reservoir. The circuit passes through the UV spectrometer to enable 






Figure 5-13: Schematic of the experimental set-up for diffusion of tartrazine in agarose 






Figure 5-14: Photographs of the experimental set-up for diffusion of tartrazine in 
agarose gel housed within the INsmart device. 
 
After the INsmart device was assembled as described above the following steps were 
followed; 
1) The assembled device with tubing was placed in the empty donor beaker.  
2) The receptor reservoir with tubing from the device was placed on a magnetic stirrer, 
Electronic Stirrer Model 300 Rank Brothers Ltd, Cambridge, England.  
3) The circuit was completed by placing a quartz flow cell in the Perkin Elmer 
UV/Vis Spectrometer Lambda 40 
4) The Watson-Marlow 101U peristaltic pump and the UV spectrometer were 
switched on. The pump speed was kept constant with tubing volume output of 7.4 
mL/min. 
5) A known volume of water was placed in the receptor reservoir and passed through 
the entire circuit filling the device receptor compartment and ensuring no air 
bubbles were present in the circuit. 




7) As soon as the blank reading was taken on the spectrophotometer, the tartrazine 
solution was placed in the donor beaker and the experiment was started to record 
readings at 1min interval.  
8) The UV spectrophotometer monitored the amount of tartrazine dye diffusing 
through the gel from the donor side by recording the absorbance of the solution in 
the receptor side passing through the flow cell at 427 nm wavelength. 
Measurements were taken at 1min intervals over time (minimum 5 hours). All 
experiments were performed at 20°C and in triplicate. The UV Winlab wavelength 
program application provided by PerkinElmer, UK enabled time dependent absorbance 
measurements at fixed wavelengths at defined time intervals over a specified period of 
time. The UV Winlab software in wavelength mode was set to the above wavelength to 
record absorbance measurements per minute. A macro, Waveprog was used to group 
data for import into Excel for concentration time plots. The absorbance at 427 nm 
wavelength was found to be linear to tartrazine concentration (0-20 µg/mL) thus 
enabling simple conversion of absorbance data into concentration values observed for 






Figure 5-15: Calibration graph for tartrazine (0-20 µg/mL) (using quartz flow cell). 
(Data represent mean±SD of ten measurements, error bars present but may not be 
visible as smaller than marker size). 
 
Absorbance data was converted into tartrazine concentration using the calibration curve, 
Figure 5-15. The data was plotted based on the mathematical methods; Laplace 
transform, QSS, TL slope and TL intercept methods for calculating diffusion coefficient 
as discussed in Section 5.3.4. 
 
5.5.2 Results and discussion 
The diffusivities of tartrazine in agarose gel concentrations 2% and 1.5% w/w were 
determined using the Laplace transform, QSS, TL slope and TL intercept methods and 
are presented in Table 5-2.  
 
y = 0.0382x + 0.0037 
























Table 5-2: Diffusion coefficient values (D and De) for tartrazine in agarose gel using 
INsmart device determined using Laplace transform, QSS, TL slope and TL intercept 
methods. The number of replicate measurements is shown by n=x. 
Agarose gel 
concentration 
Laplace transform QSS TL slope TL intercept 























2 (n=4) 0.34 ± 0.05 2.47 ± 0.44 1.72 ± 0.30 2.11 ± 0.23 
1.5 (n=1) 0.38 2.38 1.66 2.56 
 
It can be seen in Table 5-2 that the diffusivities estimated using the Laplace transform 
method for tartrazine diffusion in device are a decade slower than the values determined 
using QSS, TL slope and TL intercept methods. Diffusion coefficient values (D or De) 
for tartrazine determined using QSS, TL slope and TL intercept methods were found to 






/s for 2 and 1.5 %w/w agarose gel 
respectively). The diffusivity of tartrazine in 2% w/w agarose gel determined in the 
INsmart device was also comparable to D values obtained when determined using tube 
where the D values in 2% w/w agarose with equal donor and receptor side volumes 




/s.   
Using the experimental set-up with the INsmart device a QSS state was achieved and 
the QSS and TL methods gave reliable results. Hence these mathematical models can be 
taken forward for future diffusivity estimations.  
The experimental data are graphically presented for the Laplace transform method the 
data has been presented as Cx/C0 vs. Time(s), for QSS method ln (CA(t)-CB(t) /CA(t0)-
CB(t0)) vs. Time(s) and for TL slope and TL intercept method Q(g) vs. Time(s), 
representative data for 2.0 %w/w  and 1.5 %w/w agarose gels are presented in 





5.6 Determination of diffusion coefficient of tartrazine in non-
polymerised dex2M-conA mixture in INsmart device 
Mixtures of dextran, molecular weight 2 million daltons (dex2M) and concanavalin A 
(conA) will be referred to as non-polymerised dex2M-conA gel (NP gel) hereafter. 
 In the previous section it was understood that the Laplace transform method for 
tartrazine diffusion in device did not give comparable diffusion coefficient values to 
those determined using QSS, TL slope and TL intercept method which were all found to 
be similar. Therefore these three mathematical models are being taken forward for 
diffusivity estimations of tartrazine in NP gel in device.  
Diffusivity of tartrazine was determined in presence of physiologically relevant glucose 
concentrations. As glucose responsiveness forms the basis for the closed-loop drug 
delivery mechanism of the INsmart device, the effect of this response on the diffusivity 
of tartrazine was determined. Here, glucose concentration of 0.1% w/w as used in the 
experiments corresponds to ~5.5 mmolL
-1 
the basal normal limit of fasting plasma 
glucose for most individuals, 0.2% w/w corresponds to ≥ 11.1 mmolL
-1
 which is 
indicative of diagnosis of diabetes and higher concentrations of 0.5% w/w (27.75 
mmolL
-1
) and 1% w/w (54 mmolL
-1
) are instances of glucose challenges following a 
very high sugary meal.  
 
5.6.1 Experimental set-up and procedure for diffusion 
The experimental set-up and data analysis procedures followed were exactly the same as 
described in Section 5.5.1, the only difference being that NP gel was used instead of 
agarose. A 3 mm gel spacer was filled with weighed amount of NP gel and dialysis 
membrane with a molecular weight cut-off of 100 kDa was used. All experiments were 
performed at 20°C. 
For experiments investigating the impact of reduced gel viscosity which occurs in the 
presence of glucose, a relevant amount of glucose was added to the donor tartrazine 
solution, mixed with the gel and in the receptor solution to keep the concentration of 




density interference and to determine the true diffusivity of tartrazine in presence of a 
range of different relevant glucose concentrations. 
For diffusivity estimation experiments of tartrazine in presence of glucose, calibration 
curves for tartrazine containing the relevant glucose concentrations were generated each 
time.  
 
5.6.2 Results and discussion 
The diffusivities of tartrazine in NP gel in the presence of different glucose 
concentrations were determined using QSS, TL slope and TL intercept methods. The 
results are as presented in Table 5-3.  
 
Table 5-3: Diffusion coefficient values (D and De) for tartrazine in NP gel in presence 
of glucose determined using QSS, TL slope and TL intercept methods. The number of 
replicate measurements is shown by n=x. 
Glucose concentration in 
NP gel 
QSS TL slope TL intercept 

















0 (n=2) 0.54 ± 0.06 0.38 ± 0.04 0.73 ± 0.02 
0.1 (n=1) 0.87 0.61 0.85 
0.5 (n=1) 0.93 0.65 1.00 
 
It can be seen in Table 5-3 that the diffusion coefficient values (D or De) for tartrazine 
determined using QSS, TL slope and TL intercept methods are in close agreement based 
on the limited data set available. Higher diffusion coefficient values for tartrazine with 








Figure 5-16: Increasing diffusion coefficient values for tartrazine in NP gel in presence 
of glucose determined using QSS, TL slope and TL intercept methods. 
 
The diffusion coefficient for tartrazine increases with increasing glucose concentration. 
The diffusivity of tartrazine increased in the gel containing 5.4 mmol/L (0.1 %w/w) as 
the viscosity of the gel decreased to aid free movement of tartrazine molecules, further 
fall in viscosity in gel containing 27.75 mmol/L (0.5 % w/w)of glucose did not make 
much difference to the diffusivity of tartrazine. This could be due to the fact that 
tartrazine being a small molecule, its free movement is impeded by the micro viscosity 
created by increased glucose molecules.  
Representative experimental data are graphically presented in Appendix 3; data for NP 
gel with no glucose is presented in Figure A3-8, with 0.1 %w/w glucose in Figure A3-9 
and with 0.5 %w/w glucose is presented in Figure A3-10. 
 
5.7 Determination of diffusion coefficient of fluorescein sodium in NP 
gel in INsmart device 
The diffusivity of fluorescein sodium, which has a smaller size than tartrazine, was 
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experimental technique development using a fluorimeter, which is required later for 
determination of fluorescently labelled insulin diffusion through the gel as presented in 
Chapter 7. 
Here effect of gel thickness (pathlengths) and two batches of conA used to prepare NP 
gel on diffusivity were also investigated.  
 
5.7.1 Experimental set-up and procedure for diffusion 
The device was assembled as described in Section 5.5.1. Experiments were performed 
using 2.50 mm gel spacer and then with a 1.17mm gel spacer with an aim to reduce the 
amount of gel used. Dialysis membrane with molecular weight cut off of 100 kDa was 
used. All experiments were performed at 20°C. 
One major modification to the experimental device set-up was to mimic the diffusion 
cell design, to this effect; the INsmart device was coupled with a receptor compartment. 
They were held together by an in-house developed system made of perspex which could 
be tightened to ensure a perfect seal as shown in Figure 5-17. Parafilm and silicone gel 
was applied at the point of contact to further ensure the seal. The receptor compartment 








Figure 5-17: Diffusion cell design using the INsmart device. 
 







Figure 5-18: Schematic of the experimental set-up for diffusion of fluorescein sodium 







Figure 5-19: Photograph of the experimental set-up for diffusion of fluorescein sodium 
in NP gel housed within the INsmart device. 
  
The test rig comprised of the receptor and donor compartment circuits forming a closed 
circuit system; both sides have a reservoir in the circuit in order to maintain same 
volumes.  
For experiments investigating the impact of reduced gel viscosity in the presence of 
glucose, relevant amount of glucose was added to the donor fluorescein sodium 
solution, the gel and the receptor solution to eliminate any osmotic interference and to 
determine the true diffusivity of fluorescein sodium in the presence of a range of 
different relevant glucose concentrations. 
The NP gel was prepared as described in Section 5.3.3. After the INsmart device was 




1) The donor reservoir containing fluorescein sodium solution of known concentration 
and volume and the receptor reservoir containing distilled water with glucose of 
same volume were placed on a magnetic stirrer. 
2) The fluorimeter, PerkinElmer LS55 Luminescence Spectrometer was switched on at 
least 15 min before the start of the experiment. The method was set-up using the 
FLWinlab wavelength program, with fluorescence intensity measurements recorded 
at every 1 min interval. 
3) The circuit was set-up using tubing as shown in Figure 5-18.  
4) The peristaltic pump (Watson-Marlow 101U) speed was kept constant, with tubing 
volume output of 9.8 mL/min, to draw only the receptor solution first into the device 
receptor compartment ensuring the compartment was full with no air bubbles.  The 
receptor side was made closed circuit by emptying into and drawing from the same 
receptor reservoir. All the tubing was checked to ensure there were no air bubbles. 
The receptor solution passed through a special fluorimeter quartz flow cell (with 3 
sides clear) which was placed in the fluorimeter. 
5) The background reading was taken which the software subtracts from the 
measurements. As soon as the blank reading was taken, the device donor 
compartment was filled with fluorescein sodium solution by placing the tubing in the 
donor reservoir. Measurements were started when the device donor compartment was 
filled with the donor fluorescein sodium solution.  
6) The Fluorimeter monitored the amount of dye diffusing through the gel from the 
donor side by recording the absorbance of the solution in the receptor side passing 
through the flow cell at 515 nm wavelength. 
7) As fluorescein sodium is photosensitive, the entire set-up was protected from light by 
covering with a black paper. 
Fluorescein sodium shows strong fluorescence at excitation wavelength 485nm and 
emission wavelength 515 nm as shown in Figure 5-20. The FL Winlab software in 
wavelength mode was set to the above excitation and emission wavelengths to record 
fluorescence measurements per minute. Sampling was performed over a period of 






Figure 5-20: Fluorescence spectrum for fluorescein sodium showing strong 
fluorescence intensity at excitation wavelength 485 nm and emission wavelength 515 
nm. 
 
The fluorescence data was imported into Excel to produce concentration versus time 
plots. The fluorescence intensity at 515 nm wavelength was linear with respect to 
fluorescein sodium concentration thus enabling simple conversion of intensity data into 
concentration values observed for fluorescein sodium using the calibration curve shown 

















































Figure 5-21: Calibration graph for fluorescein sodium (0-0.25 µg/mL) ((using 
fluorimeter quartz flow cell). (Data represent mean±SD of four measurements, error 
bars present but may not be visible as smaller than marker size). 
 
For diffusivity experiments of fluorescein sodium in presence of glucose, a calibration 
curve for fluorescein sodium containing the relevant concentration of glucose was 
generated each time.  
For experiments investigating the impact of reduced gel viscosity in the presence of 
glucose, a calibration curve for fluorescein sodium containing the relevant concentration 
of glucose was generated. 
 
Data Analysis  
The fluorescence intensity data was first converted into fluorescein sodium 
concentration using the calibration curve as shown in Figure 5-21. The data was plotted 
based on the mathematical methods; QSS, TL slope and TL intercept method for 
calculating diffusion coefficient as described in Section 5.3.4.  
y = 3999.5x + 13.057 




























5.7.2 Results and Discussion  
The diffusivities of fluorescein sodium in NP gel with 0 and 0.1% w/w glucose 
concentration were determined using QSS; TL slope and TL intercept methods. The 
results are as presented in Table 5-4;  
 
Table 5-4: Diffusion coefficient values (D and De) for fluorescein sodium in NP gel in 
absence and presence of 0.1% w/w glucose determined using the QSS, TL slope and TL 
intercept methods. The number of replicates for each experiment was 2. 
Glucose concentration in 
NP gel 
QSS TL slope TL intercept 

















0  0.82 ± 0.03 0.81 ± 0.03  0.91 ± 0.04 
0.1  0.85 ± 0.02  0.85 ± 0.01 0.84 ± 0.14  
 
As shown in Table 5-4 the diffusion coefficient values (D or De) for fluorescein sodium 
determined using the QSS, TL slope and TL intercept methods were in close agreement. 
Higher diffusion coefficient values for fluorescein sodium in the presence of glucose are 
due to drop in viscosity of the gel which aids higher diffusivity. Representative 
experimental data using the three methods are graphically presented in Appendix 3, 
Figure A3-11 for NP gel with no glucose and Figure A3-12 for NP gel with 0.1% w/w 
glucose. 
 
Effect of gel thickness on fluorescein sodium diffusion coefficient values 
With an aim to reduce the amount of gel used, reduced gel thickness (pathlength) was 
investigated. The impact of a reduced gel thickness of 1.17 mm over 2.50 mm on the 
diffusivity of fluorescein sodium was assessed. The gel spacer thickness should not 





The experiments for estimating diffusivities of fluorescein sodium in NP gel using 2.50 
mm and 1.17 mm gel spacer were performed using gel with 0.1% w/w glucose. The 
diffusivities were determined using QSS, TL slope and the TL intercept methods. The 
results are as presented in Table 5-5. 
 
Table 5-5: Diffusion coefficient values (D and De) for fluorescein sodium in NP gel 
with 0.1% w/w glucose determined for 2.50 mm and 1.17 mm gel thickness using QSS, 
TL slope and TL intercept methods (limited number of repeats due to shortage of conA). 
NP gel thickness  QSS TL slope TL intercept 

















2.50 0.78 0.78 0.86 
1.17 0.79 0.78 1.88 
 
The diffusion coefficient values (D or De) for fluorescein sodium determined using the 
QSS and TL slope methods for the two gel thickness were in close agreement based on 
the limited data set available; however the TL intercept method gave higher value for 
1.17 mm gel thickness compared to the 2.50 mm gel thickness, as the time lag has been 
reduced due to reduced pathlength. This attribute is useful if a faster delivery is required 
when the device is first placed in the receptor environment. The data (limited) also 
suggests the unreliability of the TL intercept method for determination of diffusion 
coefficient. 
Representative experimental data are graphically presented in Appendix 3; Figure 
A3-13 for NP gel with 0.1% w/w glucose with 2.50 mm and 1.17 mm gel thickness. 
 
Comparison of effect of two different batches of conA on fluorescein sodium 
diffusivity in NP gel with no glucose in device 
Batch to batch consistency of available conA was investigated to assess its impact on 
diffusivity of fluorescein sodium. The reason for this being that one of the batches of 




previous experiments in terms of both the appearance of the gel formed and its gelling 
properties; the gel formed was very opaque and sloppy; when the same procedure for 
gel preparation as described in Section 5.3.3 was followed. It was eventually found that 
the gel formed had a pH below 6 and on adjusting the pH above 7, it displayed similar 
gelling and glucose responsiveness as the gel prepared using the first conA batch. The 
pH of the gel prepared using the new conA batch was adjusted to physiological pH7.6 
and it appeared clear after storage at 4°C for 24 hours. Hereafter, the gel formed using 
the first conA batch will be referred to as NP1 and one prepared using the second conA 
batch will be referred to as NP2. Some preliminary assessments were performed to 
compare the results obtained using the two conA batches. Rheological assessments of 
the gels formed using the two conA batches showed that the NP2 gel produced higher 
viscosity profiles with time compared to NP1 gel however both show graded response 
to increasing glucose concentrations. The comparison of the viscosity profiles for the 
two NP gels highlighted the batch to batch variation of conA that should be considered 
when preparing and using these gels, refer to Chapter 6, Section 6.3.1 for the 
rheological assessments.  
Diffusivity experiments were performed on NP gels prepared using the two batches of 
conA in the absence of glucose to compare the effect on fluorescein sodium diffusivity. 
The diffusivities were determined using QSS, TL slope and TL intercept methods. The 
results are as presented in Table 5-6. 
 
Table 5-6: Diffusion coefficient values (D and De) for fluorescein sodium in NP gel 
prepared using two different conA batches determined using QSS, TL slope and TL 
intercept methods (Note: the data for first conA batch is using 2.50 mm gel spacer and 
for the second conA batch is using 1.17 mm gel spacer). The number of replicates for 
each experiment was 2. 
NP gel with no Glucose  QSS TL slope TL intercept 

















NP1 gel (first conA) 0.82 ± 0.03 0.81 ± 0.03 0.91 ± 0.04 





The diffusivity of fluorescein sodium in NP1 gel was determined through a gel 
thickness of 2.50 mm compared to 1.17 mm for NP2 gel, this should not affect the 
diffusion coefficient value calculated but does affect the lag time (time when fluorescein 
sodium starts appearing in the receptor compartment). The diffusion coefficient values 
(D or De) for fluorescein sodium determined using  QSS and TL slope methods for the 
two conA batches were in close agreement; however the TL intercept method showed 
that using the second conA a slower value compared to the first conA batch as expected 
due to the difference in pathlength (gel thickness).  
Representative experimental data are graphically presented in Appendix3; Figure A3-14 
for NP gel with two different batches on conA. 
 
5.8 Chapter summary  
An experimental protocol was developed and suitable mathematical models were 
applied with an aim to determine the insulin diffusivity through the glucose-responsive 
gel in the INsmart device. A sequential approach adopted here has enabled to select a 
suitable system and mathematical model using a model dye (tartrazine) in a model gel 
(agarose) initially for determining diffusivity of a solute molecule. 
A simple diffusion cell (using a tube) investigated initially using model dye, tartrazine 
through a model gel, agarose allowed a quick, easy and efficient system to test 
feasibility of the system to determine diffusion properties of a molecule with a small 
size through a hydrophilic gel. The four mathematical methods for determining the 
diffusion coefficient namely: Laplace transform, diffusion cell-QSS, TL, slope and 
intercept analysis were assessed and compared for their applicability using the tube 
model and model dye and gel. The diffusivities of tartrazine determined in increasing 
agarose gel concentrations from 0.5% to 2% w/w using the four methods showed that 







/s respectively) were significantly different from the 









other and that QSS was achieved, the  D values for the Laplace transform, QSS and TL 




/s), however the D using the TL intercept 




/s). The D values for tartrazine 
(molecular weight 534.3 Da) in agarose gel was observed to be in the correct range in 
comparison to similar molecular weight solute, raffinose D value in aqueous solution as 
shown in Table 5-7.  From the tube experiments, it was understood that it was 
paramount that the volumes in the donor and receptor compartments need to be kept the 








Table 5-7: Reported diffusion coefficient values in aqueous solution and corresponding 










Methanol 32 1.3 x 10
–09 
(25ºC) (Friedman, 2008) 
Urea 60 1.2 x 10
–09
(25ºC) (Friedman, 2008) 
Glycerol 92 8.3 x 10
–10
(25ºC) (Friedman, 2008) 
2-Deoxyglucose* 164 5.3 x 10
-10
  (Hazel and Sidell, 1987) 
Glucose 180 6.8 x 10
–10 
(25ºC) (Friedman, 2008; RENKIN, 1954) 
Antipyrine 188 6.8 x 10
-10
 (25ºC) (Snyder et al., 2001) 
Sucrose 342 5.5 x 10
–10 
(25ºC) (Friedman, 2008) 
Dexamethasone 392 4.0 ± 2.0 x 10
-10
  (25ºC) (Moussy, Dungel and Hersh, 2006) 
Raffinose 504 4.2 x 10
–10 
(25ºC) (Friedman, 2008) 
Vitamin B12* 1355 4.1 x 10
-10
  (Kanamori et al., 1994) 




 (WEBER, LOPEZ and ANSETH, 
2009; Lin-Gibson et al., 2005) 




 (WEBER, LOPEZ and ANSETH, 
2009; Lin-Gibson et al., 2005) 
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 (WEBER, LOPEZ and ANSETH, 
2009; Lin-Gibson et al., 2005) 




 (WEBER, LOPEZ and ANSETH, 







 (WEBER, LOPEZ and ANSETH, 
2009; Lin-Gibson et al., 2005) 
* Temperature for diffusion coefficient measurement not reported. 
”
 D calculated by the Stokes-Einstein equation. 
 
Following the tube diffusion experiments, experiments undertaken with the INsmart 
device using tartrazine and agarose gel held within the device, further aided in assessing 
the applicability of the four mathematical models for determination of diffusion 
coefficient with the device. Here the learning from the tube experiments in terms of 
maintaining similar volumes in donor and receptor side was incorporated in the 










/s for 2 and 1.5 %w/w agarose gel 
respectively) did not give comparable diffusion coefficient values to those determined 







/s for 2 and 1.5 %w/w agarose gel respectively), which were all found to be similar. 
This further suggested that using the experimental set-up a QSS state was achieved and 
the three mathematical models could be taken forward for diffusivity estimations of 
tartrazine in NP gel housed in the INsmart device.  





tartrazine in NP gel in the device determined using QSS, TL slope and TL intercept 
methods were in close agreement. The higher diffusion coefficient values for tartrazine 
observed with increasing physiologically relevant glucose concentrations were as 





/s) as the viscosity of the gel decreased to aid free movement of 





/s)did not make much difference to the diffusivity of tartrazine which 
could be due to the fact that tartrazine being a small molecule, its free movement is 
impeded by the micro viscosity created by increased glucose molecules.  
 
The diffusivity of fluorescein sodium salt, a common fluorescent tracer of relatively 
small size was determined in order to develop the experimental method using the 
Luminescence spectrometer and to understand the diffusional properties of glucose 
through the NP gel due to the difficulty in determining its diffusivity in the NP gel as 
free glucose dismantles the gelatinous three- dimensional complex of the gel by 
competitive displacement thus dropping its viscosity which forms the basis for the 
responsiveness of the gel. The diffusivities of fluorescein sodium in NP gel with 0 and 
0.1% w/w glucose concentration determined using QSS; TL slope and TL intercept 







for 0 and 0.1 %w/w glucose respectively ) for fluorescein sodium determined using the 
QSS, TL slope and TL intercept methods were in close agreement.  
Diffusivity of fluorescein sodium determined for two different path lengths, 2.50 mm 










/s for 2.50 and 1.17mm gel thickness 
respectively); however the TL intercept method gave higher value for 1.17mm gel 







/s for 2.50 and 1.17mm gel thickness respectively). This attribute is 
useful if a faster delivery is required when the device is first placed in the receptor 
environment. However this also highlighted the unreliability of using only the TL 
intercept method for determination of diffusion coefficient. 
Batch to batch variability in conA was highlighted during experimental work, as a 
second batch of conA formed a gel which differed in consistency, which on adjusting to  
pH 7.6 displayed similar gelling properties. Rheological assessments of the gels formed 
using the two conA batches highlighted the batch to batch variation of conA that must 
be considered when preparing and using these gels. Diffusivity experiments performed 
on NP gels prepared using the two batches of conA in the absence of glucose to 







/s for NP1 gel and NP2 gel respectively) for 
fluorescein sodium determined using QSS and TL slope methods for the two conA 







/s for NP1 gel and NP2 gel respectively) was 





Chapter 6 Rheological testing of gels 
 
 6.1 Introduction 
The design of the INsmart device for the management of diabetes is based on the small 
changes occurring in the glucose responsive gel in response to the diabetic 
physiological glucose levels and its corresponding ability to modulate the diffusion of 
insulin through the material. The viscoelastic properties of the material should be such 
as to allow the relevant degree of relaxation required to produce a change in state upon 
glucose triggering. The gels are actually mixtures as shown by their rheological tan 
delta values (which will be discussed later in this chapter), however throughout the 
thesis the mixtures are referred to as gels for simplicity. 
The NICE recommended target fasting plasma glucose level ranges for most individuals 














) are reliably diagnosed as diabetes (NICE, 2004; World Health 
Organization Expert Committee, 1999; World Health Organization, 2011b). The device 
must always be able to deliver basal insulin amounts to cope with the continuous 
physiological release of glucose (glucose range from 4.0 to 5.9 mmolL
-
1) from 
glycogen from the liver. The device also needs to deliver appropriate doses of insulin in 
response to post-prandial glucose levels above 5.9 mmolL
-1
. A glucose concentration of 
0.1% w/w as used in the experiments corresponds to a ~5.5 mmolL
-1
. Therefore the 
glucose responsive gel needs to show a small change in viscosity between 0% and 0.1% 
w/w glucose and a major change between 0.1-1% w/w glucose, which is an upper 
glucose limit of ~55 mmolL
-1
. The rheological characteristics of various dextran-
concanavalin A mixtures have been extensively studied within the INsmart group over 
the last decade (Tanna et al., 2006a; Tanna et al., 2006b; Taylor et al., 2006). Learning 





The rheological properties of non-polymerised dex2M-conA mixture (NP mixture) 
prepared using two different batches of conA and the cross linked dexMA-conAMA 
mixture (CL mixture) used in in vitro diffusion studies in the presence of glucose were 
determined and compared. The mixtures were examined in the presence of glucose in 
oscillatory mode to yield viscoelastic properties of the mixtures and to gauge their 
glucose sensitivity and glucose responsiveness with respect to differential delivery of 
insulin from the device. 
The rheological characteristics of glucose sensitive mixtures containing dextran and 
concanavalin A (conA) with and without glucose were studied using oscillatory 
rheometry at 20 and 37°C. The rheological data gathered in the linear viscoelastic 
(LVE) range were used to compare the mixtures used in in vitro diffusion studies. 
A rheometer measures two independent variables namely the deflection angle and the 
phase shift angle in the constant torque, controlled shear stress oscillatory mode. 
From this raw data, G’ (storage modulus which is a measure of the stored energy, the 
elastic part), and G” (loss modulus which is a measure of the energy lost as heat, the 
viscous part), η*, the complex viscosity and tan delta ( the ratio of G”/ G’) of the 




6.2.1 Preparation of NP mixture and CL mixture 
The preparation of the non-polymerised dex2M-conA mixture (NP mixture) containing 
underivatised conA and dextran (RMM 2000 kDa) has been described in Chapter5, 
Section 5.3.3. 
The cross-linked dex500MA-conAMA mixture (CL mixture) was prepared using 
methacrylated dextran 500 kDa, DS 3% (dex500MA ) and methacrylated concanavalin 
A (conAMA), crosslinking them by irradiation for 5mins, which was enough to retain 
the gel behind a 100k dialysis membrane. Similar mixture was used in the previous 




(Taylor and Sahota, 2012). Briefly, conAMA (100 mg) was dissolved in distilled water 
(800 mg) and photoinitiator Irgacure® (0.178 µmoles) was added. Dex-MA (RMM 
500Da) (100 mg) was added to the mixture and stirred to form a viscous solution, 
covered in foil and allowed to stand for 2 hours at room temperature; the mixture was 
then placed between two glass plates separated by a 60 µm thick gasket and was 
irradiated under UV-light (365 nm, 10 mJ cm
-2
) for 5 minutes. The CL mixture formed 
was stored aseptically at 4° C for at least 24 hours prior to use.  
For experiments with glucose, weighed amounts of glucose were added to the NP 
mixture or the CL mixture, mixed well and stored overnight at 4°C before use. 
 
6.2.2 Rheological testing of mixtures 
The rheological testing of the mixtures was conducted on a Physica MCR 300 
rheometer (Anton Paar, Germany) with cone and plate geometry (CP 25-1) and Peltier 
temperature control. The tests were conducted in the non-destructive oscillation mode 
using controlled strain. NP mixtures (NP1 and NP2) formulated with dextran and two 
different batches of conA and CL mixture formulated with dexMA and conA MA, in the 
presence of glucose from 0 to 1% w/w have been compared at 20 and 37 ± 0.1°C using 
frequency sweeps. Firstly, a strain sweep between 0.1% and 10% was conducted at a 
frequency of 1Hz for all the mixtures containing no glucose and 1% w/w glucose 
respectively and a 1% strain value, which was within the LVE region for both samples, 
was selected for the subsequent frequency sweeps. The strain profile for all mixtures 
was linear - representative data for NP mixtures are presented in Figure 6-1 and Figure 
6-2. Frequency sweeps at this constant strain was then conducted between 0.01 and 50 
Hz and a solvent trap was used to prevent sample dehydration during the test. All tests 
were done in triplicate using fresh sample for each test. Constant sample mass was used 
and care was taken to ensure that the sample geometry remained unchanged throughout 
the testing period. The rheological data generated in controlled strain across varying 
frequency range within the LVE ensured that any deformation applied to the sample did 
not destroy its structure and that no slippage occurred between the cone and plate. All 





Figure 6-1: Storage modulus, loss modulus, complex viscosity and tan delta profiles 
across a strain sweep range of 0.1-10% at 20°C for NP2 mixture with no glucose. 
 
Figure 6-2: Storage modulus, loss modulus, complex viscosity and tan delta profiles 
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6.3 Results and Discussion 
Dynamic rheological data was generated for the mixtures to compare and monitor their 
glucose sensitivities. Figure 6-3 a-d show the viscoelastic behaviour components G’ 
(storage modulus), G” (loss modulus), η* (complex viscosity) and tan delta ( the ratio 
of G”/ G’) throughout the chosen frequency range at 20°C for CL dexMA-conAMA 
mixture. Figure 6-3 a and b show an increase in both G’ and G” as the frequency 
increased and there was a graded gradual decrease in the respective frequency sweep 
profiles with increasing glucose concentration. Figure 6-3 c shows complex viscosity 
decreasing across the frequency range suggesting pseudoplastic behaviour and a graded 
decrease in the frequency sweep profiles with increasing glucose concentration. These 
results confirm the ability of the cross linked mixture to interact reversibly with glucose, 
by dismantling the temporary three-dimensional network and forming a less viscous sol 
state by competitive displacement between free glucose and dextran. As the results 
show the viscoelastic changes (transformation from high viscosity gel-like to low 
viscosity sol-like state) occur in response to increasing glucose concentration it further 
confirms that the underlying mechanism of the smart glucose responsive gel is 
functioning and the lectin sites remain freely accessible and are not impeded by glucose 
ingress.  
The complex viscosity profiles showing a graded gradual drop through the 
physiologically relevant glucose levels confirms the response criterion of the INsmart 
device in the control of diabetes. Tan delta frequency sweep profiles for the mixture 
show a decrease as the frequency is increased, however in the presence of glucose, the 
profiles show a graded increase with increasing glucose concentration. Tan delta which 
is a ratio of the loss modulus to the storage modulus and a value above 1 indicates a 
material with dominant liquid-like behaviour and a value below 1 show a material with 
dominant elastic (solid-like) behaviour. As all values at 1Hz are above 1, it would 
indicate that the glucose responsive gels exhibit predominantly liquid-like behaviour 
and hence are referred to as mixtures. The tan delta profiles suggest with increasing 









                  
 Figure 6-3: (a) Storage modulus, (b) loss modulus, (c) complex viscosity and (d) tan 
delta profiles across a frequency range of 0.05-50Hz at 20°C for CL mixture with 
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For all the mixtures studied, the general trends of G’, G”, complex viscosity and tan 
delta from frequency sweep profiles with increasing glucose was similar to that 
described in Figure 6-3 a-d. For purposes of comparison of mixtures with different 
levels of glucose, indicating their glucose responsiveness, further data were compared at 
a single frequency of 1 Hz (mid-way through the frequency sweeps). 
A comparison for the viscoelastic behaviour components G’, G”, complex viscosity and 
tan delta for the NP mixtures prepared using two different batches of conA (NP1 and 
NP2) and CL mixture at 20°C and 37°C with increasing glucose concentrations are 
presented in Figure 6-4 to Figure 6-7. 
 
 
Figure 6-4: Storage modulus values at different glucose concentrations for the three 
mixtures at 20 and 37°C. Data were taken at a frequency of 1 Hz from frequency 
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Figure 6-5: Loss modulus values at different glucose concentrations for the three 
mixtures at 20 and 37°C. Data were taken at a frequency of 1 Hz from frequency 
sweeps conducted in the range 0.01-50 Hz. (Data represent mean±SD of three 
measurements) 
Figure 6-6: Complex viscosity values at different glucose concentrations for the three 
mixtures at 20 and 37°C. Data were taken at a frequency of 1 Hz from frequency 
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Figure 6-7: Tan delta values at different glucose concentrations for the three mixtures at 
20 and 37°C. Data were taken at a frequency of 1 Hz from frequency sweeps conducted 
in the range 0.01-50 Hz. (Data represent mean±SD of three measurements) 
 
6.3.1 Comparison of the mixtures 
The NP2 mixture produced higher viscosity profiles with time compared to NP1and CL 
mixtures. The comparison of the viscosity profiles for the two NP mixtures highlight the 
batch to batch variation of conA that need to take into account when preparing and 
using these mixtures. The NP mixtures were used in the in vitro diffusion studies 
initially for technique and experimental model development. These mixtures were non-
polymerised mixtures and used a higher molecular weight dextran(average molecular 
weight 2,000,000 Da) compared to the cross linked mixture which used the 
methacrylated dextran (dextran average molecular weight 473,000 Da) and 
methacrylated conA and were UV irradiated for 5 min. It is interesting to see that the 
complex viscosity profile for the CL mixture shows more graded response to increasing 
glucose concentration compared to the NP2 mixture. The CL mixture shows ~90% drop 
1 
10 
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in complex viscosity between the physiologically useful glucose concentration range 
(0.1-1% w/w) compared to the NP mixtures which showed ~75% drop at 20 °C. 
 
6.3.2 Effect of temperature 
In many polymeric systems, a rise is temperature results in a drop in viscosity of the 
material due to fewer polymer chain entanglements (Mezger, 2002). Dispersions with a 
gel or paste like character become more flexible at higher temperatures. At low 
temperatures, G’ > G”, this relation can reverse at high temperatures and the value of 
tan delta may increase (Mezger, 2002). As seen in Figure 6-4 to Figure 6-7, at 37°C 
lower viscosity profiles were obtained throughout the glucose range for all three 
mixtures. Their loss modulus, was G” > G’ at 37°C and the higher viscosity mixtures 
with 0% glucose show greater temperature-dependence than those with 1% w/w 
glucose. The CL mixture shows ~80% drop in complex viscosity between the 
physiologically useful glucose concentration ranges (0.1-1% w/w) compared to the NP 
mixtures which showed ~63% drop. The viscosity profiles suggest that the viscoelastic 
behaviours of the different mixtures are suitable for the intended use in the implantable 
device. 
 
6.4 Chapter summary 
Rheological studies on the mixtures have shown that they are glucose responsive and 
their glucose sensitivity was shown by graded lowering of their viscosity due to change 
in the physical cross-linking in response to increasing glucose concentration. 
The viscoelastic components; namely storage modulus, loss modulus, complex viscosity 
and tan delta for the non-polymerised dex2M-conA (NP) mixtures and the cross-linked 
dexMA-conAMA (CL) mixture examined using oscillatory rheometry within the linear 
viscoelastic range across a frequency range of 0.05-50 Hz confirm their ideal elastic and 
viscous responses. The storage modulus, loss modulus, complex viscosity profiles for 
the mixtures show a graded decrease in viscosity with increasing glucose concentration 
when compared at 1 Hz. These results confirm the ability of the polymerised mixtures 




network and forming a less viscous sol state by competitive displacement between free 
glucose and dextran. The results show that the viscoelastic changes (transformation 
from high viscosity gel-like to low viscosity sol-like state) occur in response to 
increasing glucose concentration further confirming that the underlying mechanism of 
the smart glucose responsive gel is functioning. The results for the NP mixtures suggest 
their suitability for in vitro diffusion studies, however it also highlighted the batch to 
batch variation of conA that should be taken into account when preparing and using 
these mixtures.   
The comparison of the mixtures at 20 and 37°C suggest that the viscoelastic behaviours 
of the different mixtures are suitable for the intended use in the device. The CL mixture 
shows ~90% drop in complex viscosity between the physiologically useful glucose 
concentration range (0.1-1% w/w) at 20°C and ~80% drop at 37°C thus confirming its 






Chapter 7 Drug delivery mechanism and 
diffusion kinetics of FITC-insulin 
 
7.1 Introduction 
Mathematical modelling of drug delivery and predictability of drug release kinetics is a 
field of steadily increasing academic and industrial importance with enormous potential. 
Mathematical predictions allow good estimates of the required composition, geometry, 
dimensions and preparations of the required dosage taking into account the route of 
administration, drug dose to be incorporated and the targeted drug release profiles 
(Siepmann and Siepmann, 2012; Siepmann and Peppas, 2012).  
The classical mathematical equation, Equation 7-1, for drug delivery was proposed by 
Higuchi in 1961 where he described drug release from an ointment base exhibiting a 






                   Equation 7-1 
 
Where, Mt is the cumulative absolute amount of drug released at time t, A is the surface 
area of film exposed to the release medium, D is the drug diffusivity in the carrier 
material, C0 and Cs represent the initial drug concentration and the solubility of the drug 
in the carrier material, respectively. 
Apparently numerous mathematical theories for drug delivery since then described in 
literature still lack in accuracy and/or ease in application according to Siepmann 
(Siepmann and Siepmann, 2008). The mathematical models generally used are either 
empirical/semi-empirical or mechanistic realistic types. A number of factors need to be 
considered when trying to understand drug release from a dosage form or system such 
as type of drug, formulation, preparation technique, environmental conditions during 




the release is influenced by a number of factors such as wetting of the system’s surface 
with water, water penetration into the device, creation of water-filled pores, changes in 
the drug and/or excipient solubility due to altered micro environmental conditions and 
many more potentially involved phenomena, among which is the diffusion of drugs 
and/or excipients out of the dosage form or device with potentially time and/or position-
dependent diffusion coefficients (Siepmann and Siepmann, 2008). 
 
7.1.1 Determining the drug delivery mechanism - the Power law (Peppas 
equation) 
One of the most frequently used and easy to apply semi-empirical mathematical models 
used to describe drug release is the power law or the so-called Peppas equation, 
Equation 7-2 (Peppas, 1985). This model helps to determine the drug release 





     Equation 7-2 
 
Where, Mt and M∞ are the absolute cumulative amount of drug released at time t and 
infinite time, respectively; k is a constant incorporating structural and geometric 
characteristics of the system and n is the diffusional exponent, which is indicative of the 
mechanism of drug release. The classical Higuchi equation and Peppas equation 
(Equation 7-2) are an approximation of Fick’s second law for thin films and represents 
a special case of the power law where n=0.5. The power law can be seen as a 
generalisation of two independent mechanisms of drug transport, Fickian diffusion and 
a case-II transport (non-Fickian transport mechanism with effects of polymer swelling, 
stresses, structural changes and influence of polymer relaxation on movement of 
molecules in the matrix (Kosmidis et al., 2003)). Thus the power law has two distinct 
physical realistic meanings in the two special cases, where n=0.5 indicates diffusion 
controlled drug release and n=1 indicating swelling controlled drug release. Values of n 




phenomena (anomalous transport). However the above values for n are only valid for a 
slab/thin film geometry. For spheres and cylinders different values have been derived as 
listed in the Table 7-1. 
 
Table 7-1: Drug release exponent n of the power law and corresponding drug release 
mechanism from polymeric controlled delivery systems of different geometry 
(Siepmann and Siepmann, 2008). 
Exponent, n Drug release 
mechanism 
Thin Film Cylinder Sphere  
0.5 0.45 0.43 Fickian diffusion 
0.5<n<1.0 0.45<n<0.89 0.43<n<0.85 Anomalous 
transport 
1.0 0.89 0.85 Case-II transport 
 
7.1.2 Determination of diffusion coefficient using mathematical models  
The mechanistic mathematical models describe real phenomena such as mass transfer 
by diffusion, dissolution of drug and/or excipient, transition of a polymer from the 
glassy to the rubbery state. The drug releases that are purely diffusion controlled with 
constant diffusion coefficients are commonly based on Fick’s law of diffusion. Various 
modifications and variations are applied to the Fick’s law of diffusion equation for 
mathematical modelling purposes depending on the system, shape and boundary 
conditions. As discussed in Chapter 5, the experimental protocol developed to 
determine diffusion coefficient was used. The mathematical models, the diffusion cell 
technique – Quasi steady state (QSS), the Time lag (TL) slope and the TL intercept 
methods based on Fick’s law as discussed in Chapter 5 were used for determination of 






7.1.3 Glucose responsiveness   
Glucose responsiveness forms the basis for the closed-loop drug delivery mechanism of 
the INsmart device. The device encases a glucose-sensitive gel of co-polymerised 
dextran methacrylate (dexMA) and concanavalin A methacrylamide (conAMA), which 
produces a reversible change in consistency on contact with glucose to modulate insulin 
transport and thus acts as a self adjusting system. The design of the closed loop self 
regulating implantable insulin delivery device for the management of diabetes is based 
on the small changes occurring in the glucose sensitive gel in response to the diabetic 
physiological glucose levels and its corresponding ability to modulate diffusion of 
insulin through the material. The device implanted in the peritoneal cavity, works on a 
very fast feedback mechanism for controlling insulin release. This mimics a normal 
pancreas and may overcome inherent problems encountered in maintaining 
normoglycaemia with current electronically or biologically based closed loop systems. 
For the responsive drug delivery system to operate effectively for the management of 
diabetes, changes in viscosity need to be in the clinically useful glucose range and need 
to occur in a physiologically relevant timescale. Figure 7-1 shows the well known 
sigmoid relationship between tissue glucose concentration (dashed line) and beta cell 
insulin release (solid line) (Taylor et al., 2006). Either differential beta cell sensitivity or 
cellular insulin granule content has been argued to be responsible for this sliding scale 






Figure 7-1: Profile of viscosity and insulin secretion (bold line) as a function of glucose 
plasma concentration (dotted line) (Taylor et al., 2006). 
 
Insulin secretion is quite low under normal conditions (with basal glucose levels) and is 
required to control post-prandial glucose levels from absorbed food by raising secretion 
appropriately. A normal pancreas responds to post-prandial glucose levels by gradual 
ramping up of insulin secretion and is capable of high output if glucose reaches 
abnormal levels. At the same time, a normal pancreas is capable of responding to falling 
glucose levels if there is a risk of hypoglycaemia for any reason (although counter 
regulatory systems also contribute to restoring normality). The gel held within the 
INsmart device should also respond in a similar manner to increasing physiologically 
relevant concentrations of glucose (0.1% to 1% w/w glucose). 
 
7.2 Experimental outline 
In order to determine if the drug delivery mechanism from the INsmart device was 
“Fickian diffusion”, the release of fluorescein sodium from the non-polymerised 
dex2M-conA gel (NP gel) was recorded over time and the power law applied to the 
data. Following this fluorescently labelled insulin synthesised in-house, as discussed in 




gel and the cross-linked dex500MA-conAMA gel (CL gel). The experimental protocol 
developed, as discussed in Chapter 5 and selected mathematical models were applied 
to the INsmart device to determine the diffusion coefficient of FITC- insulin. Glucose 
sensitivity of the NP gel was assessed by challenging the system with increasing 
physiologically relevant concentrations of glucose (0.1% to 1% w/w glucose). 
 
7.3 Experimental conditions and data analysis for INsmart device 
experiment 
 
7.3.1 Chemicals and reagents 
Concanavalin A, from Canavalia ensiformis, Type VI lyophilised powder (Type VI) 
(conA) and dextran (produced by Leuconostoc mesenteroides, strain no. B512; average 
molecular weight 2000 kDa) (dex2m) were purchased from Sigma-Aldrich Chemical 
Company Ltd. (Poole, Dorset, UK). Dialysis membranes (MWCO.100 kDa) were 
obtained from Medicell International Ltd (Liverpool,UK). Radical photoinitiator 1-[4-
(2-hydroxyethoxy)-phenyl]-2-hydroxy-2-methyl-1-propane-1-one (Irgacure® 2959) 
(IRG) from Ciba Speciality Chemicals (Cheshire,UK). Metric 180 PVC tubing-
FDA/USPVI (1mmID, 2mmOD, 5mmWall) was purchased from Nalgene® Brand 
products,USA. All other chemicals were of analytical grade and distilled water was used 
throughout. FITC-insulin synthesised in-house and characterised as discussed in 
Chapter 4 was used. 
 
7.3.2 Preparation of NP gel and CL gel 
The preparation of the non-polymerised dex2M-conA gel (NP gel) containing 
underivatised conA and dextran (RMM 2000 kDa) has been described in Chapter5, 
Section 5.3.3. The preparation of the cross-linked dex500MA-conAMA gel (CL gel) 
prepared using methacrylated dextran 500 kDa, DS 3% (dex500MA ) and methacrylated 
concanavalin A (conAMA) and crosslinking them by irradiation for 5mins has been 




of glucose was added to the NP gel or the CL gel, mixed well and stored overnight at 
4°C before use. 
 
7.3.4 Experimental set-up 
The device was assembled as described in Chapter 5, Section 5.5.1. All experiments 
were performed at 20°C, using 1.17 mm gel spacer and dialysis membrane with 
molecular weight cut off 100 kDa. 
The experimental set-up was the same as described in Chapter 5, Section 5.7.1. Here 
the donor compartment had FITC-insulin solution. Also, for these experiments the pH 
of the donor FITC-insulin solution, the receptor distilled water and the gel was always 
adjusted to approximately pH 7.6 with either 0.1M HCl or 0.1 M NaOH. This was to 
keep the FITC-insulin in dissolved state as any drop in pH compromises its solubility 
and leads to precipitation in the gel. Peritoneal fluid similar to serum fluids contains 
phosphorus, uric acid, blood urea nitrogen, creatinine, potassium, bicarbonate, sodium 
and lower concentrations of calcium and albumin. Because the peritoneal fluid is in 
equilibrium with the serum, it also contains other low molecular-weight substances 
in vivo that cross the peritoneal membrane (Kelton et al., 1978). However for the 
diffusion experiments in order to determine the diffusion coefficient for FITC-insulin, 
these components of the peritoneal cavity were not included as these could interfere 
with the measured diffusion rate. The schematic of the experimental set up is as 






Figure 7-2: Schematic of the experimental set-up for diffusion of FITC-insulin in NP 










Figure 7-3: Photographs of the experimental set-up for diffusion of FITC-insulin in NP 
gel or CL gel housed within the INsmart device. 
 
The receptor and donor compartment circuits were closed circuit; with reservoirs in the 
circuit to maintain equal volumes on both sides. For determination of FITC-insulin 




concentrations i.e. the diffusivity due to reduced gel viscosity in the presence of 
glucose, physiologically relevant amount of glucose was added to the donor FITC-
insulin solution, the gel and the receptor solution to eliminate any osmotic interference 
and density interferences.  
For glucose responsiveness experiments, to determine FITC-insulin diffusivity due to 
reduced gel viscosity that occur real time in presence of glucose triggers, glucose was 
present only in the receptor solution. 
 The NP gel was prepared as described in Chapter 5, Section 5.3.3 and CL gel as 
described in Chapter 6, Section 6.2.1. Once the INsmart device was put together the 
steps as described in Chapter 5, Section 5.7.1 were followed. 
FITC-insulin shows strong fluorescence at excitation wavelength 494 nm and emission 
wavelength 518 nm as shown in Figure 7-4. FITC-insulin diffusing through the gel 
from the donor side to the receptor side was monitored over time, using the FLWinlab 
wavelength program application, by conversion of fluorescence intensity recordings at 
518 nm into concentration values using calibration curves. Sampling was performed 







Figure 7-4: Fluorescence spectrum of FITC-insulin showing strong fluorescence 
intensity at excitation wavelength 494 nm and emission wavelength 518 nm. 
 
The FL Winlab software in wavelength mode was set to plot the data per minute. The 
data was imported into Excel for generation of concentration versus time plots. The 
fluorescence intensity at 518 nm showed a second degree polynomial fit with respect to 
concentration for FITC-insulin as shown in Figure 7-5, thus enabling simple conversion 
of fluorescence intensity data into concentration values observed for FITC-insulin. 






































Figure 7-5: Calibration graph of various concentrations of FITC-insulin (using 
fluorimeter quartz flow cell). (Data represent mean±SD of six measurements, error bars 
present but may not be visible as smaller than marker size). 
 
For diffusivity estimation experiments of FITC-insulin in presence of glucose, 
calibration curves for FITC-insulin containing the relevant concentrations of glucose 
were generated each time.  
 
7.3.5 Data analysis  
The fluorescence intensity data was first converted into FITC-insulin concentration 
using the calibration curve as shown in Figure 7-5. The data was plotted based on the 
requirements of the mathematical methods; QSS, TL slope and TL intercept method for 





y = 5.9211x2 + 141.33x - 26.716 






























7.4 Results and Discussion  
7.4.1 Determining the drug delivery mechanism - The Power Law (Peppas 
equation) 
The release of fluorescein sodium from the NP gel was recorded over time and applied 
to the power law as discussed in Section 7.1.1 to determine if the drug delivery 
mechanism from the INsmart device was Fickian diffusion. 
The gel (thickness 1.17 mm) housed in the INsmart device can be considered as a thin 
film or slab with no edge effects and the power law fit, for n=0.5 for the release of 
fluorescein sodium through the gel is as shown in Figure 7-6:; 
 
 
Figure 7-6: Power law fit for fluorescein sodium release through NP gel. Dotted line 
represents the power law fit for n=0.5, indicating diffusion controlled release.  
 
The power law fit, for n=0.5 for the release of fluorescein sodium through the gel 



















7.4.2 Determination of diffusion coefficient using mathematical models  
The diffusivities of FITC-insulin in NP gel and in the presence of 0.1, 0.2, 0.5 and 1% 
w/w glucose are as presented in Table 7-2;  
 
Table 7-2: Diffusion coefficient values (D and De) for FITC-insulin in NP gel and in 
presence of glucose determined using different methods. The number of replicate 
measurements is shown by n=x. 
Glucose concentration 
in NP gel 
QSS TL slope TL intercept 

















0 (n=2) 1.05 ± 0.02 1.04 ± 0.02 1.12 ± 0.11 
0.1 (n=1) 0.46 0.46 2.24  
0.2 (n=1) 0.57 0.57 2.11 
0.5 (n=1) 0.43 0.43 3.76 
1.0 (n=1) 0.90 0.89 3.59 
 
Based on the limited data set the diffusion coefficient values for FITC-insulin using the 
QSS method, the TL slope and intercept method are in agreement for the NP gel; 
however for experiments in presence of glucose the D calculated using the TL intercept 
method were higher than D calculated using the QSS and the TL slope method. 
In presence of glucose the D for FITC-insulin seems to be lower than in absence of 
glucose, the reason for which could be the micro viscosity created by glucose within the 
gel structure contributing towards interference in the diffusion of FITC-insulin. The D 
values show an increase with increasing glucose concentration as the viscosity of the gel 




The diffusivities of FITC-insulin in CL gel and in presence of 0.1, 0.2, 0.5 and 1% w/w 
glucose were determined using the mathematical models. The results are as presented in 
Table 7-3;  
 
Table 7-3: Diffusion coefficient values (D and De) for FITC-insulin in CL gel and in 
presence of glucose determined using different methods. The number of replicate 
measurements is shown by n=x. 
Glucose concentration 
in CL gel 
QSS TL slope TL intercept 

















0 (n=2) 0.75 ± 0.06 0.75  ± 0.06 1.44 ± 0.57 
0.1 (n=2) 0.98 ± 0.55 0.97 ± 0.55 6.10 ± 5.40 
0.2 (n=1) 0.34 0.34 1.93 
0.5 (n=1) 0.39 0.39 15.67  
1.0 (n=1) 0.44 0.44 4.47 
 
The diffusion coefficient values for FITC-insulin using the QSS and the TL slope 
methods are not in agreement with their corresponding TL intercept method values for 
CL gel, both in absence and presence of glucose. This highlights the unreliability of the 
TL intercept method in determining diffusion coefficient as discussed in Chapter 5, 
Section 5.1.3.3.  
In presence of 0.1% glucose the D for FITC-insulin in CL gel was slightly higher than 
in absence of glucose, however the FITC-insulin D values in CL gel with 0.2 to 1% 
glucose are lower than in the absence of glucose. For CL gel, microviscosity created by 
higher concentration, 0.2% glucose seems to contribute towards interference in the 
diffusion of FITC-insulin. The D values do show an increase with increasing glucose 
concentration as the viscosity of the gel (macroviscosity) drops with increasing glucose 




The QSS and TL methods gave reliable correlations in diffusion coefficient values for 
FITC-insulin in NP gel and CL gel. The TL intercept method gave different values, 
approximately a decade faster in some instances, which is consistent with the findings 
of others (Zhang and Furusaki, 2001). Representative experimental data are graphically 
presented in Appendix 4; Figure A4-1 to Figure A4-5 for NP gel with no glucose, 0.1, 
0.2, 0.5 and 1.0% w/w glucose and in Appendix 4; Figure A4-6 to Figure A4-10 for 
CL gel with no glucose, 0.1, 0.2, 0.5 and 1.0% w/w glucose. 
 
7.4.3 Glucose responsiveness 
The response to physiologically relevant glucose triggers was determined in the NP gel. 
The diffusivity of FITC-insulin in response to triggers of physiologically relevant 
glucose concentrations was determined using the test rig by challenging the NPgel in 
the device with glucose added to the receptor side. In Figure 7-7, the total mass of 
FITC-insulin released from the device in response to 0.1 to 1.0% w/w glucose triggers 
are presented. For glucose triggers from 0.1 to 0.5% w/w an initial FITC-insulin release 
is observed followed by a period of slight drop in release rate and then a second steady 
state release. A possible explanation for this could be that on glucose trigger, the FITC-
insulin present in the gel layers close to the receptor side drop in viscosity due to 
glucose diffusing into these layers and hence release the amount of FITC-insulin present 
in these layers, then there is a short period where the FITC-insulin diffusing from the 
donor side reaches these outermost layers and which then achieves a steady state 
release. In real time scenario however, the feedback loop is quick, less than 10 min and 





Figure 7-7: FITC-insulin total mass delivered with increasing glucose concentration 
triggers in NP gel. The data set presented here has been reduced to every 10
th
 data point 
for 0.1 and 0.2% w/w glucose triggers and 5
th
 data point for 0.5 and 1% w/w glucose 
triggers to aid visual clarity (A: first slope, B: second slope). 
 
The diffusion coefficient of FITC-insulin in NP gel in response to the glucose triggers, 
0.1, 0.2, 0.5 and 1% w/w was estimated. The diffusion coefficients were calculated 
using the first and second slopes (A and B) as shown in Figure 7-7. When the values of 
D found in this way were plotted against glucose concentration, FITC-insulin diffusivity 
showed a second and third order polynomial fit to increasing glucose concentration 
showing its sensitivity and graded response to increasing glucose concentration. The 
FITC-insulin D values increase with increasing glucose concentration in NP gel. The 
diffusion coefficient values calculated using the first slopes (initial drug release 
following the trigger) were found to be comparable to the values calculated using 
second slopes. In real-time scenario, the trigger response and sol to gel transformation 
following a drop in glucose levels is assumed to be much quicker and hence only the 
















Figure 7-8: Figure showing FITC-insulin diffusion coefficient values with increasing 
glucose concentration triggers in NP gel from first and second slopes showing 
polynomial fit. 
 
Rheological studies on the NP and CL gels (mixtures) as discussed in Chapter 6 have 
shown that they are glucose responsive and their glucose sensitivity was shown by 
graded lowering of their viscosity due to change in the physical cross-linking in 
response to increasing glucose concentration. The storage modulus, loss modulus, 
complex viscosity profiles for the gels which showed a graded decrease with increasing 
glucose concentration when compared at 1 Hz confirm the viscoelastic changes 
(transformation from high viscosity gel-like to low viscosity sol-like state) occurring in 
response to increasing glucose concentration. This confirmed that the underlying 
mechanism of the smart glucose responsive gel was functioning. This was further 
demonstrated by the relationship (third order polynomial fit) between diffusion 
coefficient values for FITC-insulin in NP gel (using second slope) and the complex 
viscosity of the gel measured in response to increasing glucose concentration as shown 
in Figure 7-9. 
 
First slope: 
y = 7.5325x2 - 0.1521x + 0.1796 
R² = 0.9982 
Second slope: 
y = 5.4367x3 + 0.248x2 + 1.7091x + 0.1532 
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Figure 7-9: Relationship between FITC-insulin diffusion coefficient values in NP gel 
and complex viscosity of the gel measured in response to increasing glucose 
concentration at 20°C.  
 
The FITC-insulin D values calculated following glucose challenges to the NP gel were 
compared to the D value in NP gel and CL gel in the presence of the relevant glucose 
concentration (where the system had glucose present throughout to avoid osmotic 
interferences) (refer to D values in Table 7-2and Table 7-3). As shown in Figure 7-10, 
the FITC-insulin D values determined in NP gel following glucose challenges and 
actual D values in NP and CL gel in presence of different glucose concentrations were 
plotted graphically for comparison. The FITC-insulin D values calculated in NP gel and 
CL gel in presence of relevant glucose concentrations show only a slight graded 
response to increasing glucose concentration; however the D values in NP gel show a 
much more graded response to glucose challenges, which is more representative of a 
real-time trigger scenario.  
The in vitro diffusivity experiments have aided in determining the actual diffusivity of 
FITC-insulin in presence of different glucose concentrations, however the potential 
limitation for using these values to calculate drug release is that these may not be the 
0.1% w/w Glu 
0.2% w/w Glu 
0.5% w/w Glu 
1 % w/w Glu 
y = -2E-07x3 + 0.0003x2 - 0.1193x + 17.832 







































actual diffusivities observed in real-time in vivo situation. This highlights the 
importance of understanding the device design-specific parameters to achieve greater 
understanding of the underlying drug release mechanism. The glucose trigger 
experiment is a much better approximation of what is really happening when the gel is 
challenged with glucose.  
 
 
Figure 7-10: FITC-insulin diffusion coefficient values with increasing glucose 
concentration triggers in NP gel in comparison to values determined using NP gel and 
CL gel with relevant glucose concentration present throughout the system. 
  
y = 5.4367x3 + 0.248x2 + 1.7091x + 0.1532 
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7.5 Chapter summary 
The drug release mechanism of FITC-insulin from the glucose sensitive gel held in the 
INsmart device, studied using fluorescein sodium was found to be diffusion controlled. 
Fluorescein sodium release from the NP gel over time demonstrated the Peppas 
equation (power law) fit, for n=0.5 thus indicating a Fickian diffusion controlled release 
mechanism. 
The diffusion coefficient (D) for FITC-insulin in the NP gel determined using 





diffusion coefficient (D) for FITC-insulin in the CL gel determined using mathematical 





In presence of glucose the D values determined using the mathematical models for 
FITC-insulin seems to be lower than in its absence, the reason for which could be the 
micro viscosity created by glucose within the gel structure contributing towards 
interference in the diffusion of FITC-insulin. However, the D values do show an 
increase with increasing glucose concentration, approximately 48% from 0.1 to 1% w/w 
for NP gel and approximately 23% from 0.2 to 1% w/w for CL gel. Here, the increase in 
glucose having a greater effect on the macroviscosity of the gel.  
In response to physiologically relevant glucose triggers in the NP gel, the diffusivity of 




/s ) with increasing glucose 
concentrations (from 0.1% to 1% w/w), showing a polynomial fit, device thus showing 
glucose sensitivity and graded response, mimicking pancreas. It also shows that the 
diffused glucose molecules in the gel drop the viscosity of the gel but do not hinder the 
diffusivity of FITC-insulin in the gel thus the release kinetics is controlled entirely by 





Chapter 8 Predicting the performance of 
the INsmart device  
 
8.1 Introduction 
Using the available information and assumptions and the set initial and boundary 
conditions, mathematical equations were selected for the type of system used (as has 
been shown in the model selection Chapter 5). Using the diffusion coefficient values 
calculated by fitting the respective equation to sets of experimental data it is possible to 
minimize the difference between experimental and theoretical data. Also, using these 
diffusion coefficient values, the model can be used to quantitatively predict the impact 
of a certain parameter (e.g., area or thickness of gel) on the resulting drug release 
kinetics. Such theoretical predictions can be then compared with independent 
experimental results (Siepmann and Siepmann, 2008).  
As discussed in Chapter 7, the INsmart device can be considered as a reservoir system 
with constant activity source where the drug is physically completely separated from the 
barrier gel. The gel is housed within the device in such a way that there is minimum 
likelihood of gel swelling. Importantly, the water uptake is minimal, very rapid and 
complete upon exposure to the release medium. Thus, during the drug release period, 
constant device dimensions (stationary boundary conditions) are maintained and the 
drug diffuses out of the system through the gel. The drug release mechanism from the 
device has been confirmed as Fickian diffusion; refer to Chapter 7.  
 
8.2 Theoretical estimations 
An idealised artificial pancreas should be able to maintain normal glucose control by an 
automated continuous negative feedback (closed-loop) causing appropriate response to 
losses and gain in glucose levels akin to normal pancreatic flux of insulin. Such dose 




achieved by the INsmart device containing the glucose responsive gel which is the 
sensor and insulin delivery port.  
Daly et al have presented the profiles for blood glucose and serum insulin, as shown in 
Figure 8-1 and Figure 8-2, for eight healthy adults from a randomised, crossover trial 
which reveal higher peaks and lower troughs with the high-sucrose diet whereas higher 
area under the curve for the high starch diet (Daly et al., 1998; Daly, 2003). 
 
 






Figure 8-2: Insulin responses to high-sucrose and high-starch diets (from Ref (Daly, 
2003)). 
 
The capability of the INsmart device relies on it being efficient, consistent and 
reproducible in maintaining the automated continuous negative feedback and being able 
to achieve real-time serum insulin profile as shown in Figure 8-2. Based on the in vitro 
diffusion kinetics measured for FITC-insulin through the glucose-responsive gel held 
within the device some theoretical calculations and design improvements could be 
suggested to achieve this real-time insulin response clinically.  
Insulin release rates from the device in response to real-time glucose in mammal/human 
as discussed in Chapter 2 depend on the device design; gel thickness and surface area 
available for release. The concentration gradient achieved may vary with decreasing 
insulin on the donor side. And the glucose responsiveness of the gel and diffusion 
coefficient of insulin could be affected by gel polymer content, gel thickness or the site 






8.2.1 Predictive capability of the device 
 
Can the device deliver the daily insulin requirement? 
 
Most patients with T1DM require an insulin dosage of 0.5 to 1.0 IU per kg per day 
(Hirsch, 1999).  The average adult male body mass by world region in 2005 published 
by Walpole et al in 2012 for Europe was reported as 70.8 kg and for the world 
(excluding some countries and territories due to insufficient data) as 62 kg  (Walpole et 
al., 2012). Considering the body weight as 70.8 kg the daily insulin requirement for a 
patient with T1DM diabetes would be 2.14 x 10
-4
 to 4.25 x 10
-4





Here an assessment is made into whether the device is capable of delivering the daily 
insulin requirement for an average body weight of 70.8 kg. Using Fick’s law, Equation 
8-1 and the calculated diffusion coefficient values for FITC-insulin in the NP gel in 
response to glucose triggers, estimations were made of whether the device can deliver 
the daily requirement. These were made when in the gel state with basal glucose present 
and with elevated glucose levels, 0.2% w/w (equivalent to 11 mmol/mL, which is 
diagnosed as diabetes). Here it was assumed that a maximum insulin concentration of 





     
  
  
 Equation 8-1 
Daily insulin requirement for T1DM = 0.5 – 1 IU per kg per day 
1IU = 0.0349 mg = 3.49x10-5 g 




g per kg per day 
For a 70.8Kg adult = 0.124 x 10
-2
 to 0.247 x10
-2














The delivery rates from the device are dependent on the diffusion in gel state and sol 
state (which define the performance window). 
Using the following criteria, the insulin delivered from the device was calculated and is 
presented in Table 8-1; 
 


























These were made under the conditions; 
CD = 10ml of 500 IU/mL (3 x 10
-5
 mol). 
CR = 0 (assuming rapid elimination of insulin in the body) 
Surface area - 6.2 cm
2
 
Gel thickness – 0.117 cm    
 










Daily requirement for an 
average body weight (max) 
- - 4.25 x 10
-04
 




 5.28 x 10
-08
 4.56 x 10
-03
 
Device delivery with presence 
of  0.2% w/w glucose 
1.41 x 10
-08
 8.75 x 10
-08
 7.56 x 10
-03
 
Device delivery with presence 
of 0.5% w/w glucose 
4.49 x 10
-08
 2.78 x 10
-07
 2.41 x 10
-02
 
Device delivery with presence 
of 1% w/w glucose 
1.94 x 10
-07
 1.20 x 10
-06







As shown in Table 8-1 the device is capable of delivering the daily required insulin 
amount in sol state (in response to different glucose challenges) and also under basal 
glucose conditions using the current experimental design comprising of gel thickness 
0.117 cm and surface area 6.2 cm
2
. The calculations shown here is using the assumption 
is that the value of D changes throughout the gel thickness in a relevant time period. In 
real-time the value of D changes for the exposed layers of the gel which allows for the 
quick gel to sol and again to gel state based on the level of glucose present. 
Another main requirement that needs to be satisfied is whether the device is capable of 
matching the basal insulin concentration requirement. The distribution volume of 
insulin in the body as determined by Hipszer et al using insulin pharmacokinetics model 
to study distribution and elimination of insulin in the body was found to be 15.6 ± 4.0L 
(Hipszer, Joseph and Kam, 2005). The basal insulin concentration observed in a non-
diabetic person is ~10 mU/L (Daly, 2003) which is equivalent to a concentration of 6.01 
x 10
-8
 mmol/L, assuming the body distribution volume as 19.6L the total mass of insulin 
present in circulation would be 1.18 x 10
-6
 mmol. Based on the flux per unit area from 




s calculated for device in presence of basal 
glucose, the mass transferred from the device was found to be 5.28 x 10
-8
 mmol/s. 
Therefore in 22.34 sec the device should be able to deliver 1.18 x 10
-6







We can say that the insulin delivered from the device in gel state (in presence of basal 
glucose) can meet the basal insulin requirement (based on basal insulin concentration in 
non-diabetic person). 
The insulin endogenously produced by the pancreatic beta cell has a half life of 
approximately 4 to 6 min (Duckworth, Bennett and Hamel, 1998; Hulse, Ralat and 
Wei Jen, 2009). The basal insulin delivery rate from the device in presence of basal 





 g/L  
               =3.49x10
-7
/ 5808 (RMM for insulin) 





Total mass of basal insulin in circulation =6.01x10
-8
 x 19.6 = 1.18x10
-6
mmol. 
Mass delivered from device per sec = 5.28x 10
-8
 mmol/s 
Time taken to deliver basal amount of 1.18 x 10
-6









Daily insulin requirement for T1DM = 0.5 – 1 IU per Kg per day 
1IU = 0.0349 mg = 3.49x10-5 g 




g per Kg per day 
For a 70.8Kg adult = 0.124 x 10
-2
 to 0.247 x10
-2














glucose levels might seem too fast. However, a point to note here is that these are 
theoretical estimations based on in-vitro experiments made purely to gain some 
understanding of the performance window for the device. 
 
8.2.2 Exploring different device geometries 
The gel thickness in the device for in vitro diffusivity experiments using FITC-insulin 
with the NP gel and CL gel was 0.117 cm. The diffusion coefficients of FITC-insulin 
within the polymeric matrix determined experimentally are as presented in Chapter 7. 
The solution for Fick’s law (TL method) which gives the total amount of solute 
transferred through the gel (refer to Chapter 5, Equation 5-13) was used to predict the 
impact of varying gel thickness. The drug released for the gel thickness from 0.1 to 2 
cm was measured. Figure 8-3 shows the insulin delivered from the device per day with 
varying gel thickness from 0.1 to 2 cm. As the gel thickness increased the drug 
delivered decreased due to the increasing diffusion pathlengths. Figure 8-3 shows the 
performance window for the device with respect to gel thickness, gel thickness 0.1 to 1 






Figure 8-3: Effect of gel thickness on the insulin mass delivered from the device. 
 
The drug delivered from the device in response to basal and post-meal glucose levels for 
gel thickness from 0.1 to 2 cm was also compared with the real time basal and bolus 
insulin levels observed (calculated from Figure 8-2). The real time basal insulin 
concentration observed in a non-diabetic person is ~10 mU/L (Daly, 2003) which is 
equivalent to a concentration of 6.01 x 10
-8
 mmol/L, assuming the body distribution 
volume as 19.6L the total mass of insulin present in circulation would be 1.18 x 10
-6
 
mmol and a bolus insulin level of ~70 mU/L equates to 8.25 x 10
-6
 mmol. Figure 8-4 
shows the insulin delivered per 3 minutes meet the basal requirement with gel thickness 
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Figure 8-4: Effect of gel thickness on the insulin mass delivered from the device 
(mmol/3min). 
 
The surface area available for diffusion in the device for in vitro diffusivity 
experiments using FITC-insulin with the NP gel and CL gel was 6.2 cm
2
. The diffusion 
coefficient of FITC-insulin through the glucose-sensitive gel determined experimentally 
is as presented in Chapter 7. Fick’s law was used to predict the impact of varying 
surface area and gel thickness on the amount of drug delivered. Figure 8-5 shows the 
drug delivered per 10 seconds in gel state for the NP gel with increasing surface area 
from 1 to 50 cm
2
 at gel thickness 0.05, 0.1, 0.2 and 0.5 cm. It is possible to select an 
appropriate combination of gel thickness and surface area to determine the ideal 
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Figure 8-5: Effect of varying surface area and gel thickness on insulin delivered from 
the device (mmol/10s).  
 
Figure 8-5 shows that a combination of gel thickness 0.1cm and surface areas greater 
than 12 cm
2
 can deliver per 10 seconds the required basal insulin amount. Gel thickness 
less than 0.1cm with smaller surface areas and gel thicknesses greater than 0.1cm with 
larger surface areas can achieve the basal insulin amounts in 10 seconds. Figure 8-6 
shows that in 10 seconds the device was capable of delivering the bolus amount for 0.05 




0.1 cm gel thickness with 
surface areas greater than 50 cm
2
. 
Thus if a gel thickness of 0.1 cm is selected to achieve the basal insulin levels in not 
more than 10 seconds, a range of surface area greater than 50 cm
2
 can be explored 
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Figure 8-6: Effect of varying surface area and gel thickness on insulin delivered from 
the device (mmol/10s).  
 
This theoretically selected ideal performance window which meets the daily basal and 
bolus insulin requirement provides an opportunity for increasing the surface area and 
thus exploring different device geometries in place of the current device geometry as 
shown in Figure 8-7. Based on the daily insulin requirements and the bolus insulin 
required to be delivered in response to postprandial glucose levels, the optimum 
dimensions for the device could have gel thickness from 0.05 to 0.1 cm with surface 
area greater than 12 cm
2
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Current device design                                      Device with gel slab double sided  
        








Cylindrical device design 
 
         





Figure 8-7 shows the current gel as a slab design, the current device design (INsmart, 
working design) has a diameter of approximately 4.5 cm with effective surface area of 
6.2 cm
2
. Double sided gel slab design with double the surface area can also be explored 
to increase the drug delivered and improve response times. 
The spherical device design could be advantageous in terms of increased surface area 
for quicker response times. Also a smooth device surface finish can be advantageous in 
terms of lesser chances of lesions forming at the implantation site. As an example if a 
surface area of 12 cm
2
 is considered, the sphere diameter as small as 2 cm can be 
explored, however this design will have a limitation with respect to a small insulin 
reservoir in the centre. This could be overcome by decreasing the gel thickness or 
increasing the diameter appropriately so that the effective surface area increases with 
insulin levels achieved in required response times. 
A cylindrical device design would substantially increase the surface area which could 
significantly improve its performance. The device shape could have a number of 
advantages in terms of ease of implant and removal procedures, comfort to the wearer 
and also easy refilling. Here again based on a surface area of 12 cm
2
, the cylinder radius 
as small as 0.5 cm and height 1.7 cm or radius 0.2 cm and height 1.9 cm can be 
explored, however this design will again have the same limitation in terms of insulin 
reservoir size in the centre. This could be overcome by decreasing the gel thickness or 
increasing the radius and height appropriately so that the effective surface area increases 
with insulin levels achieved in required response times. 
The optimisation of the device design in favour of reducing the overall size has a 
number of advantages in terms of reduced risks of infection due to smaller size and 
smoother finish and faster recovery times in comparison to traditional more invasive 
surgical implants. However, the various geometries and design have to take into account 
the compatibility of the materials used in terms of suitability for implantation and effect 
on stability of insulin solution. Further, the surface finish for these devices should also 
be of high quality so as not to cause formation of lesions or abrasions at the 
implantation site. The most appropriate design will also depend on surgical needs, 




In order to evaluate the validity of these theoretical predictions, experiments with 
increasing pathlengths or surface area could be performed. Agreement between 
theoretical predictions and independent experiments could indicate the validity of this 
model for this type of drug delivery systems. This illustrates the practical benefit of 
mathematical modelling of drug release, the impact of design parameters on drug 
release can be simulated in silico, thus potentially replacing time- and cost-intensive 
series of experimental studies. 
 
8.2.3 Realistic scenario 
 
Meal time – can the device deliver bolus doses and how fast? 
 
An idealised insulin release profile from the device should match the insulin responses 
from a normal pancreas as shown in Figure 8-2 in response to the glucose profile 
shown in Figure 8-1. 
The device parameters as used in the in vitro experiments with surface area of 6.2 cm
2
, 
gel thickness 0.117 cm and donor initial insulin concentration of 3.00 x 10
-5
 mol, the D 
measured using the glucose trigger experiments can be used to determine the bolus 
insulin amount delivered by the device per sec. As shown in Figure 8-1, high sucrose 
diet shows a max glucose peak of approx 7.25 mmol/L for a non-diabetic individual; but 
for an individual with diabetes, levels as high as 24 mmol/L (approx 0.5% w/w glucose) 
could be observed. Table 8-2 shows how long it would take for the device to deliver the 


















for 19.6L volume) 






for 19.6L volume) 
 (mmol/s) (s) (s) 
~5.5 mmolL
-1
 5.28 x 10
-08
 156.1 178.4 
~11 mmolL
-1
 8.75 x 10
-08
 94.2 107.6 
~27.5 mmolL
-1
 2.78 x 10
-07
 29.6 33.8 
~55 mmolL
-1
 1.20 x 10
-06
 6.9 7.9 
 
Thus in response to post prandial high glucose concentration (extreme observed in 
diabetic patients), the device is capable of delivering a dose in 33.8 s. 
It is common knowledge that insulin is released from the pancreas in vivo in a biphasic 
manner with a first burst of insulin secretion occurring rapidly at 2-4 min and lasting 10 
min and then again gradually increases progressively to a pseudo-steady state, second 
phase insulin release in 2-3 hours as seen in rats and humans (Gerich, 2002; Rorsman et 
al., 2000; Ohara-Imaizumi et al., 2002; Seino, Shibasaki and Minami, 2011). The 
calculations show that the device is capable of post-prandial insulin release within the 





Figure 8-8: Schematic of diurnal profile of serum insulin concentration and insulin 
delivered from device with current geometry and optimum geometry in response to 
postprandial glucose concentrations. 
 
A schematic of the diurnal profile of insulin delivered from the device with the current 
geometry in response to high postprandial glucose levels observed for diabetic 
individuals (meal time glucose level – 11 mmolL
-1
 and supper – 8.3 mmolL
-1
) was 
compared to the required serum insulin levels (from Figure 8-2 as presented by Daly 
(2003)) and is presented in Figure 8-8. 
Figure 8-8 shows that the device with the current dimensions show lower amounts of 
basal insulin per second and bolus insulin delivered per 5 second. The device with the 
current geometry is capable of delivering the required basal amount in 30 s and bolus 
amount in 100 s. Thus the device is capable of delivering until the required amount of 
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gel state. Also, if the device geometry is modified to optimum dimensions of gel 
thickness 0.1 cm and surface area 50 cm
2
 as discussed in Section 8.2.2 it could achieve 
the ideal performance required to match the serum insulin concentrations with faster 
response times, achieving basal amount per 2s and bolus amount in 12 s.  
 
8.2.4 Service intervals 
How long will the insulin in the reservoir last? 
 
The ‘service interval’ applies to both the glucose-responsive gel and the insulin in the 
reservoir, the replacement time for the gel and the replenishment of reservoir insulin 
solution. Long term stability studies on the glucose-responsive gels by rheological 
characterisation when stored with and without 0.1% w/w glucose have found the gels to 
have a stable complex viscosity for over 730 days at 20°C and 37°C indicating that over 
time the gel components do not undergo degradation when stored in dialysis membrane, 
molecular weight cut off 50kDa (Sahota and Taylor, 2013).This has given confidence in 
the long term performance capability of the gel. Ideas for future device development 
include compartmentalising the gel in a cartridge which can be easily replaced if needed 
by non-invasive means.  
The service intervals for the insulin formulation in the reservoir will depend on the 
insulin concentration and volume of the reservoir. The depletion of insulin in the 
reservoir and replacement strategies depends on daily insulin consumption by the 
individual with diabetes. This consumption depends on a number of factors such as 
onset, peak and duration of action, patient factors such as individual variations in insulin 
absorption affecting the basal dose required, due to levels of exercise and types of meals 
consumed. 
Based on the calculations and estimations it has been shown that the device insulin 
release profiles is capable of mimicking the real-time serum insulin profile in response 




Based on the insulin dosage requirement of 0.5 to 1.0 unit per kg per day for most 
patients with C-peptide–negative T1DM diabetes (Hirsch, 1999), the insulin used up for 
an average male with body weight of 70.8 kg can be calculated. 
The daily insulin requirement for an average man with body weight of 70.8 kg and the 
insulin requirement from the device per day are 2.14 x 10
-4
 to 4.25 x 10
-4
 mmol. The 
initial insulin reservoir mass based on current device design is 3.00 x 10
-2
 mmol, 
therefore the insulin in the reservoir would be depleted in 70.7 days. 
Another key consideration in deciding upon the service interval for insulin would be to 
determine the donor concentration when the driving force is impacted which would 
result in lower mass transfer (flux).Based on the diffusion coefficient data for FITC-
insulin in NP gel in presence of basal glucose, as shown in Figure 8-9 the flux from the 
device remains constant over a period of time but decreases as the insulin concentration 
in receptor increases.  
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Flux from device 
100% 
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In vivo the insulin delivered would quickly diffuse away into the tissues maintaining 
perfect sink conditions, thus would not affect the flux as observed in in.vitro condition. 
For the given experimental data the calculated donor concentration corresponds to 2.9 x 
10
-2
 mmol (which is 96.4%). Hence when the donor concentration drops by 96.4% the 
flux might get affected. Based on the daily insulin requirement for an average man with 
body weight of 70.8 kg and the max insulin requirement from the device per day of 4.25 
x 10
-4
 mmol, the donor insulin mass of 2.9 x 10
-2
 mmol corresponds to ~ 68 days. Thus 
here if the device insulin reservoir is replenished on a monthly basis, it should provide a 
safety margin of 100% in terms of amount of insulin delivered without affecting the 
flux. 
 
8.3 Chapter summary 
The knowledge of diffusion kinetics of FITC-insulin in the glucose-responsive gel as 
discussed in Chapter 5 and Chapter 7 have aided in understanding the capability and 
performance of the INsmart device along with making some design recommendations, 
service intervals and developing some replacement strategies for insulin solution. 
Theoretical calculations have shown that the following capability and performance 
attributes of the INsmart device, 
 The device is capable of delivering the daily required insulin amount in gel and sol 
state (in response to different glucose challenges) using the current experimental 
device design comprising of gel thickness 0.117 cm and surface area 6.2 cm
2
.  
 Calculations show that the insulin delivered from the device in gel state (in 
presence of basal glucose) meets the in vivo basal insulin requirement (based on 
basal insulin concentration in a non-diabetic person). 
 The ideal performance window with respect to gel thickness was identified as less 
than 0.25 cm for the current device design (surface area 6.2 cm
2
) to deliver the 
required basal and bolus insulin amounts per 3 minutes. 
 The ideal performance window with respect to different combination of gel 




provides an opportunity for exploring different device geometries in place of the 
current device geometry. Based on the basal and bolus insulin amounts required to 
be delivered, the optimum dimensions for the device could have gel thickness from 
0.05 to 0.1 cm with surface area greater than 12 cm
2 
in 10 s. Device with gel 
thickness of 0.1cm and surface are of 50 cm
2 
achieving basal amounts per 2 s and 
bolus amounts per 12 s. 
 The device design could be modified to achieve the ideal diurnal performance 
required to match the serum insulin concentrations observed in a non-diabetic 
person. A double sided gel slab design can be explored to increase the amount of 
drug delivered. A spherical device design with surface area of 12 cm
2
 and diameter 
as small as 2 cm or a cylindrical device design based on surface area of 12 cm
2
 with 
the cylinder radius as small as 0.5 cm and height 1.7 cm or radius 0.2 cm and height 
1.9 cm can also be explored. The design can be optimised appropriately to house 
the required insulin reservoir by increasing the size whilst maintaining the optimum 
surface area. The cylindrical design can provide a number of advantages in with 
respect to ease of implant and reduced risks of infection and recovery times 
associated with traditional more invasive surgical implants.  
 The current device design with a donor insulin concentration of 10 ml of 500 IU 
would last for 70.7 days based on the daily insulin requirement for an average man 
with body weight of 70.8 kg. Taking into consideration the effect of decreasing 
driving force (concentration gradient) on flux based on in vitro calculation, the 
insulin in the reservoir would need to be replaced in ~ 68 days. Thus a monthly 





Chapter 9 Overall Conclusions and 
Future work 
 
9.1 Overall Conclusions 
In this investigation, the aim was to assess the key INsmart device reliability and 
performance criteria for successful future clinical use. Returning to the questions posed 
at the beginning of this study, in Chapter 2, it is now possible to draw the following 
conclusions; 
 An investigation into insulin stability and compatibility with materials that formed 
part of the device or have a potential to be considered for use in future device designs 
was conducted using three validated RP-HPLC methods to determine insulin loss and 
degradants formed and loss of FITC-insulin conjugates. The study highlighted the 
necessity for presence of phenolic compound (m-cresol) for maintaining the stability 
of insulin solution and showed greater loss in insulin recovery at 37°C. 
 The material compatibility have shown that PC (polycarbonate, thermoplastic 
polymer with monomer bisphenolA) and SS (stainless steel Grade 316) are 
compatible with insulin solution remaining stable for up to 31 days (study period) at 
20°C, however at 37°C, insulin solution was stable with SS for up to 21 days and 
with PC up to 11 days. Ti (titanium, 99.99% purity) was found to be the most stable; 
Ti is a good material to consider in future device designs. R (resin, polyurethane two 
part thermosetting resin, polyol and isocyanate mixed) might not be the best material 
to consider and PU (polyurethane, long chain thermoplastic polymer, polyol and 
isocyanate mixed) is definitely the least compatible and hence not suitable for future 
device designs. 
 The compatibility study of the device materials with FITC-insulin solution which is 
being used in the in vitro studies has revealed that the device materials were 
compatible up to only 3 days. This finding did not pose a problem for the in vitro 
studies as such as FITC-insulin solutions were always freshly prepared just before 




findings from this study has highlighted the fact that FITC-insulin solution needs 
formulation adjuncts and stabilisers, which should be assessed for stability if it is 
intended to be used in experiments with the device over a longer period. 
 FITC-labelled insulin was synthesised in-house for use in in vitro diffusion 
experiments, to improve analytical quantification and aid detection to understand 
release profiles from the closed loop insulin delivery device. The major limitation to 
producing singly labelled biologically active mono-labelled FITC-insulin conjugate 
(B1) using human insulin was the presence of unlabelled native insulin at shorter 
reaction time. 
 For the purposes of the in-vitro experiments, reaction time of 25 hrs was selected for 
production of FITC-insulin where predominantly di-labelled FITC-insulin conjugate 
(over 75%) was produced with the absence of any unlabelled native insulin. For the 
in vitro diffusion experiments, it was more important to know the size of the FITC-
insulin conjugate produced and presence of any unlabelled native insulin was 
undesirable. 
 The presence of phenol or m-cresol there appears to be a 10% decrease in amount of 
mono-labelled conjugate and a slight increase in di-labelled conjugate produced.  
 It was hugely advantageous to synthesise FITC-insulin in-house as product with 
predominantly di-labelled conjugate was successfully produced without presence of 
any unreacted FITC or native insulin in comparison to the commercially available 
Sigma FITC-insulin product which was predominantly tri-labelled conjugate (most 
biologically inactive conjugate species) and had unreacted FITC in the product which 
is highly undesirable. Also, clinically used insulin analogues were successfully 
fluorescently labelled to produce FITC-insulin conjugates with potential future 
applicability, in biological and in vitro applications for tracing and relevant specific 
receptor binding studies. 
 
 An experimental protocol was developed and four mathematical methods were 
investigated for determining insulin (FITC-insulin) diffusivity through the glucose-
responsive gel in the INsmart device. The Laplace transform, diffusion cell-QSS, TL, 
slope and intercept analysis were assessed and compared for their applicability using 




 The QSS and the TL slope and intercept methods were found to give similar results, 
however the unreliability of using only the TL intercept method for determination of 
diffusion coefficient in some instances was also highlighted.  
 The diffusivity of fluorescein sodium salt was determined in order to develop the 
experimental method using the Luminescence spectrometer and to understand the 
diffusional properties of glucose through the NP gel due to the difficulty in 
determining its diffusivity in the NP gel as free glucose dismantles the gelatinous 
three- dimensional complex of the gel by competitive displacement thus dropping its 
viscosity which forms the basis for the responsiveness of the gel. The diffusivities of 
fluorescein sodium in NP gel with 0 and 0.1% w/w glucose concentration were found 






/s respectively.  
 Pathlength was shown not to affect the diffusivity of fluorescein sodium salt. 
 Batch to batch variability in conA was highlighted during experimental work. 
Rheological assessments of the gels formed using the two conA batches further 
highlighted the need to consider the conA batch to batch variation when preparing 
and using these gels.  
 Rheological studies on the NP gel and CL gel have shown that viscoelastic changes 
occur in response to increasing glucose concentration further confirming that the 
underlying mechanism of the smart glucose responsive gel is functioning. This was 
further demonstrated by the relationship between diffusion coefficient values for 
FITC-insulin in NP gel and the complex viscosity of the gel measured in response to 
increasing glucose concentration which gave a third order polynomial fit. The results 
for the NP mixtures suggest their suitability for in vitro diffusion studies. The 
comparison of the gels at 20°C and 37°C suggest that the viscoelastic behaviours of 
the different gels are suitable for the intended use in the device. The CL mixture 
shows ~90% drop in complex viscosity between the physiologically useful glucose 
concentration range (0.1-1% w/w) at 20°C and ~80% drop at 37°C thus confirming 
its suitability for use in the closed-loop insulin delivery device for the management 
of diabetes. 
 The drug release mechanism of FITC-insulin from the glucose sensitive gel held in 
the INsmart device, studied using fluorescein sodium was found to be diffusion 




Peppas equation (power law) fit, for n=0.5 thus indicating a Fickian diffusion 
controlled release mechanism. 
 The D for FITC-insulin in the NP gel determined using mathematical models, QSS 










 In presence of 0.1% glucose the FITC-insulin D seems to be lower than in its 
absence, the reason for which could be the micro viscosity created by glucose within 
the gel structure contributing towards interference in the diffusion of FITC-insulin. 
However, the D values do show an increase with increasing glucose concentration as 
expected, approximately 48% from 0.1 to 1% w/w for NP gel and approximately 
23% from 0.2 to 1% w/w for CL gel, the increase in glucose having a greater effect 
on the macroviscosity of the gel.  
 In response to physiologically relevant glucose triggers in the NP gel, the diffusivity 




/s ) with increasing glucose 
concentrations (from 0.1% to 1% w/w), showing a polynomial fit, device thus 
showing glucose sensitivity and graded response, mimicking pancreas.  
 It also showed that the diffused glucose molecules in the gel drop the viscosity of the 
gel but do not hinder the diffusivity of FITC-insulin in the gel thus the release 
kinetics are controlled entirely by the diffusivity of FITC-insulin in the gel. 
 The knowledge of diffusion kinetics of FITC-insulin in the glucose-responsive gel 
has aided in understanding the capability and performance of the INsmart device 
and in making some design recommendations and developing some replacement 
strategies for insulin solution. The device is capable of delivering the daily required 
insulin amount in gel and sol state (in response to different glucose challenges) 
using the current experimental device design comprising of gel thickness 0.117 cm 
and surface area 6.2 cm
2
.  
 Calculations show that the insulin delivered from the device in gel state (in 
presence of basal glucose) meets the in vivo basal insulin requirement (based on 




 The ideal performance window with respect to gel thickness was identified as less 
than 0.25 cm for the current device design (surface area 6.2 cm
2
) to deliver the 
required basal and bolus insulin amounts per 3 minutes. 
 Based on the basal and bolus insulin amounts required to be delivered, the optimum 
dimensions for the device could have gel thickness from 0.05 to 0.1 cm with 
surface area greater than 12 cm
2
. Device with gel thickness of 0.1cm and surface 
are of 50 cm
2 
achieved basal amounts per 2 s and bolus amounts per 12 s. This 
understanding provides an opportunity for exploring different device geometries in 
place of the current device geometry. 
 Different device designs can be explored, from a double sided design, spherical 
design or cylindrical design with increased surface areas depending on the response 
time needed to meet daily basal and bolus insulin demands.    
 The current device design with a donor insulin concentration of 10 ml of 500 IU 
would last for ~ 68 days based on the daily insulin requirement and consideration 
made for effect of decreasing flux. Thus a monthly service interval (insulin 
replenishment) should provide a 100% safety margin. 
 
9.2 Future work plans 
This research has revealed several opportunities for further work. 
 It was very difficult to produce a sample with purely 100% mono-labelled conjugate 
without presence of any unlabelled insulin using the FITC-insulin synthesis method. 
Therefore a method to isolate the monolabelled conjugate produced needs to be 
explored in the future. Moreover, it couldn’t be ascertained if the mono-labelled 
conjugate produced at short reaction times was A1 or B1 labelled conjugate from the 
chromatogram and mass spectra alone. In order to locate the exact positions where 
FITC were attached, a Staphylococcus aureous digestion of the separated/isolated 
conjugates as described by Hentz et al would need to be employed.  Also, a 
biological test, an autophosphorylation assay using insulin receptor would aid in 




 The diffusion kinetics experiments had to be restricted due to unavailability of conA. 
Further diffusion experiments using FITC-insulin to confirm the diffusion 
mechanism and determine the kinetics at 37°C would be advantageous. 
 From previous in vivo experiments in pigs it was observed that the BG levels were 
maintained in diabetic pig even when the solution from the device reservoir had 
almost no insulin left in it, which implied that insulin had migrated into the gel and 
deposited insulin in the gel which acted as a depot in the smart gel. Thus a sustained 
release insulin delivery system can be explored with solid insulin precipitate in the 
CL gel, which allows the gel still to switch on and off by its viscosity change and 
thus enabling to modulate the output. Such a mechanism will allow the device to be 
made without a liquid reservoir of insulin and thus be safer. 
 The material compatibility study performed here could be extended further to tubing 
material used for filling the insulin reservoir and any other material considered for 
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Appendix 1 - Guidelines for method 
validation parameters 
 
The FDA guidance document – ‘Guidance for Industry, Q2B Validation of Analytical 
Procedures: Methodology’ details and acceptance criteria for each validation parameter; 
System suitability 
The FDA Document – ‘Guidance for Industry, Q2B Validation of Analytical Procedures: 
Methodology’ states 
“System suitability testing is an integral part of many analytical procedures. The tests are based 
on the concept that the equipment, electronics, analytical operations, and samples to be 
analyzed constitute an integral system that can be evaluated as such. System suitability test 
parameters to be established for a particular procedure depend on the type of procedure being 
validated.” 
Linearity 
The FDA Document – ‘Guidance for Industry, Q2B Validation of Analytical Procedures: 
Methodology’ states 
“A linear relationship should be evaluated across the range of the analytical procedure. It may 
be demonstrated directly on the drug substance (by dilution of a standard stock solution) and/or 
separate weighings of synthetic mixtures of the drug product components, using the proposed 
procedure. The latter aspect can be studied during investigation of the range.........................” 
“For the establishment of linearity, a minimum of five concentrations is recommended. Other 
approaches should be justified”. 
Range 





“The specified range is normally derived from linearity studies and depends on the intended 
application of the procedure. It is established by confirming that the analytical procedure 
provides an acceptable degree of linearity, accuracy, and precision when applied to samples 
containing amounts of analyte within or at the extremes of the specified range of the analytical 
procedure. 
The following minimum specified ranges should be considered. 
• For the assay of a drug substance or a finished (drug) product: Normally from 80 to 120 
percent of the test concentration;..........” 
Accuracy  
The FDA Document – ‘Guidance for Industry, Q2B Validation of Analytical Procedures: 
Methodology’ states 
“Accuracy should be established across the specified range of the analytical procedure.” 
Several methods of determining accuracy are available. 
“Assay of Drug substance  
a) Application of an analytical procedure to an analyte of known purity (e.g., reference 
material); 
(b) Comparison of the results of the proposed analytical procedure with those of a second well-
characterized procedure, the accuracy of which is stated and/or defined (independent 
procedure); 
(c) Accuracy may be inferred once precision, linearity, and specificity have been established. 
 “Accuracy should be assessed using a minimum of 9 determinations over a minimum of 3 
concentration levels covering the specified range (e.g., 3 concentrations /3 replicates each of 
the total analytical procedure).” 
Accuracy should be reported as percent recovery by the assay of known added amount of 
analyte in the sample or as the difference between the mean and the accepted true value 
together with the confidence intervals.” 
Precision 





“Validation of tests for assay and for quantitative determination of impurities includes an 
investigation of precision. 
 Repeatability  
Repeatability should be assessed using: 
(1) A minimum of 9 determinations covering the specified range for the procedure 
(e.g., 3 concentrations/3 replicates each); or 
(2) A minimum of 6 determinations at 100 percent of the test concentration. 
 Intermediate Precision  
The extent to which intermediate precision should be established depends on the circumstances 
under which the procedure is intended to be used. The applicant should establish the effects of 
random events on the precision of the analytical procedure. Typical variations to be studied 
include days, analysts, equipment, etc. It is not necessary to study these effects individually. The 
use of an experimental design (matrix) is encouraged. 
Detection and Quantitation limits (Sensitivity) 
The FDA Document – ‘Guidance for Industry, Q2B Validation of Analytical Procedures: 
Methodology’ details several approaches for determining the detection limit and quantification 
limits such as based on visual examination, based on signal to noise ratio or based on standard 
deviation of the response and the slope, it states 
“DETECTION LIMIT 
Several approaches for determining the detection limit are possible, depending on whether the 
procedure is noninstrumental or instrumental. Approaches other than those listed below may be 
acceptable. 
A. Based on Visual Evaluation  
Visual evaluation may be used for noninstrumental methods but may also be used with 
instrumental methods. 
The detection limit is determined by the analysis of samples with known concentrations of 
analyte and by establishing the minimum level at which the analyte can be reliably detected. 
B. Based on Signal-to-Noise  




Determination of the signal-to-noise ratio is performed by comparing measured signals from 
samples with known low concentrations of analyte with those of blank samples and establishing 
the minimum concentration at which the analyte can be reliably detected. A signal-to-noise 
ratio between 3 or 2:1 is generally considered acceptable for estimating the detection limit. 
C. Based on the Standard Deviation of the Response and the Slope  
The detection limit (DL) may be expressed as: 
        
 
 
 Equation A1-1 
 
Where F = the standard deviation of the response 
S = the slope of the calibration curve 
The slope S may be estimated from the calibration curve of the analyte. The estimate of F may 
be carried out in a variety of ways, for example: 
1. Based on the standard deviation of the blank  
Measurement of the magnitude of analytical background response is performed by analyzing an 
appropriate number of blank samples and calculating the standard deviation of these responses. 
2. Based on the calibration curve  
A specific calibration curve should be studied using samples containing an analyte in the range 
of DL. The residual standard deviation of a regression line or the standard deviation of y-
intercepts of regression lines may be used as the standard deviation. 
D. Recommended Data  
The detection limit and the method used for determining the detection limit should be presented. 
If DL is determined based on visual evaluation or based on signal-to-noise ratio, the 
presentation of the relevant chromatograms is considered acceptable for justification. 
In cases where an estimated value for the detection limit is obtained by calculation or 
extrapolation, this estimate may subsequently be validated by the independent analysis of a 
suitable number of samples known to be near or prepared at the detection limit. 
QUANTITATION LIMIT  
Several approaches for determining the quantitation limit are possible, depending on whether 
the procedure is noninstrumental or instrumental. Approaches other than those listed below 




A. Based on Visual Evaluation  
Visual evaluation may be used for noninstrumental methods, but may also be used with 
instrumental methods. 
The quantitation limit is generally determined by the analysis of samples with known 
concentrations of analyte and by establishing the minimum level at which the analyte can be 
quantified with acceptable accuracy and precision. 
B. Based on Signal-to-Noise  
This approach can only be applied to analytical procedures that exhibit baseline noise. 
Determination of the signal-to-noise ratio is performed by comparing measured signals from 
samples with known low concentrations of analyte with those of blank samples and by 
establishing the minimum concentration at which the analyte can be reliably quantified. 
A typical signal-to-noise ratio is 10:1. 
C. Based on the standard deviation of the Response and the Slope  
The quantitation limit (QL) may be expressed as: 
       
 
 
 Equation A1-2 
 
Where F = the standard deviation of responses 
S = the slope of the calibration curve 
The slope S may be estimated from the calibration curve of the analyte. The estimate of F may 
be carried out in a variety of ways, for example: 
1. Based on standard deviation of the blank  
Measurement of the magnitude of analytical background response is performed by analyzing an 
appropriate number of blank samples and calculating the standard deviation of these responses. 
2. Based on the calibration curve  
A specific calibration curve should be studied using samples containing an analyte in the range 
of QL. The residual standard deviation of a regression line or the standard deviation of y-





Appendix 2 – Chromatogram data and 
Mass spectra for Chapter 4. 
 
Figure A2-1: Mass spectra for FITC-insulin conjugates synthesised using Humulin®R after 
2hrs reaction time (no EDTA added) (peaks present in raw data at m/z 968.7816 z6, 1162.3363 
z5 and 1452.6683 z4 corresponding to unlabelled human insulin; peaks at m/z 889.5278z7, 
1771.4869z7 and 2066.5662z3 corresponding to mono-labelled conjugate; peaks at m/z 
1098.6266 z6 and 1647.4355 z4 corresponding to di-labelled conjugate not labelled in spectra). 
 
 
Figure A2-2: Mass spectra for FITC-insulin conjugates synthesised using Humulin®R after 
20hrs reaction time (peak present in raw data at m/z 1163.4668 z6 and 1395.958 z5 





Figure A2-3: Mass spectra for FITC-insulin conjugates synthesised using Actrapid® after 2hrs 
reaction time(peaks present in raw data at m/z 1452.6682 z4 and 1936.5548 z3 corresponding to 
unlabelled human insulin; peaks at m/z 1771.6305 z7 and 2066.2323 z3 corresponding to mono-
labelled conjugate; peak at m/z 2004.8541 z10 corresponding to di-labelled conjugate not 




Figure A2-4: Mass spectra for FITC-insulin conjugates synthesised using Actrapid® after 
20hrs reaction time (peak present in raw data at m/z 1098.7937 z6 corresponding to di-labelled 








Figure A2-5: Mass spectra for FITC-insulin conjugates synthesised using NovoRapid® (insulin 
aspart) after 2hrs reaction time (peak present in raw data at m/z 1321.7463 z5 corresponding to 
di-labelled conjugate not labelled in spectra). 
 
 
Figure A2-6: Mass spectra for FITC-insulin conjugates synthesised using NovoRapid® (insulin 








Figure A2-7: Mass spectra for FITC-insulin conjugates synthesised using Apidra® (insulin 
glulisine) after 2hrs reaction time (peak present in raw data at m/z 1165.7376 z5 corresponding 
to unlabelled insulin glulisine;  peak at m/z 1775.6291 z7 corresponding to mono-labelled 
conjugate not labelled in spectra). 
 
 
Figure A2-8: Mass spectra for FITC-insulin conjugates synthesised using Apidra® (insulin 
glulisine) after 20hrs reaction time (peak present in raw data at m/z 1101.1275 z6 corresponding 
to di-labelled conjugate;  peak at m/z 1170.1286 z6 and 1399.1584 z5 corresponding to tri-








Figure A2-9: Mass spectra for FITC-insulin conjugates synthesised using Humalog® (insulin 
lispro) after 2hrs reaction time (peak present in raw data at m/z 1162.3364 z5 corresponding to 
unlabelled insulin lispro;  peak at m/z 1771.3447 z7 and 2066.5680 z3 corresponding to mono-
labelled conjugate; peak at m/z 1647.4363 z4 corresponding to di-labelled conjugate not 
labelled in spectra). 
 
 
Figure A2-10: Mass spectra for FITC-insulin conjugates synthesised using Levemir® (insulin 
determir) after 20hrs reaction time (peak present in raw data at m/z 1262.1732 z5 and 








Table A2-1: RP-HPLC Area % with retention times for Sigma FITC-bovine insulin 
commercial product. 
Peak# Ret. Time Area Height 
Peak 
Start Peak End Area% 
1 21.4 17106 1925 21.1 21.6 9.4 
2 21.7 1507 175 21.6 21.8 0.8 
3 22.0 33627 3686 21.8 22.3 18.5 
4 22.5 7005 692 22.3 22.6 3.9 
5 22.8 74886 8238 22.6 23.0 41.2 
6 23.1 9082 751 23.0 23.5 5.0 
7 23.9 38577 4038 23.6 24.6 21.2 
 
 
Figure A2-11: Mass spectra for Sigma FITC-bovine insulin commercial product (peaks present 
in raw data at m/z 1147.5280 z5 and 1434.4113 z4 corresponding to unlabelled bovine insulin;  
peaks at m/z 1086.1198 z6, 1303.3430 z5 and 1628.9264 z4 corresponding to di-labelled 
conjugate not labelled in spectra). 
 




(min) Area Height Peak Start Peak End Area% 
1 12.9 3263 318 12.7 13.2 0.5 
2 22.1 17589 2036 21.9 22.3 2.5 
3 22.4 22651 2694 22.3 22.6 3.2 
4 22.8 10834 963 22.6 23.0 1.5 
5 23.4 648351 62650 22.967 25.7 90.4 
6 24.1 6743 958 24.025 24.3 0.9 
7 24.6 3027 206 24.475 25.1 0.4 






Figure A2-12: Mass spectra for Sigma FITC-human insulin commercial product (peak present 
in raw data at m/z 1647.4269 z4 corresponding to di-labelled conjugate not labelled in spectra). 
. 
 
Figure A2-13: Mass spectra for FITC- bovine insulin synthesised in-house with reaction time 
of 20 hrs (peak present in raw data at m/z 1531.6674 z4 corresponding to mono-labelled 






Appendix 3 Figures for determination of 
diffusion coefficient from Chapter 5. 
Appendix 3.1 Figures (representative data) for determination of 
diffusion coefficient of tartrazine in agarose using tube set-up  
Appendix 3.1.1 Diffusion of tartrazine in 0.5% w/w agarose gel  
 
 
Figure A3-1: Evaluation of diffusivity D or De for tartrazine in 0.5% w/w agarose gel using the 






































































Appendix 3.1.2 Diffusion of tartrazine in 0.7% w/w agarose gel  
 
Figure A3-2: Evaluation of diffusivity D or De for tartrazine in 0.7% w/w agarose gel using the 






































































Figure A3-3: Evaluation of diffusivity D or De for tartrazine in 1% w/w agarose gel using the 





































































Figure A3-4: Evaluation of diffusivity D for tartrazine in 2% w/w agarose gel using the tube 




























































Appendix 3.1.5 Diffusion of tartrazine in 2% w/w agarose gel with matched 




Figure A3-5:  Evaluation of diffusivity D for tartrazine in 2% w/w agarose gel using the tube 
experiment with matched donor and receptor volumes from a plot of A: the Laplace transform 


























































Appendix 3.2 Figures (representative data) for determination of 
diffusion coefficient of tartrazine in agarose in INsmart device  




Figure A3-6:  Evaluation of diffusivities D for tartrazine in 2% w/w agarose gel using the 
device from a plot of A: the Laplace transform method, B: the QSS method and C: the TL 
method. The data set presented here has been reduced to every 10
th




























































Appendix 3.2.2 Diffusion of tartrazine in 1.5% w/w agarose Gel  
 
 
Figure A3-7: Evaluation of diffusivities D for tartrazine in 1.5% w/w agarose gel using the 
device from a plot of A: the Laplace transform method, B: the QSS method and C: the TL 
method. The data set presented here has been reduced to every 10
th





























































Appendix 3.3 Figures (representative data) for determination of 
diffusion coefficient of tartrazine in non-polymerised dex2M-conA 
mixture in INsmart device 
Appendix 3.3.1 Diffusion of tartrazine in NP gel in device with no glucose 
 
 
Figure A3-8: Evaluation of diffusivities D for tartrazine in NP gel using the device from a plot 
of A: the QSS method and B: the TL method. The data set presented here has been reduced to 
every 10
th
 data point to aid visual clarity. 
 
Appendix 3.3.2 Diffusion of tartrazine in NP gel in device with 0.1% w/w 
glucose 
 
Figure A3-9: Evaluation of diffusivities D for tartrazine in NP gel with 0.1% w/w glucose using 
the device from a plot of A: the QSS method and B: the TL method. The data set presented here 
has been reduced to every 5
th























































































Appendix 3.3.3 Diffusion of tartrazine in NP gel in device with 0.5% w/w 
glucose 
 
Figure A3-10: Evaluation of diffusivities D for tartrazine NP gel with 0.5% w/w glucose using 
the device from a plot of A: the QSS method and B: the TL method. The data set presented here 
has been reduced to every 5
th
 data point to aid visual clarity. 
 
Appendix 3.4 Figures (representative data) for determination of 
diffusion coefficient of fluorescein sodium in NP gel in INsmart device 
Appendix 3.4.1 Determination of diffusion coefficient of fluorescein sodium 
in NP gel in device with no glucose 
 
Figure A3-11: Evaluation of diffusivities D for fluorescein sodium in NP gel using the device 
from a plot of A: the QSS method and B: the TL method. The data set presented here has been 
reduced to every 5
th






















































































Appendix 3.4.2 Determination of diffusion coefficient of fluorescein sodium 
in NP gel in device with 0.1% w/w glucose 
 
Figure A3-12: Evaluation of diffusivities D for fluorescein sodium in NP gel with 0.1% w/w 
glucose using the device from a plot of A: the QSS method and B: the TL method. The data set 
presented here has been reduced to every 5th data point to aid visual clarity. 
Appendix 3.4.3 Effect of gel thickness on fluorescein sodium diffusion 
coefficient in NP gel in device with 0.1% w/w glucose 
  
 
Figure A3-13: Evaluation of diffusivities D for fluorescein sodium in NP gel with 0.1% w/w 
glucose using the device with 2.50 mm and 1.17mm gel thickness from a plot of A: the QSS 
method and B: the TL method. The data set presented here has been reduced to every 5
th
 data 
























































































Appendix 3.4.4 Comparison of effect of two different batches of conA on 
fluorescein sodium diffusivity in NP gel with no glucose in device 
 
Figure A3-14: Evaluation of diffusivities D for fluorescein sodium in NP gel with 0.1% w/w 
glucose using the device with the two conA batches from a plot of A: the QSS method and B: 
the TL method. The data set presented here has been reduced to every 5
th
 data point to aid visual 
clarity. 
 
Appendix 4 Figures for determination of 
diffusion coefficient of FITC-insulin from 
Chapter 7. 
 
Figure A4-1: Evaluation of diffusivities D or De for FITC-insulin in NP gel with no glucose 
from a plot of A: the QSS method and B: the TL method. The data set presented here has been 
reduced to every 10
th
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Figure A4-2: Evaluation of diffusivities D or De for FITC-insulin in NP gel with 0.1% w/w 
glucose from a plot of A: the QSS method and B: the TL method. The data set presented here 
has been reduced to every 10
th
 data point to aid visual clarity. 
 
 
Figure A4-3: Evaluation of diffusivities D or De for FITC-insulin in NP gel with 0.2% w/w 
glucose from a plot of A: the QSS method and B: the TL method. The data set presented here 
has been reduced to every 10
th
 data point to aid visual clarity. 
 
 
Figure A4-4: Evaluation of diffusivities D or De for FITC-insulin in NP gel with 0.5% w/w 
glucose from a plot of A: the QSS method and B: the TL method. The data set presented here 
has been reduced to every 10
th
 data point to aid visual clarity. 
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Figure A4-5: Evaluation of diffusivities D or De for FITC-insulin in NP gel with 1.0% w/w 
glucose from a plot of A: the QSS method and B: the TL method. The data set presented here 
has been reduced to every 10
th
 data point to aid visual clarity. 
 
 
Figure A4-6: Evaluation of diffusivities D or De for FITC-insulin in CL gel with no glucose 
from a plot of A: the QSS method and B: the TL method. The data set presented here has been 
reduced to every 10
th
 data point to aid visual clarity. 
 
 
Figure A4-7: Evaluation of diffusivities D or De for FITC-insulin in CL gel with 0.1% w/w 
glucose from a plot of A: the QSS method and B: the TL method. The data set presented here 
has been reduced to every 10
th
 data point to aid visual clarity. 
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y = -2.4070E-07x + 2.4103E-03 


































Figure A4-8:  Evaluation of diffusivities D or De for FITC-insulin in CL gel with 0.2% w/w 
glucose from a plot of A: the QSS method and B: the TL method. The data set presented here 
has been reduced to every 10
th
 data point to aid visual clarity. 
 
 
Figure A4-9: Evaluation of diffusivities D or De for FITC-insulin in CL gel with 0.5% w/w 
glucose from a plot of A: the QSS method and B: the TL method. The data set presented here 
has been reduced to every 10
th
 data point to aid visual clarity. 
 
 
Figure A4-10: Evaluation of diffusivities D or De for FITC-insulin in CL gel with 1.0% w/w 
glucose from a plot of A: the QSS method and B: the TL method. The data set presented here 
has been reduced to every 10
th
 data point to aid visual clarity. 
  
y = 3.5696E-12x - 4.2346E-08 













tlag =  11849 s  
y = 4.0748E-12x - 5.9343E-09 











tlag =  1456s  
B 
y = 4.6343E-12x - 2.3678E-08 










tlag =  5109 s  
B 
y = -5.9691E-08x + 7.1358E-04 






























y = -7.6713E-08x + 4.4853E-04 





























y = -7.7665E-08x + 3.9784E-04 
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The drug delivery mechanism of fluorescently labelled 
insulin (FITC-Insulin) from a glucose sensitive gel held in 
an implantable closed loop insulin delivery device was 
found to be diffusion controlled. The diffusion coefficient 
of FITC-Insulin in the gel was determined and response to 
glucose triggers assessed. 
 
INTRODUCTION 
A fully functional implantable insulin delivery device 
which has shown to control blood glucose in diabetic rats 
and more recently in diabetic pigs has been developed [1, 
2].The device encases a reversible glucose-sensitive gel of 
co-polymerised dextran methacrylate (dex-MA) and 
concanavalin A methacrylamide (conA-MA), which 
produces a reversible change in consistency on contact 
with glucose to modulate insulin transport and thus acts as 
a self adjusting system. The device, implanted in the 
peritoneal cavity, works on a very fast feedback 
mechanism for controlling insulin release, mimicking a 
normal pancreas enabling to overcome inherent problems 
encountered in maintaining normoglycemia with current 
electronically or biologically based closed loop systems. 
In this work we present the drug release kinetics data for 




Synthesis and characterisation of fluorescently labelled 
insulin 
Human Insulin was labelled with fluorescein 
isothiocyanate (FITC). Briefly, 10mg/ml human insulin in 
0.1M phosphate buffer containing 200µM EDTA (pH 7.0) 
was prepared. FITC solution prepared in acetone 
(5mg/mL) was added dropwise to the human insulin stock 
solution (3:1 molar ratio) at pH 7.0 in the dark and stirred 
for 25 hours. After this time the reaction was stopped and 
the FITC-Insulin conjugates were fractionated by Gel 
Permeation Chromatography using a Sephadex G25 
column. Fractionated FITC-Insulin conjugates were 
characterised using HPLC and EI Mass Spectroscopy [4]. 
The FITC-Insulin synthesised were predominantly di-
labelled conjugates and contained no unlabelled insulin. 
 
Preparation of gel 
The preparation of the gel has been described previously 
[3]. Briefly, Con-MA (100mg) was dissolved in distilled 
water and photoinitiator Irgacure® (0.178 µmoles) was 
added. Dex-MA (RMM 500Da) (100mg) was added to 
the mixture and stirred to form a viscous solution, covered 
in foil and allowed to stand for 2 hours; the mixture was 
then placed between two glass plates separated by a 60µm 
thick gasket and was irradiated under UV-light (365nm, 
10mJ cm
-2
) for 5 minutes. The crosslinked gel (CLgel) 
formed was stored aseptically at 4°C for at least 24 hours 
prior to use. A non-polymerised version of the gel 
(NPgel) containing underivatised conA and dextran 
(RMM 2000kDa) was prepared in the same way but not 
irradiated. 
 
Evaluation of drug delivery mechanism 
An experimental set-up was designed using the same 
InSmart device as was used in in vivo pig trials previously 
[2] as shown in Figure 1.  
 
Figure 1: Schematic of the experimental set-up. 
 
FITC-Insulin diffusing through the gel from the donor 
side to the receptor side was monitored over time by 
conversion of fluorescence intensity recordings at 518nm 
into concentration values using calibration curves. 
Preliminary experiments using probe dye fluorescein 
sodium and using NPgel aided selection of appropriate 
mathematical models.  
 
The Power Law (Peppas equation): The release of 
fluorescein sodium from the NPgel was recorded over 
time and applied to the power law shown below to 




=  tn  
Where, Mt and M∞ are the absolute cumulative amount of 





a constant incorporating structural and geometric 
characteristics of the system and n is the diffusional 
exponent, which is indicative of the mechanism of drug 
release.  
 
Mathematical models for determination of Diffusion 
coefficient: The diffusion cell technique – Quasi steady 
state (QSS), the Time lag (TL) slope and the TL intercept 
methods based on Fick’s law were identified for 
determination of diffusion coefficient of FITC-Insulin [5]. 
QSS:  
  
  ,  ( )    ,𝐵( )
  , 0    ,𝐵0
=   
  
 






     0  
De is calculated from the slope of the line obtained by 
plotting the left-hand side of equation against time t. 
TL slope: 
  =   𝐵0  ,𝐵( ) =  
 𝑔   , 0
 




D is calculated by plotting the total amount of solute 
transferred through the gel (Qt) against time (t). 
TL intercept: 




D is calculated from the lag time, tlag, the intercept of the 
linear part of the TL plot.  
(Key: De & D are the effective diffusion coefficient and 
diffusion coefficient, VA & VB volumes of the two 
chambers separated by the gel, Ag is effective membrane 
area, l is gel thickness, CLA & CLB are the concentration of 
the drug solute in the two chambers at initial time t0 or at 
time t). 
 
Glucose sensitivity of the gel was assessed by 
challenging the system with increasing physiologically 
relevant concentrations of glucose (0.1% to 1%). 
 
RESULTS AND DISCUSSION 
 
The Power Law: The gel (thickness 1.17mm) housed in 
the device can be considered as a thin film or slab with no 
edge effects and the power law fit for the release of 
fluorescein sodium through the gel indicates diffusion 
controlled release (Figure 2). 
 
Figure 1: Power law fit for fluorescein sodium release 
through NPgel. Dotted line represents the power law fit for 
n=0.5, indicating diffusion controlled release.  
Determination of Diffusion coefficient: Table 1 shows 
diffusion coefficients from mathematical models for 

















NPgel 1.05E-11 1.04E-11 1.12E-11 
NPgel + 0.1% 
Glucose 
4.59E-12 4.58E-12 2.24E-11 
CLgel 7.54E-12 7.52E-12 1.44E-11 
CLgel + 0.1% 
Glucose 
5.90E-12 5.89E-12 9.92E-11 
Table 1: Diffusion coefficient values (D and De) for FITC-
Insulin in NPgel and CLgel with and without 0.1% basal 
glucose determined using the QSS method, the TL slope 
method and the TL intercept method. 
 
The QSS and TL methods gave reliable correlation in 
diffusion coefficient values for FITC Insulin in NPgel and 
CLgel. The TL intercept method gave different values, 
approximately a decade faster in some instances, which is 
consistent with the findings of others [5].  
 
Glucose sensitivity: Figure 3 shows increasing D values 
with increasing glucose concentrations in NPgel. 
 
Figure 2: FITC-Insulin diffusion coefficient values with 
increasing glucose concentration in NPgel. 
 
CONCLUSION 
The drug release mechanism from the glucose sensitive 
gel held in an implantable closed loop insulin delivery 
device was found to be diffusion controlled. The diffusion 








/s. The D values 
increase with increasing glucose concentrations, device 
thus showing glucose sensitivity, mimicking pancreas. 
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